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Summary !
In recent years, substantial evidence has been generated demonstrating the importance 
of the immune system in preventing and controlling the growth of many cancers, 
including colorectal adenocarcinomas. In particular, populations of tumour-specific 
effector T cells appear to play a crucial role in restricting the generation and 
expansion of transformed neoplastic cells. However, the fact that tumours continue to 
grow in the presence of a seemingly intact immune system suggests that these 
responses are often inadequate.  
CD4+Foxp3+ T regulatory cells (Tregs) have been shown to play a key role in 
modulating the immune system by keeping immune responses to self-antigens in 
check, thereby preventing autoimmunity. These cells also appear to be employed by 
tumours to protect against recognition and eradication, and have been demonstrated to 
impinge upon the anti-tumour immune response in humans. Furthermore, it appears 
that the tumour microenvironment facilitates the development of highly 
immunosuppressive T cells, which may also allow subsequent tumour progression. 
In colorectal cancer, the relationship between Tregs and tumour progression is 
less clear – despite their well-documented ability to impinge on anti-tumour immune 
responses, increased tumour infiltrates have also been associated with prolonged 
survival. In this thesis, the phenotype and function of CD4+ T cells derived from 
PBMC, colon and tumour samples were analysed for suppressive markers by FACS, 
and anti-tumour responses by IFN-γ ELISpot. CRC patients with more advanced 
tumours responded to fewer epitopes and generated a significantly weaker epitope-
specific T cell response to the oncofoetal antigen, 5T4 than healthy donors. Human 
depletion experiments both in vitro and in vivo indicated suppression by Foxp3+ 
regulatory CD4+ T cells. These cells were found in abundance amongst tumour-
infiltrating lymphocytes; however, another equally prominent population of IL-10 and 
TGF-β-producing CD4+Foxp3- T cells were found to be >50-fold more suppressive. 
Thus, a major caveat to cancer immunotherapy is the suppressive tumour 
microenvironment, which contributes to the selective decline of measurable anti-
tumour CD4+ T cell responses as tumours progress. These responses were enhanced 
in metastatic CRC patients by depleting regulatory T cells. 
It is hoped such findings will augment our understanding of how anti-tumour 
CD4+ T cells are activated and conversely regulated, with the intention of designing 
better treatment for patients with colorectal cancer.  
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Chapter 1 – Introduction 
1.1 Tumourigenesis 
 
1.1.1 The Initiation and Establishment of Cancer  
 
The processes underlying the transformation of normal cells into malignant 
neoplasms involve epigenetic and mutational alterations, leading to unregulated 
cellular differentiation and proliferation. In the seminal review, ‘The Hallmarks of 
Cancer’, Hanahan and Weinberg describe six common principles that govern this 
transformation (Hanahan and Weinberg 2000). They comprise:  
- The ability to sustain chronic proliferation by deregulating the production and 
release of growth promoting signals;  
- Evading growth suppressors, either by circumventing the effect of tumour 
suppressor genes or by nullifying cell-cell contact inhibition;  
- Resisting cell death and becoming resistant to multiple apoptotic mechanisms;  
- Unlimited replicative potential by protecting against telomere erosion;  
- Inducing angiogenesis via production of vascular endothelial growth factors, 
and;  
- Activating invasion and metastasis by altering expression of cell-cell adhesion 
molecules. 
Whilst these processes must occur for tumours to progress, the cancer cells actively 
interact with, and are heavily influenced by, their immediate environment comprising 
many different cell types. Thus, it is the totality of the tumour microenvironment that 
determines the outcome of tumourigenesis and much research has gone into analyzing 
the constituents of tumours. !
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1.1.2 Cancer Immunosurveillance 
 
In 1909, Paul Ehrlich originally hypothesized that the growth of carcinomas 
could be constrained by cells of the host’s immune system (reference in German*). 
Over the following 50 years, advances in the understanding of cancer immunobiology 
took a step forward with the development of inbred mouse strains and the successful 
immunisation of mice against syngeneic tumours (Old and Boyse 1964). This work 
led F. MacFarlane Burnet to propose the concept of “immunological surveillance”. 
His experimental evidence suggested that “thymus-dependent cells of the body” 
constantly surveyed host tissues for transformed cells, given that neo-antigens would 
become upregulated on mouse tumours (Burnet 1964; Burnet 1970).  
At the time, such work was considered controversial in the face of evidence 
that appeared to disprove the immunosurveillance hypothesis. Some of the most 
convincing research was based on findings in immunocompromised athymic nude 
mouse, which have far fewer T cells than wild type mice. When these mice were 
given chemically induced tumours (a fibrosarcoma after 3-methylcholanthrene 
injection) the latency period before tumour formation and the overall number of 
tumours were no different to those found in wild type mice (Stutman 1974). In 
addition, nude mice did not exhibit an increased incidence of spontaneous non-viral 
tumour formation (Outzen, Custer et al. 1975). This led some investigators to 
speculate that tumour cells were too similar to the normal cells from which they 
derived, thus the immune system could not recognize these cells or could become 
tolerized to them (Matzinger 1994).  
Since then, technological advances in mouse genetics and monoclonal 
antibody production have helped substantiate the theory of cancer 
* Ehrlich, P. Über den jetzigen stand der karzinomforschung. Ned. Tijdschr. Geneeskd. 5, 273–290 (1909). 
 12 
immunosurveillance. Some of the key findings involve the use of mouse strains 
deficient in recombination-activating gene (Rag-1 / -2), essential for the generation of 
mature B, T and NKT cells. These mice demonstrate an increased frequency and a 
broader spectrum of spontaneous tumours over wild type, age-matched littermates 
(Shankaran, Ikeda et al. 2001). Moreover, tumours that develop in Rag-2 deficient 
mice are rejected when transplanted into wild-type recipients; however, tumours from 
wild type mice are not rejected in other wild type or Rag-2 knockout mice. These 
experiments demonstrate a clear role for the adaptive immune system in recognising 
and eliminating cancerous cells (outlined in Figure 1.1); yet they also indicate how 
tumours developing in immune-competent hosts can lose immunogenicity, 
demonstrating how cancer immunosurveillance represents only one step of a broader 
immunological process. 
 
1.1.3 Cancer Immunosurveillance in Humans 
Whilst evidence for cancer immunosurveillance occurring in mice comes 
largely from data in immunocompromised animals, so too does evidence of cancer 
immunosurveillance occurring in humans. Patients receiving transplants are routinely 
given immunosuppressants to reduce the risk of organ rejection; these recipients have 
a 3-fold increased risk of cancer relative to the age and sex-matched general 
population (Vajdic and van Leeuwen 2009). A meta-analysis of the incidence of 
cancer in people with HIV/AIDS compared with immunosuppressed transplant 
recipients revealed that the similarity of the pattern of increased risk of cancer in the 
two populations was suggestive of immune deficiency, rather than other risk factors 
for cancer (Grulich, van Leeuwen et al. 2007). Whilst many of these cancers, 
including Kaposi’s sarcoma and non-Hodgkin’s lymphoma, have a known infectious 
 13 
cause (usually viral, i.e. human papillomavirus or Epstein-Barr virus), some cancers 
such as non-melanoma skin cancer and lung cancer are markedly increased without a 
known cause. One potential explanation arises from the cancer immunosurveillance 
hypothesis, and the increase in rates of cancer in immunocompromised individuals is 
a result of reduced recognition or elimination of aberrant cells; certainly a reduced 
anti-viral immune capacity can result in increased rates of tumourigenesis. Given that 
there is not a general increase in all cancers, however, questions the cancer 
immunosurveillance hypothesis.  
 
1.1.4 Cancer Immunoediting 
 
The cancer immunoediting hypothesis describes how host immune responses 
can both protect against and promote tumour development (Dunn, Old et al. 2004; 
Schreiber, Old et al. 2011). The process of cancer immunoediting has been defined by 
three distinct phases: Elimination, representing the classical concept of cancer 
immunosurveillance; equilibrium, whereby tumour cells are not sufficiently removed 
and remain in a latent phase; and escape, when tumours have overcome the 
immunological restraints of the equilibrium phase and growth proceeds unabated. 
This hypothesis also describes how tumours can arise in seemingly immunocompetent 
hosts, despite the multitude of immune effector functions in place to protect against 
carcinogenesis. 
During the elimination phase, it is likely that many tumour cells are effectively 
destroyed by immune cells, however new variants carrying more mutations may also 
arise. Thus, MCA tumours established in mice lacking either T cells, NKT cells, 
perforin or IFN-γ, are more immunogenic than those originating in an intact immune 
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system, since wild-type mice can easily reject tumours transplanted from such mice 
(Svane, Engel et al. 1996; Smyth, Thia et al. 2000; Street, Cretney et al. 2001). For 
tumour cells to evade immunosurveillance, certain resistance mechanisms must be 
acquired to disguise them. This can be achieved through a number of mechanisms. 
Firstly, tumour cells are known to be capable of altering and losing expression of 
immunogenic antigens. In one clinical trial, metastatic melanoma patients received 
adoptively transferred T cells specific for the tumour antigen MART-1; three out of 
five patients studied exhibited specific loss of MART-1 expression on the tumour 
cells after first infusion of T cells (Yee, Thompson et al. 2002). Secondly, 
immunologically sculpted tumour cell variants may overproduce certain cytokines, 
such as IL-6, IL-10, TGF-β and VEGF (vascular endothelial growth factor), which are 
capable of inactivating effector immune responses (Cabillic, Bouet-Toussaint et al. 
2006), however, this may also represent a mere side-effect of the angiogenic and 
growth factor functions of these cytokines. In particular, TGF-β has been found to 
have a critical role both in suppressing immune cell effector functions and activating 
an epithelial-to-mesenchymal transition, which confers traits associated with high-
grade malignancy on cancer cells, e.g. metastatic capability (Xu, Lamouille et al. 
2009). Finally, tumour cells can also overcome the cytotoxic effects of immunity by 
inducing anti-apoptotic effector molecules such as the BCL-2 (B Cell Lymphoma-2) 
family of proteins (Placzek, Wei et al. 2010). Other mechanisms of tumour immune 
escape have been reviewed previously (Khong and Restifo 2002).  
Transformed cells that do manage to evade elimination next enter a period of 
equilibrium. According to the immunoediting hypothesis, this is a period of dynamic 
interaction between the tumour cells and the host immune response, resulting in a 
dormant phase that may last up to several years in humans before the onset of 
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clinically apparent symptoms (Aguirre-Ghiso 2007). Evidence supporting this comes 
from the identification of minimal residual disease in the bone marrow and liver of 
patients with colorectal cancer, and the fact it can take a number of years for 
metastatic disease to become clinically apparent (Merrie, Yun et al. 1999). Further 
experimental evidence to corroborate these findings came from primary 
tumourigenesis experiments, whereby wild type mice were injected with low doses of 
MCA (Koebel, Vermi et al. 2007). These mice harboured occult cancer cells for 
prolonged periods but did not go on to develop palpable tumours, unless given 
antibodies to deplete T cells and IFN-γ; tumours would then appear at the injection 
site in half of these mice. Interestingly, both CD4+ and CD8+ T cells, but no innate 
immune cells, were crucial to the maintenance of the tumour cells in the equilibrium 
phase. These tumours are highly immunogenic, akin to the unedited MCA-induced 
sarcomas in RAG-/- mice, indicating that T cells could inhibit the creation of new, less 
immunogenic, variant tumour cells.  
It should also be noted, that some experimental inconsistencies may 
inadvertently be implicating the adaptive immune response in controlling MCA-
induced sarcomas. In the aforementioned studies, the immune-deficient mice were 
bred locally and control mice were purchased; when the same experiments were 
performed on knockout and wild-type mice obtained from the same colony, mice 
lacking IFN-γ expressing cell types or perforin do not show increased susceptibility to 
MCA. This argues against the idea of immune surveillance of MCA-induced 
carcinogenesis mediated by T cells (Qin and Blankenstein 2004). 
Whilst the equilibrium phase of the immunoediting hypothesis may still 
provoke controversy, tumour cells must advance and evade immune responses in 
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order to become clinically identifiable. This process begins throughout the 
equilibrium phase, where tumour cell variants emerge with mutations providing them 
with increased resistance to immune attack. Ultimately, enough genetic or epigenetic 
changes occur in the tumour cells leading to variants that have acquired an ability to 
evade immune detection and elimination, utilising mechanisms described earlier. 
However, other factors appear to facilitate this transition, driven by the mobilization 
of immunosuppressive leukocytes in the tumour microenvironment. It has recently 
been shown that the transition to the escape phase from a state of equilibrium is 
mirrored by a phenotypic and functional shift in tumour-infiltrating dendritic cells 
(Scarlett, Rutkowski et al. 2012). This research utilised an inducible p53-dependent 
ovarian cancer mouse model to demonstrate that dendritic cells isolated from early 
stage carcinomas were capable of stimulating anti-tumour immune responses amongst 
T cells taken from the same tumour, yet late-stage derived dendritic cells heavily 
suppressed T cell activation and proliferation. Tumours may also promote the 
suppressive microenvironment by releasing certain cytokines and chemokines that 
result in the recruitment of immunosuppressive leukocyte populations, such as 
myeloid-derived suppressor cells and regulatory T cells (Tregs; discussed in more 
detail later) and help drive the suppression of anti-tumour effector immune responses 
both within the tumour and systemically (Curiel, Coukos et al. 2004; Frey and Monu 
2006; Frey and Monu 2008).  
Given such compelling evidence to show the role of host immunity in 
impeding tumour development, it was perhaps surprising that immune system evasion 
was omitted from the original ‘Hallmarks of Cancer’. In 2011, in acknowledgement to 
the recent surge in interest, Hanahan and Weinberg updated their paper to include 
how cancer cells are able to evade recognition and consequent elimination by cells of 
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the host immune system. However, the authors highlight the dichotomous roles of 
immune cells, as subsets exist that can both antagonize and enhance tumour 
progression (Hanahan and Weinberg 2011). This is brought about by the infiltration 
of immune cells with tumour-promoting effects, and by the fact that tumour cells can 
induce marked inflammation.  
Indeed, chronic inflammation has been shown to promote tumourigenesis and 
progression by enhancing angiogenesis and tissue invasion. This arises from the 
secretion of growth factors that sustain proliferative signaling, survival factors that 
limit cell death, proangiogenic factors and extracellular matrix-modifying enzymes 
that facilitate angiogenesis, invasion, and metastasis (reviewed in (Grivennikov, 
Greten et al. 2010)). For example, proinflammatory cytokines such as IL-1β, IL-6 and 
TNF-α are present in many tumours and associated with tumour progression (Smith, 
Hobisch et al. 2001; Balkwill 2006; Lewis, Varghese et al. 2006). The exact 
mechanisms by which these cytokines promote tumour growth remain unclear, 
however, IL-1β has previously been shown to induce expression of VEGF in 
colorectal cancer, further facilitating angiogenesis and metastatic growth (Konishi, 
Miki et al. 2005). Ardent debates have arisen as to whether inflammation enhances or 
diminishes tumour progression, as a number of reports now indicate that pro-
inflammatory tumour-associated macrophages can actually enhance beneficial anti-
tumour T cell responses (Ong, Tan et al. 2012). Indeed, the problem seems to arise 
from the disparity in different tumour locations, since tumour-associated macrophages 
that infiltrate colorectal and skin carcinomas are associated with a good prognosis, 
whereas they are associated with a poor prognosis in most other cancers (Yuan, Chen 
et al. 2008). In addition, IFN-γ production by T cells and ultimate control of tumour 
burden can still exist within the tumour microenvironment even when tumours 
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containing high-levels of pro-inflammatory cytokines have become established (Teng, 
Andrews et al. 2010). Therefore, this work demonstrated that tumour-promoting 
inflammation and cancer immunosurveillance mechanisms could coexist within the 
same tumour model. 
 
1.2 T cells 
1.2.1 T cell Subsets 
The immune system has evolved to protect humans from invading pathogens 
by recruiting cells of the adaptive immune system, namely B and T cells, that are 
capable of recognising non-self antigens, generating effector responses to eliminate 
specific pathogens or pathogen-infected cells, and develop memory to that specific 
pathogen. As a result, T cells with distinct functions exist to promote different types 
of immune responses and provide a homeostatic mechanism to regulate the response 
generated. T cells can therefore be grouped based on these effector functions, such as 
cytokine profile, and their corresponding molecular phenotype associated with those 
cells. For example, T cells expressing the TCR co-receptor CD8 are capable of 
producing cytolytic proteins to kill infected or transformed cells, whilst other T cells 
expressing CD4 can both help this cytotoxic response, by producing IL-2 and IFN-γ, 
and dampen excessive inflammation by producing IL-10 and TGF-β. Basic 
immunological research has focused on definitively identifying specific T cell subsets, 
since targeting individual subgroups of cells will likely be essential for the 
development of new treatments, particularly in the setting of cancer immunotherapy. ! !
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Figure 1.1 Cancer Immunosurveillance. Neoplastic cells, which become 
transformed by one of the methods indicated, can be recognised and killed by effector 
mechanisms of the immune system, mediated by the presentation of tumour antigens 
to T cells. However, cancer cells can become immunologically sculpted over time to 
avoid rejection, upregulate suppressive molecules that drive growth, and eventually 
proliferate to clinically identifiable tumours even in the presence of tumour 
infiltrating lymphocytes. 
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1.2.2 Regulatory T cells (Tregs) 
 
Although evidence to show that some T cell subsets were capable of limiting 
immune responses has been around for over 40 years (Baker, Stashak et al. 1970), it is 
only in recent years that interest has intensified. Initial findings from Fiona Powrie’s 
lab in the 1990’s suggested that a subset of T cells expressing certain activation / 
memory cell markers could protect mice from autoimmune disease (Powrie and 
Mason 1990; Powrie, Leach et al. 1993). One major piece of evidence definitively 
identifying their existence was the discovery that the IL-2 receptor α-chain, CD25, is 
significantly upregulated on these suppressive CD4+ T cells (Sakaguchi, Sakaguchi et 
al. 1995). This article demonstrated that the inoculation of athymic nude mice with 
spleen and lymph node cell suspensions depleted of CD25+ cells caused severe multi-
organ autoimmunity within 2 weeks and even death in 30% of the mice within 3 
weeks. Research into these cells quickly accelerated with a number of reports 
showing that these CD4+CD25+ regulatory T cells could limit TCR induced expansion 
and activation of CD4+ and CD8+ T cells in vitro, both in mice (Thornton and 
Shevach 1998) and humans (Ng, Duggan et al. 2001; Stephens, Mottet et al. 2001). 
Numerous studies have since demonstrated the potent influence of Tregs in 
suppressing pathologic immune responses in autoimmune diseases, transplantation 
and more recently, cancer. 
 
1.2.3 Phenotypic Markers of Tregs 
 
For many years, the definitive identification of regulatory T cells was 
hampered by the fact that upregulation of CD25 also denoted activated T cells with a 
non-suppressive function (Kmieciak, Gowda et al. 2009). A key advancement was the 
 21 
discovery that the forkhead / winged helix transcription factor, Foxp3, seemed to play 
a critical role in the development and function of Tregs (Fontenot, Gavin et al. 2003; 
Hori, Nomura et al. 2003). CD4+CD25+ T cells in wild-type mice exclusively 
expressed Foxp3, whereas mice that lacked expression of the Foxp3 gene (‘scurfy’ 
mice) have a phenotype associated with defective T cell tolerance, including massive 
lymphoproliferation, diabetes, exfoliative dermatitis, thyroiditis and enteropathy. 
Such autoimmunity can be reversed by a transgene encoding the wild-type Foxp3 
allele (Brunkow, Jeffery et al. 2001). A very similar phenotype is observed in humans 
suffering from a rare X-linked fatal autoimmune disease, known as IPEX (immune 
dysregulation, polyendocrinopathy, entereopathy, X-linked) syndrome (Wildin, 
Ramsdell et al. 2001). Such findings implicate an important role for Foxp3 in 
allowing T cells to control excessive autoimmunity and maintain immune 
homeostasis. 
In mice, activation of non-Tregs, i.e. CD4+CD25- T cells, does not induce 
Foxp3 expression, and ectopic expression of Foxp3 is sufficient to activate 
suppressive function in T cells (Fontenot, Gavin et al. 2003); hence Foxp3 appears to 
be a specific marker for murine Tregs. However, these findings are not completely 
replicable in human T cells. For example, TCR stimulation of CD4+CD25-Foxp3- 
effector T cells results in the induction of Foxp3 expression, but this is not sufficient 
to confer suppressive T cell activity (Wang, Ioan-Facsinay et al. 2007), thus arguing 
against a role for Foxp3 as a key regulator of suppression in human CD4+ T cells 
(reviewed in (Roncarolo and Gregori 2008)).  
Despite the controversy surrounding Foxp3 as a marker of suppressive T cells 
in humans, no other marker, either surface-bound or intracellular, can denote a larger 
proportion of T cells with immunoregulatory function and it is still currently 
 22 
considered as the gold standard for Treg phenotyping in humans (Ziegler 2006; 
Feuerer, Hill et al. 2009). When T cells are isolated ex vivo, suppression of effector T 
cell cytokine production and proliferation correlates very strongly with the proportion 
of Foxp3+ T cells present (Kryczek, Liu et al. 2009). However, the intracellular 
location of Foxp3 precludes its use as a phenotypic marker for Tregs in many 
experimental situations. Crucially, live cells cannot be sorted or depleted based on 
Foxp3 expression since antibody staining requires that the cell be permeabilised and 
fixed. Researchers wishing to isolate human Tregs from peripheral blood now do so 
using a panel of surface markers; most commonly this is done by sorting CD4+ cells 
based high expression of CD25 and low expression of the IL-7 receptor α chain, 
CD127, which is downregulated specifically on suppressive T cells in the peripheral 
blood (Liu, Putnam et al. 2006).  
 
However, many reports suggest that a significant number of regulatory T cells 
exist outside of this classical Treg phenotype. Of particular note is the demonstration 
that Foxp3 is expressed on a significant percentage (3-5%) of healthy human PBMC-
derived CD4+CD25- T cells. Thus, CD25-negative CD4+CD127lo T cells also 
suppress effector T cell proliferation in vitro (Liu, Putnam et al. 2006). Further 
evidence compounding the phenotypic identification of Tregs came from work 
demonstrating that low CD127 expression is not an intrinsic characteristic of Foxp3+ 
Tregs either, and that CD127 expression is dependent on T cell localization and 
activation status (Simonetta, Chiali et al. 2010). Interestingly, this study also 
identified other phenotypic markers that correlated with Foxp3 expression but not 
CD25 and CD127. These include the inducible costimulatory molecule, ICOS, and 
the αE integrin, CD103, which was originally described as a marker for T cells 
residing in the skin, lung and gut wall (Parker, Cepek et al. 1992) and is thought to 
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play a role in retention of T cells within epithelial compartments, since its ligand E-
cadherin is predominantly expressed on epithelial cells but not the endothelium 
(Schon, Arya et al. 1999). Such markers have previously been attributed to activated 
Tregs (Herman, Freeman et al. 2004) and subsets of CD25+ and CD25- CD4+ T cells 
with suppressive characteristics in vitro (Lehmann, Huehn et al. 2002). Other 
phenotypic markers of Tregs are displayed in Table 1.1.  
 
1.2.4 Naturally Occurring and Peripherally Induced Tregs 
 
Clearly, a number of T cell subsets displaying disparate phenotypes are 
capable of suppressing antigen-specific immune responses. These cells can also be 
distinguished by the exact manner in which they enact immunosuppression (cell-
contact mediated or regulatory cytokine production) and also by their origin. The 
majority of the classical, ‘naturally occurring’ regulatory T cells are generated in the 
thymus, where it is thought that T cells possessing a high affinity for self-antigens, in 
conjunction with various cytokine receptor signals, differentiate into the Foxp3-
expressing Treg lineage (Liston, Nutsch et al. 2008). In the peripheral sites, these cells 
enforce self-tolerance by suppressing auto-antigen specific effector T cell responses. 
Hence, thymectomy in 3-day-old mice results in the development of autoimmunity, in 
particular destruction of the ovaries, since these mice lack naturally occurring Tregs 
(Fontenot, Dooley et al. 2005).  
In contrast, many peripherally induced, ‘adaptive’ regulatory T cell subsets do 
not express Foxp3, demonstrating that Foxp3 expression alone is not sufficient for 
commitment to the Treg lineage. Even in patients with IPEX syndrome, a 
hypoproliferative and suppressive T cell subset producing IL-10, IFN-γ but not IL-4 is 
present (Passerini, Di Nunzio et al. 2011). These findings indicate that mutations in 
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the FOXP3 gene do not impair the function of T cells with a suppressive capacity, but 
that a peripherally induced Treg subset known as Tr1 cells, distinct from the naturally 
occurring Treg lineage, plays a crucial role in resolving inflammation and maintaining 
peripheral immune tolerance (Roncarolo, Gregori et al. 2006). In particular, Tr1 cells 
mediate their suppressive function via the secretion of large amounts of IL-10 and do 
not suppress through cell-contact mechanisms (Vieira, Christensen et al. 2004). It has 
recently been shown that these cells originate from the interaction of effector memory 
CD4+CD62L-Foxp3- T cells with their cognate antigen in the presence of the 
glycosaminoglycan, hyaluronan (Bollyky, Wu et al. 2011). This suggests that 
compromised cellular matrix integrity could promote the differentiation of T cells into 
Tr1 cells in order to maintain peripheral tolerance.  
Another peripherally induced T cell subset with suppressive characteristics has 
also been observed, termed Th3 cells. These cells produce the regulatory cytokine 
TGF-β, but not IL-4 or IL-10, thus distinguishing them from Tr1-type cells (Weiner 
2001). Importantly, these Th3 cells have been shown to confer tolerance in a mouse 
model of experimental autoimmune encephalomyelitis (EAE), and to suppress 
antigen-specific responses in vitro; in both cases the suppression is mediated 
specifically by TGF-β (Miller, Lider et al. 1992).  
The distinction between adaptive Tregs and naturally occurring Tregs is the 
requirement of adaptive Tregs for further differentiation of a T cell subset post thymic 
development into a Treg phenotype as a consequence of exposure to antigen in a 
particular immunological context (Bluestone and Abbas 2003, Curotto de Lafaille and 
Lafaille 2009). Recent attempts to differentiate the two subsets by phenotype revealed 
the expression of a transcription factor called Helios, restricted to thymic-derived 
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Tregs in both mice and humans (Thornton, Korty et al. 2010). Data showed that 100% 
of CD4+CD8-Foxp3+ thymocytes and around 70% of CD4+Foxp3+ Tregs in peripheral 
lymphoid tissues expressed Helios, thus raising the possibility that a significant 
number (~30%) of CD4+Foxp3+ Tregs are generated extra-thymically, i.e. through 
peripheral conversion of conventional T cells. However, recent controversies have 
arisen with some researchers suggesting that Helios could become upregulated by 
activated, proliferating Tregs induced to express Foxp3 in vitro by peptide stimulation 
in the presence of TGF-β (Verhagen and Wraith 2010; Akimova, Beier et al. 2011), 
despite original findings showing that neither mouse nor human T cells induced to 
express Foxp3 by TCR stimulation with TGF-β, expressed Helios (Thornton, Korty et 
al. 2010). More validation of this research is required in order to unequivocally denote 
Helios as a marker for thymic-derived Tregs, although a number of groups have since 
utilised this marker for this purpose, giving credence to the original research (Elkord, 
Sharma et al. 2011; McClymont, Putnam et al. 2011). Regardless of the controversy, 
recent findings from a number of groups identify Helios+ Tregs as having greater 
suppressive properties than Helios- Tregs, and represent a distinct subset associated 
with CD103 and GITR expression and TGF-β production (Elkord 2012; Elkord and 
Al-Ramadi 2012; Zabransky, Nirschl et al. 2012).  
 
1.2.5 Mechanisms of Suppression Mediated by Tregs 
 
Extensive research into the mechanisms of T cell mediated suppression aims to 
unearth the control processes of peripheral tolerance with the potential of identifying 
novel therapeutic targets, given the importance of Tregs in a wide range of disease 
settings. Currently, it appears that Tregs are capable of inhibition at multiple levels, 
utilizing a plethora of inhibitory mechanisms depending on the nature, localization  
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Marker Function and Expression in Human T cells 
Foxp3 Transcription factor controlling many Treg functions and phenotypic 
markers, found to be a critical factor for maintaining immune 
homeostasis. Proposed to be a more specific marker of T regulatory 
cells than most cell surface markers.  
Helios A member of the Ikaros family of zinc finger transcription factors, 
Helios plays an important role in T cell development and 
homeostasis. It was originally proposed as a marker of thymus-
derived Tregs, though expression also found on activated, 
proliferating Tregs.  
CD25 The low affinity IL-2 receptor α chain may act as an IL-2 sink on 
Tregs, thus giving these cells regulatory potential by starving effector 
T cells of IL-2. CD25 is also markedly expressed on activated non-
suppressive T cells. 
CD39/CD73 Ectonucleotidases involved in the generation of extracellular 
adenosine, which may suppress effector T cell activation and effector 
function. CD73 has also mediates adhesion of lymphocytes to 
follicular dendritic cells and endothelial cells. 
LAP (TGF-β) The immunosuppressive cytokine TGF-β is synthesized as a large 
protein precursor and then secreted as a complex of TGF-β and LAP 
(latency-associated peptide), in which LAP associates with the 
mature TGF-β to prevent its activity. Cells expressing LAP appear to 
have suppressive function and it has been proposed as a marker for 
activated Tregs. 
GARP A receptor for latent TGF-β, GARP has been proposed to play a role 
in controlling various suppressor functions of Tregs. Tumour cells 
may also use GARP to express TGF-β or to capture TGF-β from 
their surroundings resulting in local suppression of anti-tumour 
immune responses or to induce Treg differentiation. 
ICOS The inducible costimulatory molecule is homologous to the CD28 / 
CTLA-4 proteins. It is expressed on TFH cells, TCR-activated T cells 
and Tregs, particularly amongst TILs, and is known to induce 
secretion of IL-10 and TGF-β. 
CD103 The αE integrin is primarily found on intestinal intraepithelial 
lymphocytes but is also expressed on a small subset on peripheral T 
cells and could denote T cells with a suppressive capacity. It is 
thought to play a role in T cell retention within mucosal tissues, such 
as the gut and skin. 
CD127 
 
The IL-7 receptor α chain has a role on regulating T cell 
development and proliferation, but appears to be downregulated 
specifically on peripheral Foxp3+ Tregs. 
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Table 1.1 Summary of common regulatory T cell markers and their function. 
Tregs have been shown to express a number of different markers and molecules that 
contribute to their function and/or delineation, reflecting their heterogeneous nature. 
A summary of many of these markers/molecules is given in the table above, including 
the purported function and expression in human T cells. 
Marker Function and Expression in Human T cells 
CTLA-4 
(CD152) 
Cytotoxic T lymphocyte antigen-4 is expressed predominantly on 
Foxp3+ Tregs and negatively regulates T cell-mediated immune 
responses through interaction with CD80 and CD86 present on 
antigen presenting cells. It can therefore play a role in the induction 
and maintenance of immunological tolerance and can suppress 
dendritic cell maturation and function. 
LAG-3 
(CD223) 
The CD4-homologue Lymphocyte Activation Gene-3 (CD223) is 
expressed on activated T cells and NK cells, as well as T regulatory 
cells. LAG-3 binds MHC class-II molecules, but with higher affinity 
than CD4. In association with the CD3 complex, LAG-3 can inhibit 
TCR-mediated signaling and regulate homeostatic T cell expansion.  
GITR Glucocorticoid-induced TNF receptor family-regulated gene is 
expressed on activated lymphocytes (upregulated by T cell receptor 
engagement) and by Tregs. GITR signaling has been shown to 
regulate T cell proliferation and TCR-mediated apoptosis. Once 
bound to the GITR-ligand, this serves to regulate the activation of 
Th1 cell subsets. 
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and extent of the immune response. In particular, identifying which mechanisms are 
used and in what context will be paramount to our further understanding of this 
heterogeneous T cell subset. 
A three-tiered model of Treg function has been proposed to differentiate the 
mechanisms of immunological suppression (Tang and Bluestone 2008). The first tier 
represents Tregs exerting homeostatic control over immune responses, initially in 
lymphoid organs to prevent the outgrowth of autoreactive T cells. When this steady-
state is breached, for example in the presence of heightened frequencies of self-
reactive effector T cells in autoimmune and transplantation settings, activated Tregs 
produce immunosuppressive cytokines and upregulate suppressive molecules, thereby 
engaging a second tier of ‘damage control’. Finally, infectious tolerance is established 
through the induction of adaptive Tregs, since tissue destruction presents tissue 
antigens leading to more immune cell activation and TGF-β production. In the colon, 
TGF-β causes dendritic cells to express CD103, which in turn, are able to induce 
naïve T cells to differentiate into adaptive Treg cells via the production of retinoic 
acid (Coombes, Siddiqui et al. 2007). Throughout these tiers, many mechanisms exist 
to prevent and terminate immune responses; Vignali and colleagues have grouped 
these mechanisms into four ‘basic modes of action’ (Vignali, Collison et al. 2008). 
These incorporate the suppression by inhibitory cytokines, suppression by cytolysis, 
suppression by metabolic disruption and suppression by modulation of dendritic cell 
maturation or function (summarized in Figure 1.2). 
 
1.2.5.1 Inhibitory Cytokines 
 
The inhibitory cytokines IL-10 and TGF-β have been associated with Treg 
activity in many studies, and are known to play a role in both preventing and causing 
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the pathogenesis of many diseases, including cancer. Initial support for the crucial 
role of TGF-β in regulating immune responses comes from studies in TGF-β 
knockout or TGF-β-receptor knockout mice. In both cases, mice develop a fatal 
autoimmune lymphoproliferative disease; further analysis of these mice reveals a 
normal phenotype and suppressive function of naturally occurring CD4+CD25+ Tregs, 
suggesting that TGF-β production by adaptive Tregs is responsible for the pathology 
(Lucas, Kim et al. 2000). Similarly, TGF-β deficient Foxp3+ Tregs could not prevent 
the development of colitis, demonstrating an essential role for Treg derived TGF-β in 
dampening immune responses in the colon (Li, Wan and Flavell 2007). 
A number of reports now demonstrate a role for membrane-bound TGF-β in 
mediating regulatory T cell function (Nakamura, Kitani et al. 2001; Ostroukhova, Qi 
et al. 2006). TGF-β is synthesized as a large protein precursor and then tethered to the 
cell membrane as a complex of TGF-β and LAP (latency-associated peptide) and 
LAP-expressing T cells are known to confer suppressive characteristics (Gandhi, 
Farez et al. 2010), consistent with the observation that Tregs inhibit via cell-to-cell 
contact. However, the phenotypic and functional relevance of LAP expression on T 
cells in human pathology is still to be fully researched, but current data suggests that 
soluble and/or membrane bound TGF-β is important for the function of Tregs and is 
implicated in tumour pathogenesis (Flavell, Sanjabi et al. 2010). 
Likewise, IL-10 is known to play a crucial role in many immunoregulatory 
processes. A key study to analyse the role of IL-10 in mediating Treg suppression was 
performed by generating mice that lacked the ability to produce IL-10, specifically in 
Foxp3+ Tregs (Rubtsov, Rasmussen et al. 2008). Although gut pathology was 
intensified in older mice, and heightened autoimmune responses in the lungs and skin 
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observed, no systemic autoimmunity was observed in these mice. This suggests that 
IL-10 derived from Foxp3+ Treg is necessary for immune homeostasis but may be 
restricted to the control of inflammatory responses at environmental and mucosal 
interfaces. In humans, a large number of putative, adaptive Treg subsets have been 
identified which express IL-10 in various settings (reviewed in (Fujio, Okamura et al. 
2010)). These include the aforementioned Tr1 cells, CD46-stimulated T cells, and IL-
10-secreting T cells induced by vitamin D3 and dexamethasone. However, assessing 
the detailed physiological function of these cells is difficult, because of the lack of 
specific markers that can reliably differentiate the population of IL-10-secreting Tregs 
from other T cells, although LAP, LAG-3 and NKG2D have been proposed as 
potential markers (Huang, Workman et al. 2004; Dai, Turtle et al. 2009; Gandhi, 
Farez et al. 2010). IL-10 can also be produced by activated, effector Th1 cells, 
demonstrating that many T cell subsets have the potential to limit an over exuberant 
immunological response (Anderson, Oukka et al. 2007). 
Another immunosuppressive cytokine, IL-35, has been shown to be required 
for the maximal suppressive activity of Treg in mice (Collison, Workman et al. 2007). 
However, another report published soon after demonstrated that human Tregs do not 
express detectable amounts of IL-35, suggesting that it does not play a role in Treg 
mediated suppression in humans (Bardel, Larousserie et al. 2008). This has recently 
been called into question, with some research now suggesting that Treg production of 
IL-35 converts suppressed target conventional T cells into IL-35-induced Tregs, 
contributing another mechanism to infectious tolerance (Chaturvedi, Collison et al. 
2011).  
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1.2.5.2 Cytolysis 
 
 A number of studies have associated regulatory function of CD4+CD25+ Tregs 
with their apparent cytotoxic activity via the secretion of granzymes A and B (Gondek, 
Lu et al. 2005; Zhao, Thornton et al. 2006). To date, this has only been demonstrated 
in mice, although these findings have been recapitulated by Cao et al., who showed 
that Tregs utilize granzyme B and perforin mediated killing to suppress the ability of 
NK cells and CD8+ T cells to clear allogeneic and syngeneic tumours (Cao, Cai et al. 
2007). Other cytolytic mechanisms associated with Treg suppressive activity include 
T cell apoptosis via galectin-1 production (Garin, Chu et al. 2007), lysis of antigen-
presenting B cells by Fas-FasL interactions (Janssens, Carlier et al. 2003) and 
perforin-dependent dendritic cell killing in tumour draining lymph nodes (Boissonnas, 
Scholer-Dahirel et al. 2010), although more work is required to understand cytolysis 
as a suppressive function of Tregs in different settings. 
 
1.2.5.3 Metabolic Disruption 
 
As previously described, the expression of CD25 by Tregs provides them with 
a competitive advantage for IL-2 over conventional T cells which only express CD25 
after TCR stimulation (Thornton and Shevach 1998). This ultimately results in 
cytokine deprivation-mediated apoptosis of conventional T cells, which require IL-2 
for maintenance of the expression of genes involved in the regulation of cell growth 
and metabolism (Pandiyan, Zheng et al. 2007). Whilst the suppressive function of 
murine Foxp3+ Tregs deficient of CD25 is not compromised in vitro, IL-2 signaling 
was found to be critical for maintaining the homeostasis and competitive fitness of 
Tregs in vivo (Fontenot, Rasmussen et al. 2005; Maloy and Powrie 2005).  
 32 
 
Other mechanisms found to disrupt conventional T cell metabolism include 
prostaglandin E2, which can be produced by Foxp3+ Tregs in humans. COX 
inhibitors and prostaglandin E2-receptor antagonists could reverse the suppression of 
effector T cell proliferation in vitro. (Yuan, Chen et al. 2010). Indeed, greater 
expression of Foxp3 in Tregs correlated with the expression of COX-2 and 
prostaglandin E2, thus it appears Foxp3 could control its production.  
The ectonucleotidase CD39 is expressed upon CD4+Foxp3+ Tregs (both 
CD25+ and CD25-) and functions by hydrolyzing exogenous ATP to ADP and 5’AMP, 
which is hydrolyzed further to adenosine by another ectonucleotidase, CD73 
(Borsellino, Kleinewietfeld et al. 2007). Adenosine nucleosides appear to inhibit the 
proliferation of conventional T cells in vitro and adenosine inhibitors are capable of 
reversing this suppression (Deaglio, Dwyer et al. 2007). In addition, intracellular 
cyclic adenosine monophosphate (cAMP) in naturally occurring Tregs play a key role 
in cell contact mediated suppression, whereby cAMP is transferred from Tregs into 
activated target CD4+ T cells and/or antigen-presenting cells via gap junctions to 
suppress CD4+ T cell function (Bopp, Becker et al. 2007; Bodor, Bopp et al. 2012). 
 
1.2.5.4 Dendritic Cell Targeting 
 
As well as targeting effector cells directly, Tregs can also modulate dendritic 
cell (DC) function, by suppressing antigen presentation and cytokine production 
required for the activation of effector T cells. Intravital microscopy has demonstrated 
that Tregs directly interact with DCs and are also able to reduce the period of 
interaction between effector T cells and DCs (Tadokoro, Shakhar et al. 2006; Tang, 
Adams et al. 2006). It was proposed that effector T cell function was attenuated due to 
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interactions between DCs and Tregs via the costimulatory molecule, cytotoxic T 
lymphocyte antigen-4 (CTLA-4). Indeed, CTLA-4 may be important for maximal 
regulatory T cell function but can also be upregulated by activated T cells to provide a 
negative signal thus limiting maximum activation potential (Greenwald, Boussiotis et 
al. 2001). Furthermore, CTLA-4-deficient Tregs are unable to suppress effector T 
cells since they cannot confer the necessary inhibitory signals to DCs in order to 
affect T cell activation (Oderup, Cederbom et al. 2006).  
Another molecule capable of blocking DC maturation and function is the CD4 
homologue and negative immunomodulator lymphocyte activation gene-3 (LAG-3 / 
CD223). LAG-3 binds MHC class-II molecules with higher affinity than CD4, has a 
negative intrinsic function and has been shown to be required for maximal Treg 
suppression (Huang, Workman et al. 2004; Workman 2004). Binding of LAG-3 to 
MHC class-II molecules expressed by immature DCs induces an immunoreceptor 
tyrosine-based activation motif (ITAM)-mediated inhibitory signaling pathway that 
suppresses DC maturation and their effector T cell stimulatory capacity (Liang, 
Workman et al. 2008). Interestingly, LAG-3 expression has been noted on a 
population of intratumoural T cells with direct suppressive effects on CD8+ T cells 
(Gandhi, Lambley et al. 2006; Camisaschi, Casati et al. 2010). Exhausted and 
tolerised TILs also express LAG-3, further contributing to tumour-mediated 
immunosuppression (Woo, Turnis et al. 2012). 
Neuropilin-1 (CD304) has been associated with increasing the interaction time 
between Tregs and DCs (Sarris, Andersen et al. 2008). Given that neuropilin-1 
expression is confined mostly to Tregs, this is likely to give Tregs an advantage over 
conventional T cells, leading to a "default" suppression of immune responses in the 
absence of "danger signals" (Mizui and Kikutani 2008). Thus, it seems an 
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immunological balance exists between DCs and Tregs whereby Tregs can modulate 
DC phenotype and function, and DCs drive the differentiation of Foxp3+ Tregs in 
order to control immune responses. Neuropilin-1 has also been proposed as a marker 
for thymic-derived Tregs (Yadav, Louvet et al. 2012), correlating with the expression 
of Helios amongst murine T cells. However, this finding is not recapitulated in 
humans (Milpied, Renand et al. 2009). 
 
1.3 Colorectal Cancer 
 
1.3.1 Incidence, Aetiology and Prevention 
 
Colorectal cancer (CRC) is the second and third most commonly diagnosed 
malignancy in females and males, respectively, with 1.2 million individual diagnoses 
and over 600,000 deaths worldwide each year (Jemal, Bray et al. 2011). In the Cardiff 
and Vale NHS Trust (covering a population of ~500,000) there are over 250 newly 
diagnosed cases each year.  
The incidence of CRC is far higher in economically developed countries than 
in developing countries, reflecting differences in environmental factors such as diet 
and lifestyle (Magalhaes, Peleteiro et al. 2012). In particular, a high intake of red and 
processed meat, most commonly associated with a western diet, significantly 
increases the risk of developing colon cancer, but not rectal cancer. How this occurs is 
still under scrutiny; a possible explanation comes from the formation of endogenous 
N-nitroso compounds under alkaline conditions in the gut. These compounds are 
typical breakdown products of haem found in red meats, but not white meat and fish, 
and likely contribute to DNA damage amongst epithelial cells (Kuhnle and Bingham 
2007). No genetic predisposition is noted in the majority of CRC cases. However,   
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Figure 1.2 Mechanisms of suppression mediated by Treg. The mechanisms of 
suppression utilised by Tregs can be divided into four functional groups: suppression 
by inhibitory cytokines; cytolysis of target cells; suppression by metabolic disruption; 
and suppression by targeting dendritic cells. 
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most invasive colorectal tumours are thought to begin as polyps that grow on the 
inner lining of the colon or rectum. Regular colonoscopy screening tests can identify 
and remove polyps before they become cancerous. However, certain genetic 
abnormalities can lead some individuals to produce excessive numbers of colonic 
polyps; specific genetic syndromes, such as familial adenomatous polyposis (FAP), 
Lynch syndrome and Peutz-Jeghers syndrome, therefore increase the risk for 
developing CRC. In particular, mutations or deletion of the tumour suppressor gene 
APC (Adenomatous Polyposis coli) in humans leads to the development of FAP, but 
can also be responsible for other sporadic cases of CRC (Groden, Thliveris et al. 
1991); virtually all individuals with FAP develop CRC by the age of 40. This gene 
has also been exploited in the APCmin mouse model to study the causes and 
development of adenomas. 
CRC is also more common amongst individuals suffering from inflammatory 
bowel diseases such as ulcerative colitis and Crohn’s (Triantafillidis, Nasioulas et al. 
2009). A number of reports now provide strong evidence linking the use of chronic, 
low doses of non-steroidal anti-inflammatory drugs, such as aspirin, to prevent the 
growth of polyps and CRC (Thun, Jacobs et al. 2012). Such findings implicate a 
detrimental role for inflammation in colorectal tumourigenesis.  
 
1.3.2 Initiation and Development of Colorectal Adenocarcinomas 
 A number of factors affect the development of dysplastic adenomas, generally 
arising from submucosal colonic polyps, into adenocarcinomas that invade through 
the muscularis mucosae. Genetic mutations in genes such as APC, KRAS and TP53 
can accumulate amongst epithelial cells, resulting in chromosomal instability, 
microsatellite instability and DNA hypermethylation, which may further contribute to 
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tumourigenesis through transcriptional silencing of tumour-suppressor genes (Jones 
and Baylin 2002; Triantafillidis, Nasioulas et al. 2009). It has recently been proposed 
that such mutations also compromise junctional protein and mucus production by 
epithelial cells, allowing bacteria to translocate into the lamina propria. This triggers a 
local inflammatory response, activating myeloid cells, which in turn, causes a 
skewing in the cytokine profile of neighboring T cells (Grivennikov, Wang et al. 
2012; Gallimore and Godkin 2013) (Figure 1.3). Production of interleukin-17 by these 
T cells is thought to drive proliferation, invasion and survival of the aberrant 
epithelial cells via STAT3 activation, leading to the onset of invasive carcinoma and 
further compromising barrier integrity. Thus, genetic mutations in epithelial cells, 
mucosal integrity, microbiota, and inflammation all play a role in the pathogenesis of 
CRC. 
1.3.3 Colorectal Cancer Stem Cells 
 Following the initiation of colorectal carcinogenesis, the types of cells that 
propagate tumours remain unknown. Traditional stochastic models suggest that every 
cell within the tumour population is capable of tumour initiation and propagation. 
However, this has now been challenged by the recent identification of cancer stem 
cells, defined as the only cell type within tumours that can promote its growth and 
metastatic spread (reviewed in (Vaiopoulos, Kostakis et al. 2012)). Self-renewal, 
multipotency, limitless proliferation potential, angiogenic, and immune evasion 
features characterise cancer stem cells. In particular, colorectal stem cells have been 
defined by the expression of CD133, a transmembrane glycoprotein implicated in the 
organisation of the plasma membrane (Ricci-Vitiani, Lombardi et al. 2007). Only a 
small subset of CD133+ cells was capable of initiating tumour growth in 
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immunodeficient mice, while negative cells were not. Since this work, CD133 
expression has been independently correlated with stem cell potential, worse 
prognosis and low survival in colon cancer (Horst, Kriegl et al. 2008). 
1.3.4 Metastasis and the Pre-Metastatic Niche 
 Whilst the epithelial-to-mesenchymal transition and the breakdown of cell-cell 
adhesion forms an integral part of the metastatic potential of colorectal cancer stem 
cells, it has been suggested that primary tumour cells orchestrate the genetic 
regulation and activation of specific chemokines and proteases in order to direct 
metastasis to a designated organ (Kaplan, Rafii et al. 2006). The increased expression 
of CXCL1 and matrix metalloproteinases-1 and-9 appear to precede metastasis, 
forming the foundations of creating a pre-metastatic niche (Minn, Gupta et al. 2005). 
Interestingly, compromised immunosurveillance via the increased infiltration of pro-
inflammatory myeloid cells appears to be a novel mechanism through which primary 
tumours can also create favourable niches in secondary organs (Yan, Pickup et al. 
2010). 
 
1.3.5 Treatment of Colorectal Cancer 
 
For individuals diagnosed with a primary localized tumour, a colectomy to 
remove the tumour mass and surrounding tissue is performed, typically via 
laparoscopic resection of the afflicted colon. In many cases, surgery is curative, 
however, 40-50% of these patients will relapse or die from metastatic disease. 
Treatment of advanced metastatic colorectal cancer has evolved considerably in the 
last decade; the introduction of tailored treatment (e.g. cetuximab, targeting the 
epidermal growth factor receptor expressed in ~80% metastatic colorectal tumours, 
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and bevacizumab which inhibits the action of vascular endothelial growth factor) and 
combination chemotherapy (e.g. FOLFOX, a combination of 5-Fluorouracil, 
oxaliplatin and leucovorin – drugs which block DNA synthesis and replication) has 
significantly enhanced patient survival (Segal and Saltz 2009). However, these 
regimes are not curative and are only recommended to reduce symptoms and prolong 
survival. For this reason, other treatments are sought. One of the most exciting 
avenues of research, with significant future potential, centers on utilizing the immune 
system to help treat cancer (see Discussion Chapter 5). 
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Adapted from (Gallimore and Godkin 2013). 
 
Figure 1.3 Bacterial translocation can lead to gut inflammation and cancer 
progression. Genetically mutated epithelial cells, which may develop into colonic 
polyps and invasive adenocarcinomas, can become compromised in their ability to 
keep gut microbiota away from the lamina propria, since mucus production and 
junctional proteins are not formed sufficiently. This leads to a pro-inflammatory 
response whereby bacterial products stimulate toll-like receptors (TLRs). TLR 
activation causes myeloid cells to produce IL-23 in the mucosa, which has the notable 
downstream effect of causing T cells to produce IL-17. This skewed T cell cytokine 
profile is known to contribute to the progression of CRC and indeed, higher levels 
have been associated with a poorer prognosis (Tosolini, Kirilovsky et al. 2011). 
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1.4 T cells and Colorectal Cancer 
 
1.4.1 Tumour Infiltrating Immune Cells 
In 1931, American oncologist William MacCarty reported fifteen factors 
governing prognosis in the cancer patients he treated. The most compelling 
observation was that excised tumours with greater immune cell infiltrates would lead 
to an improved clinical outcome for that patient (MacCarty 1931). One of the first 
studies to formally identify the degree of tumour immune cell infiltration with patient 
prognosis was published in 1989 by Clark and colleagues. In their studies on 
melanoma tumour tissue, patients with a moderate-to-marked lymphocytic infiltrate 
within their primary melanoma had an 8-year survival rate of 88.5%, in comparison to 
59.3% in patients with a sparse or absent lymphocytic infiltrate (Clark, Elder et al. 
1989). Similar findings have since been obtained when analyzing ovarian (Zhang, 
Conejo-Garcia et al. 2003), head and neck (Shibuya, Nugyen et al. 2002), breast 
(Marrogi, Munshi et al. 1997), lung (Ito, Suzuki et al. 2005), prostate (Vesalainen, 
Lipponen et al. 1994) and colorectal (Ropponen, Eskelinen et al. 1997) carcinomas. 
 
With the advent of monoclonal antibodies to accurately identify distinct cell 
types, it soon became clear that virtually all tumours contained immune cells to some 
degree, ranging from subtle infiltrations to gross inflammations (Pages, Galon et al. 
2010). In particular, the identification of CD3+ T cell infiltrates appeared to correlate 
most strikingly with disease outcome. In a seminal study analysing 490 colorectal 
tumour specimens for the type, density and location of immune cells, patient outcome 
could be significantly correlated to the degree of CD3+CD45RO+ T cell infiltration 
(Galon, Costes et al. 2006). Most striking was the observation that T cell infiltration 
was a better identifier of patient outcome than histopathological tumour grading. 
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Patients who presented with a more advanced TNM stage III tumour would actually 
have the same outcome as a TNM stage I patient if the tumour was readily infiltrated 
by T cells; conversely, a stage I patient with low levels of infiltrating T cells had an 
equally poor prognosis as a stage III patient. These results suggest that immune cells 
can actively control tumour recurrence and reduce metastatic potential, lending 
support to the hypothesis that the adaptive immune response can positively influence 
tumour control. 
Given that the degree of immune cell infiltration into the colorectal tumour is 
a better prognostic indicator than histopathological staging, a taskforce has recently 
been established to include immunological biomarkers when classifying the excised 
tumour to facilitate stratification of patient treatment; this ‘Immunoscore’ involves 
harmonising immunohistochemical analysis of tumours to minimise variation (Galon, 
Franck et al. 2012).  
 
1.4.2 Colorectal Tumour-Associated Antigens 
 One mechanism by which CRC patients may control their tumour is through 
direct recognition of epitopes derived specifically from tumour cells. 5T4 and CEA 
are oncofoetal glycoproteins that are markedly upregulated in the vast majority of 
colorectal adenocarcinomas but rarely on normal tissues, making them excellent 
targets for cancer immunotherapy and to study anti-tumour immune responses 
(Benchimol, Fuks et al. 1989; Starzynska, Rahi et al. 1992). 5T4 is not thought to be 
expressed on normal adult tissues, however, CEA is an autoantigen expressed at low 
levels in normal intestinal epithelium. Upregulation of both antigens forms an 
integrated component of the epithelial-to-mesenchymal transition, a process important 
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during embryonic development and metastatic spread of epithelial tumours, as 
discussed previously (Southgate, McGinn et al. 2010). 
 
1.4.3 Anti-tumour T cell Responses in CRC patients  
Several lines of research have now reported that both cancer patients and 
healthy individuals seem capable of producing readily detectable tumour-specific T 
cell responses to a number of tumour antigens, Our lab has previously characterised 
ex vivo effector Th1 responses to 5T4 and CEA in CRC patients, whereby IFN-γ is 
produced in response to tumour-antigen pulsed APCs (Clarke, Betts et al. 2006; Betts, 
Jones et al. 2012). In a five-year follow-up study analysing the effect of pre-operative 
CEA and 5T4-specific T cell responses, anti-CEA responses, but not anti-5T4 
responses, were significantly associated with tumour recurrence, underlying the need 
to better characterise anti-tumour immune responses (submitted manuscript, see 
Appendix). Tumour-specific T cell responses are also significantly enhanced after the 
depletion of CD25+ Tregs, as others have previously found (Danke, Koelle et al. 
2004; Elkord, Burt et al. 2008). Thus, it seems Tregs have the potential to recognise 
tumour antigens, which are predominantly self-antigens, and suppress anti-tumour / 
anti-self responses. In one study, it appears that the repertoire of tumour antigens 
recognised by Tregs differs from those recognised by effector memory T cells in the 
majority of CRC patients (Bonertz, Weitz et al. 2009). In addition, depletion of Tregs 
in vitro only augmented effector T cell responses specific for the same epitope, thus 
detailed mapping of effector and regulatory T cell epitopes for a specific tumour 
antigen holds significant promise for future peptide based immunotherapies, and will 
be explored in more detail in this thesis.  
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An important question is whether tumour-specific T cells reside in, and are 
functional within the tumour. Currently, no studies have identified tumour-specific T 
cell responses from T cells isolated from colorectal tumours. Indeed the presence of 
highly restricted clonal T cell expansions in colorectal cancer is questionable given 
that a comparison of the TCR-Vβ repertoire restriction in the blood, colon and tumour 
tissue of CRC patients identified comparable restrictions, suggesting that colorectal 
tumours may not selectively recruit tumour-specific T cells (Ochsenreither, Fusi et al. 
2010). This is in distinct contrast with melanoma, which is considered a more 
immunogenic cancer given the number of tumour-specific T cells and high degree of 
TCR repertoire restriction within the tumour (Thor Straten, Schrama et al. 2004). 
However, TCR repertoire restriction was higher in the blood of CRC patients than in 
healthy controls, suggesting there is a degree of clonal expansion of tumour-specific T 
cells in the periphery that may also reflect the constituent cells of colorectal tumours. 
The clinical impact of different classes of colorectal tumour-infiltrating T cells 
has also been assessed through the identification of functional clusters of genes 
associated with Th1 (Tbet, IRF-1, IL-12Rb2, STAT-4), Th2 (IL-4, IL-5, IL-13), Th17 
(RORC, IL-17A) and cytotoxicity (Granulysin, Granzyme B, Perforin) in 125 tumour 
specimens (Tosolini, Kirilovsky et al. 2011). The results of this study unequivocally 
identified patients with high expression of Th1 and cytotoxic cluster genes with 
prolonged disease-free survival. This data, coupled with the findings that a higher 
infiltrate of CD3+ T cells correlates with disease-free survival (Galon, Costes et al. 
2006), demonstrates how vital an effector T cell response can be in targeting 
cancerous tissue. However, the antigen specificity of these cells remains unknown.  
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1.4.4 Immunosuppressive Tumour Microenvironment 
 
Although T cell responses can be effective at destroying tumour cells in 
certain cases, efficacy appears to be limited by the immunosuppressive influences of 
the tumour microenvironment. Enhanced expression of inhibitory molecules, e.g. PD-
L1 and CD200R, has been reported on human malignancies and in multiple cases has 
been associated with enhanced metastatic potential and poor clinical outcome (Rygiel 
and Meyaard 2012; Topalian, Drake et al. 2012). This fits with the concept of 
adaptive resistance via immunoediting, where tumour cells may escape immune 
surveillance by expressing these ligands, survive, and grow out. 
 
It is well established that colorectal cancer, like most human cancers, induces 
an increase in the frequency and proportion of regulatory T cells in peripheral blood 
and tumour infiltrating lymphocytes, as defined by Foxp3 expression amongst CD4+ 
T cells (Ling, Pratap et al. 2007). This increased Treg frequency is associated with 
poor prognosis and progression of colorectal cancer due to Treg-mediated suppression 
of anti-tumour immunity (Betts, Jones et al. 2012). Increased intratumoural Treg 
frequencies have also been noted in latter stages of ovarian cancer (Curiel, Coukos et 
al. 2004), indicative of a role for Tregs in tumour progression, although results in 
colorectal cancer remain inconclusive and disputed. For example, accumulations of 
Foxp3+ Treg in colorectal tumours, as evaluated by immunohistochemistry, are not 
always associated with a poor prognosis ((Loddenkemper, Schernus et al. 2006; 
Salama, Phillips et al. 2009) and unpublished findings from our own lab).  
 
One plausible reason why Tregs may be associated with a good outcome 
comes from microarray analysis of tumour tissue, identifying that higher levels of 
Th17-related cytokines can be overtly detrimental to host survival. Th17 cells usually 
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arise in response to intestinal bacteria (where they exert a pro-inflammatory response) 
and reside in gut-associated lymphoid tissue. Within colorectal tumours, it has been 
hypothesized that Foxp3+ Tregs regulate the production of IL-17 from Th17 cells, 
thus limiting inflammation and corresponding tumour progression, as discussed 
earlier (Whiteside 2012). However, since Tregs are also positively correlated with 
effector Th1 cell infiltrates, the positive impact of Tregs could just reflect a 
heightened, more potent anti-tumour immune response. 
 
 These findings remain controversial, however, since Tregs have commonly 
been associated with suppression of anti-tumour immune responses. A previously 
discussed mechanism of Treg suppression of immune responses is via the release of 
regulatory cytokines. Tumour infiltrating Tregs from numerous murine and human 
carcinomas are found to produce TGF-β and IL-10, and are known to inhibit anti-
tumour immune responses by suppressing CD4+ IFN-γ production and CD8+ T cell 
cytotoxicity (Jarnicki, Lysaght et al. 2006; Strauss, Bergmann et al. 2007). Within 
colorectal tumours, very few functional studies have been carried out to determine 
Treg function, however, one paper has made an attempt to answer this and found 
CD4+CD25+ TILs to suppress effector T cells in vitro (Kryczek, Liu et al. 2009). 
Clearly more work is required to decipher the role of colorectal tumour infiltrating T 
cell subsets in the disease pathogenesis. 
 
1.5 Summary 
 
Anti-tumour T cell responses in CRC patients. 
The existence and function of tumour-specific effector T cells is crucial to patient 
outcome. Currently, very little is known about the kinetics of an anti-tumour T cell 
response, and an in depth understanding is paramount to maximise the efficacy of 
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cancer vaccines utilising tumour-specific antigens to prime effector immune 
responses. In addition, evidence for cancer immunosurveillance occurring in humans 
is lacking, thus tumour antigen-specific Th1 and Treg responses were analysed in a 
cohort of healthy and age-matched donors in an effort to compare an individuals 
ability to mount an anti-tumour immune response. Finally, CRC patients were also 
examined for tumour-specific immunosuppression, and attempts made to reverse 
regulatory T cell involvement in cancer with concurrent tumour-specific T cell 
stimulation, utilising novel therapies in metastatic CRC patients. 
!
Phenotypic and functional characterisation of colorectal tumour infiltrating T cells. 
In order to design and direct anti-tumour therapies for maximal efficacy, it is of 
utmost importance to understand the network of biological interactions within the 
tumour microenvironment itself, with a particular focus on the suppressive 
mechanisms inhibiting anti-tumour immunity. A comprehensive overview of the 
phenotypic and functional characteristics of colorectal TILs will allow a greater 
understanding of the complex nature of T cell heterogeneity within the tumour, 
guiding and developing new drug treatment targets to diminish suppression and 
augment effective anti-tumour responses. The experiments described in this thesis 
aimed to establish the fundamental characteristics of T cells residing within the 
tumour, comparing these to corresponding cell subsets found in the colon and 
peripheral blood. 
 
1.6 Research Questions 
1) Can oncofoetal-antigen (5T4) specific CD4+ T cell responses in colorectal 
cancer patients predict clinical outcome? Previous work has identified that 5T4-
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specific T cells exist in CRC patients, but it is not known if cultured CD4+ T cell IFN-
γ / IL-10 responses correlates with tumour burden or disease outcome. These 
responses will be analysed in a cohort of CRC patients to determine whether the 
presence and magnitude of tumour-specific T cell responses could predict outcome 
and assess its potential as a disease biomarker. 
2) Do oncofoetal-antigen (5T4) specific T cell responses exist in healthy 
individuals? Currently, there is paucity in our understanding as to the existence of T 
cells specific for oncofoetal antigens, and whether their presence in tumour-free 
individuals could represent a mechanism of immunosurveillance. In addition, the 
effect of age, gender and HLA-type on these responses is not known and will be 
analysed. 
3) To what extent do regulatory T cells impinge on anti-tumour immune 
responses? Increased proportions of regulatory T cells have been reported in 
colorectal cancer patients, but their effect on suppressing anti-tumour immune 
responses remains largely unknown. The effect of Treg depletion on 5T4 T cell 
responses will be examined both in vitro and in vivo, using low-dose 
cyclophosphamide, to determine whether T cell-based anti-tumour immunity can be 
enhanced, leading to superior tumour control.  
4) How do colorectal tumour-derived T cells differ in their phenotype and 
function to T cells located in the colonic mucosa or peripheral blood? A detailed 
phenotype and function of colorectal tumour infiltrating T cell subsets is currently 
lacking in the scientific literature. Such knowledge is fundamental to our 
understanding of how certain T cell subsets perform distinct functions and how these 
might be manipulated to enhance cancer immunotherapies. 
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Chapter 2 – Materials and Methods 
 
2.1 Colorectal Cancer Patients 
 
Patients presenting with an operable primary colorectal adenocarcinoma were seen by 
a consultant surgeon for resection of the affected colon. At pre-operative assessment, 
no more than seven days prior to surgery, the patient was consented in order to obtain 
specimens for use in this research (see Appendix section for copy of patient 
information sheet and consent form) and 30-40 mls of blood collected. Where possible, 
blood was sent for HLA typing (Welsh Transplantation and Immunogenetics 
Laboratory, Pontyclun, Cardiff). In some instances, patients were followed up at 
various time points after the operation to determine rates of tumour recurrence. In total, 
a cohort of 69 CRC patients were enrolled; cultured T cell responses were analysed in 
27 of these patients (patient characteristics summarized in Table 2.1) and TIL analysis 
on tumour samples was performed from 33 patient samples (patient characteristics 
summarized in Table 2.2). A number of samples were analysed in both studies; some 
patient samples were used to set up and validate experimental methods and are not 
included in compiled results. The Bro Taf Local Research Ethics Committee granted 
ethical approval for this study. 
 
2.1.1 Obtaining Patient Specimens 
 
Following resection of the diseased bowel, specimens were taken to the pathology 
department for analysis. Here, a small section of the tumour was cut from the 
specimen, derived from the luminal aspect of the specimen so as not to interfere with 
the deep, invasive part of the tumour required for routine histopathological assessment.  
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Table 2.1 CRC patient characteristics where cultured 5T4 T cell responses have 
been analysed. 
 
    Male Female 
n 
 
16 11 
        
Age (Range) 
 
69 (38-86) 75 (49-90) 
        
Tumour Location (%) Ascending 2 (13) 6 (55) 
  Transverse 0 (0) 1 (9) 
 
Descending 1 (6) 1 (9) 
  Sigmoid 4 (25) 3 (27) 
 
Rectum 9 (56) 0 (0) 
        
TNM Stage, 5th Edition (%) T1 3 (19) 1 (9) 
  T2 3 (19) 3 (27) 
 
T3 9 (56) 5 (45) 
  T4 1 (6) 2 (18) 
(Lymph Node Spread) N0 9 (56) 5 (45) 
  N1 5 (31) 2 (18) 
 
N2 2 (13) 4 (36) 
        
Dukes’ Stage (%) A 6 (38) 2 (18) 
  B 3 (19) 3 (27) 
 
C1 7 (44) 3 (27) 
  C2 0 (0) 3 (27) 
 
D 0 (0) 0 (0) 
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Table 2.2 CRC patient characteristics where tumour-infiltrating lymphocytes 
have been analysed. 
 
    Male Female 
n 
 
22 11 
    Age (Range) 
 
69 (38-86) 76 (49-88) 
    Tumour Location (%) Ascending 2 (9) 5 (45) 
 
Transverse 0 (0) 1 (9) 
 
Descending 1 (5) 1 (9) 
 
Sigmoid 6 (27) 3 (27) 
 
Rectum 13 (59) 1 (9) 
    TNM Stage, 5th Edition (%) T1 3 (14) 2 (18) 
 
T2 7 (32) 2 (18) 
 
T3 11 (50) 5 (45) 
 
T4 1 (5) 2 (18) 
(Lymph Node Spread) N0 15 (68) 5 (45) 
 
N1 5 (23) 2 (18) 
 
N2 2 (9) 4 (36) 
    Dukes’ Stage (%) A 9 (41) 2 (18) 
 
B 6 (27) 3 (27) 
 
C1 7 (32) 3 (27) 
 
C2 0 (0) 3 (27) 
 
D 0 (0) 0 (0) 
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Autologous colon samples were also cut from a macroscopically normal section of the 
excised tissue, at least 10 cm from the tumour. In some cases, easily identifiable 
lymph nodes present in the mesentery proximal to the colorectal tumour were also 
obtained. Samples of placenta were obtained from women undergoing elective 
Caesarian sections and small samples of inflamed colon from patients with Crohn’s 
disease or ulcerative colitis were obtained from resected colon specimens. Informed 
consent was obtained from all participants. In most cases, samples were dissected and 
taken back to the lab within 30 minutes of the specimen being resected from the 
patient.  
 
2.1.2 Histopathological Tumour Grading 
 
Colorectal tumours were analysed for overall size, invasive status and lymph node 
involvement, confirmed by consultant pathologists at the University Hospital of Wales 
and University Hospital Llandough, Cardiff. Each specimen was then graded, 
depending on certain parameters, for Dukes’ classification and TNM staging, as 
follows: 
 
 Dukes’ A: Invasion into but not through the bowel wall. 
 Dukes’ B: Invasion through the bowel wall; no lymph node involvement. 
 Dukes’ C1: Extending into muscularis propria; local lymph nodes involved. 
Dukes’ C2: Penetrating through muscularis propria; local and Apical lymph 
nodes involved.  
 
 
T(1-4): Size or direct extent of the primary tumour. 
T1: Tumour no more than 2cm across (invades submucosa). 
T2: Tumour more than 2cm but no more than 5cm across (invades 
muscularis propria). 
T3: Tumour greater than 5cm across (invades into serosa). 
T4: Tumour has grown into adjacent tissues. 
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 N(0-2): Degree of lymph node involvement. 
N0: No spread to regional lymph nodes. 
N1: 1-3 regional lymph nodes involved. 
N2: 4+ regional lymph nodes involved. 
 
M(0/1): Presence of metastasis.  
 M0: No metastatic spread. 
 M1: Distant metastases. 
 
2.1.3 TaCTiCC Clinical Trial 
 
CRC patients with inoperable, metastatic, stable disease were enrolled on the phase II 
clinical trial, TaCTiCC. The aim of the trial was to assess the efficacy of using low-
dose cyclophosphamide alongside vaccination with a modified vaccinia Ankara based 
vaccine containing the tumour antigen, 5T4, named TroVax® (Oxford BioMedica). 
Briefly, there were four arms to this trial: no treatment, TroVax® alone, low-dose 
cyclophosphamide alone and TroVax® plus low-dose cyclophosphamide. Patients 
were consented as per the trial protocol. Peripheral blood samples were assessed for 
effective Treg depletion and 5T4 T cell responsiveness, with the primary objective of 
determining whether such treatment results in an increased magnitude of anti-5T4 
immune responses at week 7. A flowchart detailing the patient treatment regime by 
group is included in the Appendix section. 
 
2.1.4 Healthy Donor and Age-Matched Controls 
 
Blood was collected from healthy donors in the lab and also from age-matched 
controls with no history or clinical evidence of malignancy. All donors were consented 
before obtaining 20-50 ml blood samples. In all cases, samples were sent for HLA 
typing.  
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2.2 Lymphocyte Isolation 
 
2.2.1 Preparation of Single Cell Suspensions from Tissues 
 
Tumour and colon samples were minced with blades in a Petri dish and forced through 
70 µm cell strainers to collect a single cell suspension. Cells were centrifuged twice in 
extraction media (IMDM + 2% AB serum, 20 µg/ml gentamicin, 2 µg/ml 
amphotericin B + 1X Pen/Strep, L-glutamine and sodium pyruvate) before plating for 
further use. In no instances were samples subjected to enzymatic dissociation, e.g. 
with collagenase / DNase.  
 
2.2.2 Ficoll Separations 
 
PBMCs were isolated by layering whole blood over Lymphoprep (Axis-Shield, Oslo, 
Norway) before centrifugation at 2000 rpm for 20 mins at RToC, with no brake. The 
PBMC layer was extracted using a Pasteur pipette and subsequently washed twice in 
R+ (RPMI 1640 + 1X Pen/Strep, L-glutamine and sodium pyruvate). Cells were 
enumerated using a haemocytometer under a light microscope by mixing 20 µl of cell 
suspension 1:1 with Trypan blue.  
 
2.2.3 Colon / Tumour Infiltrating Lymphocyte Extraction 
 
To isolate lymphocytes from epithelial or tumour cell fractions, single cell suspensions 
from each sample were resuspended in 5 mls extraction media. A discontinuous Ficoll 
density gradient was then created by layering 10 mls of 75% Ficoll (diluted in RPMI) 
over 10 mls 100% Ficoll in a falcon tube before slowly layering the cell suspension on 
top, as previously described (Whiteside, Miescher et al. 1986) and shown (Figure 2.1).  
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Figure 2.1 Isolation of lymphocytes from colorectal tumour specimens. CRC 
samples were mashed and forced through cell-strainers to obtain a single-cell 
suspension. This was washed and resuspended in 5ml extraction media, before being 
layered onto a discontinuous ficoll gradient, as shown above. After centrifugation, two 
distinct bands are formed where tumour cells and lymphocytes have separated based 
on their size and densities.  
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Samples were centrifuged at 2000 rpm for 20 mins at RToC, with no brake. The 
lymphocyte layer was extracted using a Pasteur pipette and subsequently washed twice 
in R+. Cells were enumerated using a haemocytometer by mixing 20 µl of cell 
suspension 1:1 with Trypan blue.  
 
2.2.4 CD4+CD25+ MACS Regulatory T cell Isolation 
 
To isolate CD4+CD25+ regulatory T cell fractions, PBMC were resuspended in MACS 
buffer and CD4+ cells were negatively selected by adding 10 µl biotin-antibody 
cocktail followed by 20 µl anti-biotin microbeads per 107 PBMC in a total reaction 
volume of 100 µl MACS buffer (1x PBS, 0.5% BSA, 5 mM EDTA). Non-CD4+ cells 
were then depleted by running the cell suspension through a large depletion (LD) 
column, as per manufacturer’s instructions (Miltenyi Biotec). To isolate the CD25+ 
and CD25- fractions from the CD4+ cell fraction, cells were incubated with 10 µl of 
CD25 Microbeads II in 90 µl MACS buffer per 1x107 cells and incubated for 15 
minutes at 4oC. A positive selection (MS) column was subsequently used and both the 
effluent (CD25-/lo cells) and the CD25hi cells in the column were collected. Cells were 
washed twice with R+ before further use.  
 
2.2.5 CD25 / CD45RO Depletion Using MACS Beads 
 
CD25hi cells were depleted from whole PBMC using CD25 Microbeads II by 
incubating 1x107 PBMC with 10 µl of CD25 Microbeads II in 90 µl MACS buffer for 
15 minutes at 4oC. An LD column was used and the effluent (CD25-/lo PBMC fraction) 
collected. The effectiveness of depleting CD4+CD25+Foxp3+ Tregs using this 
method is demonstrated (Figure 2.2). For CD45RO+ T cell depletion, PBMC were 
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initially cultured with a PE-conjugated CD45RO antibody for 20 minutes at 4oC. 
PBMCs were then washed twice and incubated with anti-PE microbeads for 15 
minutes at 4oC before running down an LD column. The collected effluent of 
CD45RO- PBMC was washed, enumerated and checked for purity by FACS before 
use in assays.  
 
2.2.6 Fluorescent Activated Cell Sorting 
 
For functional studies, live PBMCs were sorted into effector (CD4+CD25-) and 
regulatory (CD4+CD25hiCD127lo) T cell subsets using the monoclonal antibodies 
listed in Table 2.9.4. Various CD4+ T cell subsets were sorted from colon and tumour 
specimens using a modified FACSAria II flow cytometer (BD Biosciences) or a Dako 
Cytomotion MoFlo (Beckman Coulter). Cell fractions were stained with fluorescent 
conjugated antibodies for 15 minutes at 4oC in a total reaction volume of 40 µl of 
FACS buffer (1x PBS, 2% FCS, 5 mM EDTA) and filtered through 70 µm cell 
strainers before running samples. Gating strategies and cell purities are demonstrated 
(Chapter 4).  
 
2.3 Freeze / Thaw PBMCs 
 
Isolated PBMCs were counted then resuspended at a concentration of 5x106/ml in 
freezing media (90% FCS, 10% DMSO). 1ml aliquots of the sample were prepared 
and placed in Mr Frosty freezing containers (Nalgene), which provide a cooling rate of 
-1oC /minute when placed in a -80oC freezer. After 24-48 hours at -80oC, vials were 
transferred to liquid nitrogen tanks for long-term storage.  
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Figure 2.2 CD25 depletion using MACS beads and an LD column. The 
effectiveness of depleting CD25+ T cells from CD4+ was assessed by FACS. 
Corresponding levels of Foxp3 expression demonstrates the removal of the vast 
majority of CD4+CD25+Foxp3+ Tregs prior to experimental use.  
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To thaw samples, vials were taken from liquid nitrogen and placed straight into 
a water bath set to 37oC. Once the sample had almost completely thawed, a P1000 
pipette was used to add the sample to pre-warmed R+ in a drop-wise fashion, to 
minimize oxidative stress on the cells. Cells were washed twice before use and 
counted. In general, a return of >70% viable cells was achieved.  
 
2.4 Antigens 
 
The common recall antigens tuberculin purified protein derivative (PPD) (Statens 
Serum Institut, Denmark), haemagglutinin protein (HA) (kindly provided by Dr John 
Skehel, NIMR) and Tetanus Toxoid (TT) (Statens Serum Institut, Denmark) were used 
to assess immune responses to a non-tumour antigen. All antigens were used at a final 
concentration of 10 µg/ml. 
 
2.4.1 5T4 Peptide Pools and Matrix System 
 
Forty-one separate 20 amino acid peptides, each overlapping by 10 amino acids, were 
designed and created to span the entire human 5T4 sequence (Table 2.3). The purity of 
each peptide was >95% (GLBiochem, Shanghai, China). In total, 13 peptide pools 
were created in a matrix system, each consisting of 5-7 peptides (as shown in Table 
2.4). Peptides were added at a final concentration of 5 µg/ml/peptide. Final DMSO 
concentration in culture was never greater than 0.33%. 
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Table 2.3: 5T4 20mer peptide sequences 
 
 
 
 
Table 2.4: 5T4 peptide pool (PP) matrix system 
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2.5 Primary T cell Culture 
 
Isolated PBMC or purified T cell fractions were washed in R+ then resuspended at 
2x106/ml in OpTmizer CTS (Invitrogen) or advanced RPMI supplemented with 5% 
AB serum, before plating 100 µl / well in a 96 well plate (Nunc). Three PBMC lines 
were established to each of the 13 5T4 peptide pools and plates were kept in sterile 
culture conditions in an incubator (37oC, 5% CO2). In addition, cell lines were 
established to certain re-call antigens including tuberculin PPD, TT, HA and also to 
phytohaemagglutinin (PHA) as a positive control for T cell activation (IFN-γ 
production) and proliferation. Cells were supplemented with 10 µl CellKine media 
(Helvetica Healthcare) on day 3, 100 µl fresh media containing 40 IU/ml IL-2 (final 
concentration in culture = 20 IU/ml IL-2) on days 6 and 9, before analysing for antigen 
specificity using ELISpot on day 12. 
 
2.6 IFN-γ / IL-10 ELISpot Assays 
 
Polymer-backed 96-well filtration plates (MAIP-S-4510) (Millipore, Moslheim, 
France) were used for all ELISpot assays and all antibodies were obtained from 
Mabtech (Natka, Sweden). Initially, wells were coated with 50 µl of anti-IFN-γ 
capture antibody (1-D1K) / anti-IL-10 capture antibody (9D7) and left in the fridge at 
4oC overnight. Wells were washed five times with 150 µl PBS to remove excess 
coating antibody and blocked by coating wells with RPMI containing 10% human AB 
serum for 1 hour at 37oC. Block was then discarded and cells were added to 
corresponding wells with and without stimulation. Plates were left overnight (18-24 
hours) in the incubator (37oC, 5% CO2). Following five more washes with PBS, 50 µl 
of 1 µg/ml secondary biotinylated antibody (anti-IFN-γ: 7-B6-1, anti-IL-10: 12G8), 
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which recognise distinct epitopes from the coating antibodies, were added to each well 
and incubated for 1 hour in the incubator (37oC, 5% CO2). Wells were washed five 
more times with PBS before adding 50 µl streptavidin-alkaline phosphatase (Mabtech, 
Sweden), diluted 1:1000, for 30 mins – 1 hour at RToC. Following five more washes 
with PBS, the ELISpot wells were developed using the alkaline-phosphatase substrate 
kit from Bio-Rad (Hercules, California), comprising 4% AP colour development, 1% 
substrate A, 1% substrate B in dH20. 100 µl of the development buffer was added to 
each well and the plate left for 5-15 mins, until spots were clearly visible. The reaction 
was stopped by washing the wells thoroughly with tap water. Cytokine-producing T 
cells were enumerated at the single-cell level by counting the number of spots per well 
using an automated ELISpot plate reader (Autoimmun Diagnostika GMBH, A.I.D., 
Strasberg, Germany) and analysed with the ELISpot 5.0 software package to ensure 
consistent analysis of spots between wells. Spots counts were verified manually.  
 
2.6.1 Ex vivo ELISpot 
 
Having isolated PBMC / T cell subsets, either fresh from whole blood or from frozen 
stocks, cells were counted and resuspended at 2-3x106/ml in OpTmizer CTS 
(Invitrogen) before adding 100-150 µl per well. Final cell counts are indicated where 
appropriate. Positive ex vivo responses were identified as having at least 10 spot-
forming cells (SFC) per 2x105 PBMC, after subtraction of the background, and an 
increase of at least 50% above background. 
 
2.6.2 Cultured ELISpot 
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PBMC lines that had been kept in culture were pooled from triplicate wells in identical 
culture conditions, washed, counted and resuspended at 2x106/ml before being plating 
100µl/well with or without the corresponding 5T4 peptide pool for direct comparison. 
Positive cultured responses were identified as having at least 20 spot-forming cells 
(SFC) per 105 PBMC, after subtraction of the background, and an increase of at least 
50% above background.  
 
2.7 Generation and Maintenance of T cell Clones 
 
To generate 5T4-specific CD4+ T cell clones, PBMC cultures were restimulated with 
the putative 5T4 epitope and cultured for a 12-day period. Strongly positive cell lines, 
as defined by a count of at least 100 SFC/105 cells minus background and double that 
of the negative control, were identified using the IFN-γ ELISpot. CD4+ cells were 
negatively sorted using MACS CD4+ T cell isolation kit II (Miltenyi-Biotec, 
Germany) as per manufacturers instructions. Isolated cells were resuspended in T cell 
clone media comprising OpTmizer CTS (Invitrogen), 10% Human AB Serum, 20 
U/ml IL-2, 2 µg/ml PHA and 2x105 irradiated allogeneic PBMC, and cloned by 
limiting dilution in 96-well plates (Nunc). Plates were analysed for clones two weeks 
later and positive clones identified using the IFN-γ ELISpot, as defined by the 
formation of at least 20 SFC/104 and double that of the negative control. Samples of 
the 5T4 T cell clone were frozen for future use when cell numbers were sufficiently 
high enough. The rest were expanded using Dynabeads Human T-Activator 
CD3/CD28 (Invitrogen) and 100 U/ml IL-2 to stimulate for a 7-day period, before 
removing the beads and splitting the cells when the media began to turn yellow. Cells 
were then fed 40 U/ml IL-2 every 3-4 days until use. 
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2.8 Suppression Assays 
 
2.8.1 3H-Thymidine Incorporation Assay 
 
Having isolated subsets of T cells using a cell sorter, CD4+CD25-CD127hi 
conventional T cells were plated at 1x105 cells per well in triplicate on a 96-well plate 
(Nunc) for studies on Tregs from peripheral blood and 2x103 cells per well to study 
functional characteristics of isolated CD4+ T cells from colon / tumour tissue. Cells 
were cultured in OpTmizer CTS media (Invitrogen) for 3 days at 37oC, 5% CO2, 
supplemented with Pen/Strep/L-Glut and stimulated with Dynabeads Human T-
Activator CD3/CD28 (Invitrogen) at a bead to effector cell ratio of 1:2. Irradiated 
autologous PBMC were added to wells to make overall cell number in each assay 
consistent. Proliferation was measured by pulsing cells with 1 µCi/well of 3H-
thymidine for 6 hours, before harvesting onto filter mats using a TomTec Cell 
Harvester and analysing levels of tritiated hydrogen. The sensitivity of this assay is 
detailed (Figure 2.3). 
 
2.8.2 CFSE-based Suppression Assay 
 
The in vitro function of actively proliferating FACS-purified T cell subsets was 
analyzed by labeling autologous effector CD4+CD25-CD127hi T cells with 0.5 µM 
carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) and potential 
regulatory subsets with 2 µM PKH-26 (Sigma-Aldrich). To assess the impact of 
isolated TIL subsets on effector T cell proliferation, cells were co-incubated in 96 well 
plates at various ratios and stimulated with Dynabeads Human T-Activator CD3/CD28 
(Invitrogen) at a bead to effector cell ratio of 1:2. After 3 days, cells were harvested 
and analysed using a FACSCanto II flow cytometer (BD Biosciences). Proliferation of  
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Figure 2.3 Sensitivity of 3H-Thymidine proliferation assay. The indicated number 
of freshly isolated PBMC were stimulated with 2 µl Dynabeads Human T-Activator 
CD3/CD28 beads (equivalent to 8x104 beads) and seeded with 2x104 irradiated 
PBMC per well. 3H-thymidine was added for the final 6 hours of a 72 hour assay 
before detecting radioactivity using a scintillation counter. cpm = counts per million. 
Significant differences are indicated; *p < 0.05, **p < 0.01.  
Sensitivity of 3H-Thy Proliferation Assay
2x102 2x101 0
0
2500
5000
7500
10000
NB: All cells stimulated with 2µl Dynabeads Human
T-Activator CD3/CD28 (equivalent to 8x104 beads) and
seeded with 2x104 irradiated PBMCs per well.
'0' = Irradiated PBMCs + CD3/CD28 Dynabeads.
*
*
**
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T cell subsets was assessed by conventional gating and the division index was 
calculated using the proliferation platform in FlowJo software version 9.4 (TreeStar 
Inc.) as described previously (McMurchy and Levings 2012) and shown (Figure 4.18, 
Chapter 4).   
 
2.9 Flow Cytometry 
 
2.9.1 Antibody Staining 
 
Cell samples were resuspended in PBS at a concentration of 2-5x106 cells/ml in 96-
well plates (Nunc). Cells were initially stained with for viability with aqua amine-
reactive viability dye (Invitrogen) for 15 minutes in the dark at RToC. Cells were then 
washed twice in FACS buffer and resuspended in 50 µl FACS buffer for surface 
marker staining. Anti-human conjugated antibodies were used in various combinations 
and allowed to incubate for 20 mins in the dark at 4oC (see Table 2.5).  
 
Following two wash steps with FACS buffer (PBS + 2% BSA), cells were 
permeabilized and fixed using a Fixation/Permeabilization kit (eBioscience) and 
incubated for 40 minutes at 4oC. Following another wash step using 1X 
Permeabilization buffer, Fc receptors were blocked using rat serum for 15 minutes at 
4oC. The antibodies against intracellular markers were then added in various 
combinations and allowed to incubate for 30 minutes in the dark at 4oC (see Table 2.6). 
The cells were then washed once with Perm buffer and fixed in PBS containing 1% 
paraformaldehyde (Sigma-Aldrich). Fixed cells were stored in the dark at 4°C until 
acquisition on a BD FACSCanto II. Representative flow cytometry plots and gating 
strategies for the analysis of comparable T cell subsets in blood, colon and tumour are  
 67 
 
 
 
Figure 2.4 Representative flow cytometry plots showing expression of the 
indicated markers on CD4+ T cells in blood (PBMC), unaffected colon and 
tumour samples.   
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Figure 2.4 Cont’d. Representative flow cytometry plots showing expression of the 
indicated markers on CD4+ T cells in blood (PBMC), unaffected colon and 
tumour samples.  
  
K
i6
7
LA
G
-3
C
D
12
7
C
TL
A
-4
IC
O
S
H
el
io
s
TUMOURPBMC COLON
C
D
12
7
CD4
C
TL
A
-4
CD4
IC
O
S
CD4
H
el
io
s
CD4
LA
G
-3
CD4
K
i6
7
CD4
 69 
 
 
Figure 2.5 FMO Controls for commonly used fluorescently conjugated 
antibodies. Blue line indicates fluorescent staining of that particular antibody with 
concurrent use of all eight fluorescence channels on a BD FACSCanto II. Solid grey 
indicates the fluorescence minus the indicated antibody with concurrent use of the 
seven other fluorescence channels.  
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shown (Figure 2.4). Gates were drawn based on fluorescence-minus-one (FMO) 
controls (Figure 2.5). 
 
2.9.2 MHC Class II Tetramer Staining 
 
For MHC Class II tetramer staining of PBMC / T cell samples, cells were washed 
twice in ice-cold PBS. On the final wash step, cell pellets were resuspended in 0.1-0.5 
µg tetramer / 1x106 cells and incubated for 20 minutes at 4oC in the dark. Cells were 
washed a further two times in ice-cold PBS. Live/dead viability and cell surface / 
intracellular stains were then carried out as described above, with the exception that 
the viability dye was incubated at 4oC.  
 
2.9.3 Activation for Intracellular Cytokine Analysis 
 
In some instances, cells were stimulated with 20 nM PMA (Sigma-Aldrich) and 1 
µg/ml Ionomycin (Sigma-Aldrich) for 4 hours at 37oC. After 1 hour, 1 µl/ml 
GolgiStop (containing monensin; BD Pharmingen) was added and the cells then 
subjected to intracellular cytokine staining using the antibodies shown below (Table 
2.6). 
 
2.10 5T4 Immunohistochemistry 
 
Fresh tissue samples obtained from surgery were immediately embedded in OCT 
compound, frozen in liquid nitrogen and stored in -80oC freezers until use. 5µm thick 
sections were cut, placed on slides and fixed in acetone or 4% PFA. Slides were 
incubated with 1.5µg/ml primary anti-5T4 antibody (H8; Oxford Biomedica) 
overnight at 4oC, alongside a mouse IgG1 negative control antibody (BD). Following 
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wash steps, DAB solution was added for 10 minutes, before counterstaining with 
haematoxylin. Slides were finally dehydrated through graded alcohols before viewing 
on a microscope. 
 
2.11 Statistical and Graphical Analysis 
GraphPad Prism Version 5 was used for all statistical analyses. All results are 
expressed as mean values together with the standard error of the mean where 
appropriate. Paired t-tests were used to compare data obtained from matched blood, 
colon and tumour tissue from the same patient. Unpaired t-tests were used for all 
other comparisons.  
Initial analysis of flow cytometry data was performed using FlowJo version 
9.3. Analyses and presentation of T cell subset distributions were performed by 
creating combinatorial Boolean gates to six parameters using Pestle software version 
1.7. This data was imported into SPICE version 5.1, downloaded from 
http://exon.niaid.nih.gov (Roederer, Nozzi et al. 2011), to create graphical pie charts 
with arcs.   
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Table 2.5: Human Antibodies – Cell Surface Stains 
 
Antigen Conjugate Clone Company Final Conc. 
(µg/ml) 
CD3 PerCPCy5.5 UCHT1 BioLegend 2 
CD3 APCh7 SK7 BD 2 
CD4 Pacific Blue RPA-T4 BD 3 
CD4 PECy7 RPA-T4 BioLegend 2 
CD4 PE RPA-T4 BioLegend 2 
CD4 APCh7 RPA-T4 BD 2 
CD4 APC RPA-T4 Miltenyi-Biotec 2 
CD4 Brilliant-Violet 421 RPA-T4 BioLegend 2 
CD8 FITC SK1 BioLegend 2 
CD8 PerCPCy5.5 RPA-T8 eBioscience 2 
CD25 PE M-A251 Miltenyi-Biotec 5 
CD25 PECy7 BC-96 BioLegend 5 
CD25 PECy7 M-A251 BD 6 
CD25 APCh7 M-A251 BD 6 
CD39 PECy7 eBioA1 eBioscience 3 
CD45RA PerCPCy5.5 HI100 eBioscience 3 
CD45RO PE UCHL1 BD 3 
CD49d PE 9F10 BioLegend 4 
CD56 Brilliant-Violet 421 HCD56 BioLegend 3 
CD56 Alexa-Fluor 647 HCD56 BioLegend 3 
CD103 PECy7 B-Ly7 eBioscience 2 
CD107a Pacific Blue H4A3 BioLegend 4 
CD127 PECy7 eBioRDR5 eBioscience 3 
HLA-DR PerCPCy5.5 L243 BioLegend 2 
HLA-DR PECy7 L243 BioLegend 2 
LAP PerCPCy5.5 BG/hLAP BioLegend 4 
LAP Brilliant Violet 421 TW4-2F8 BioLegend 3 
LAP PECy7 TW4-2F8 BioLegend 3 
ICOS FITC C398.4A BioLegend 4 
ICOS PerCPCy5.5 C398.4A BioLegend 4 
PD-1 PerCPCy5.5 EH12.2H7 BioLegend 3 
Tim-3 PE F38-2E2 BioLegend 4 
TGF-β  PE 9016 R&D Systems 5 
LAG-3 PE Polyclonal R&D Systems 4 
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Table 2.6: Intracellular Stains 
 
 
Antigen Conjugate Clone Company Final Conc. 
(µg/ml) 
BCL-2 FITC 6C8 BD 2 
Ki67 PE 20Raj1 eBioscience 1 
CTLA-4 PE BNI3 BD 2 
Helios FITC 22F6 BioLegend 2 
Helios Pacific Blue 22F6 BioLegend 2 
Foxp3 APC 236A/E7 eBioscience 6 
Foxp3 Alexa-Fluor 647 259D BioLegend 6 
TGF-β  PE 9016 R&D Systems 5 
IFN-γ  FITC 4S.B3 BioLegend 5 
IL-10 PECy7 JES3-9D7 BioLegend 6 
IL-17 APCCy7 BL168 BioLegend 6 
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Chapter 3 – T cell responses to the oncofoetal antigen 5T4 
3.1 Introduction 
 
Tumour-associated antigens are common proteins that are markedly up-regulated in 
neoplastic cells, or proteins that are expressed mainly or solely in neoplastic cells i.e. 
tumour-specific antigens. The latter is an attractive group to target for therapy, as 
there should be limited cross reactivity to healthy tissue. The trophoblast cell surface 
glycoprotein 5T4 has a restricted expression to several human carcinomas including 
colorectal cancer (Starzynska, Rahi et al. 1992); this tumour-specific antigen lends 
itself as a candidate target to study tumour-directed immune responses for the purpose 
of improving tumour immunotherapy.  
We have previously identified ex vivo CD4+ T cell responses to 5T4 in 
approximately 30% of CRC patients awaiting surgical resection (Clarke, Betts et al. 
2006; Betts, Jones et al. 2011). Despite this work, many questions remain over the 
role of CD4+ T cell responses to tumour antigens. Are they present in healthy subjects 
and if so, does increasing age, or gender, affect these responses? Do they impede 
tumour growth, or does progressive tumour growth impinge on these responses, 
through mechanisms of tolerance, anergy, deletion or regulation? 
To address some of these fundamental questions, this chapter describes the 
CD4+ T cell responses from patients awaiting surgical resection of a primary 
colorectal adenocarcinoma. Peripheral blood-derived 5T4-specific T cell responses 
were analysed and compared to age-matched healthy donors for the breadth and 
magnitude of response to the tumour-associated antigen 5T4 using an overlapping 
peptide pool covering the entire protein. A particular emphasis was placed on 
determining how the range of epitopes recognized in HLA-typed populations, and the 
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magnitude of each epitope-specific T cell response, compared to colorectal tumour 
stage.   
This chapter also explores data obtained from the phase II clinical trial, 
TaCTiCC (TroVax® and Cyclophosphamide Treatment in Colorectal Cancer). This 
trial utilizes the MVA-based vaccine TroVax®, which partly relies upon effective 
stimulation of 5T4-specific T cells to mediate anti-tumour immune responses (Harrop, 
Drury et al. 2007). A recent report has demonstrated the ability of 5T4-specific 
cytotoxic CD8+ T cells to induce tumour cell death (Al-Taei, Salimu et al. 2012), 
outlining the potential for enhancing anti-5T4-specific responses in cancer patients. 
However, the clinical benefit of such an approach may be hampered by regulatory T 
cells, which are capable of suppressing effector 5T4-specific T cells when stimulated 
in vitro (Clarke, Betts et al. 2006). Indeed in mice challenged with 5T4-positive 
tumours followed by vaccination with a 5T4-encoding adenovirus, significant 
reduction in tumour burden was only noted alongside concurrent Treg depletion 
(Castro, Al-Muftah et al. 2011). In the trial presented here, low-dose 
cyclophosphamide is given to patients prior to TroVax® vaccination in an effort to 
reduce Treg numbers. The primary endpoint at week 7 is to achieve increased anti-
5T4 immune responses after TroVax® and cyclophosphamide treatment, with a 
secondary endpoint of reduction in tumour burden. The preliminary experiments 
carried out here are designed to establish whether such immunotherapeutic strategies 
might be capable of enhancing anti-tumour immunity. 
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3.2 Results 
 
3.2.1 Antigen-specific T cell expansion in culture 
 
In order to analyse T cell specificity for 5T4 epitopes, short-term T cell cultures were 
established, as the low frequency of responses previously measured ex vivo renders 
detailed characterization of the response difficult. The effect of culturing PBMC with 
T cell epitopes was initially demonstrated using a known universal influenza 
haemagglutinin epitope (HA (305-320); “Flu 1”), which HLA-DR1+ (DRB1*01) 
individuals readily respond to. The C-terminal peptide-flanking region was also 
modified in an effort to enhance TCR binding affinity and T cell activation (“Flu 3”) 
as previously described (Cole, Gallagher et al. 2012). Utilising IFN-γ ELISpot, very 
low-level Flu-specific IFN-γ T cell responses are found ex vivo (5-15 SFC/105 
PBMC) (Figure 3.1A). This is mirrored by tetramer staining to the same epitope 
(Figure 3.1B). However, once the same PBMC fraction is cultured with the peptide 
for a 12-day period, flu-specific T cells undergo activation and clonal expansion in 
vitro to levels which become readily detectable by IFN-γ ELISpot and FACS (100-
250 SFC/105 cultured PBMC). The same principles were applied to investigate 5T4-
specific T cell responses in CRC patients.  
 
3.2.2 5T4-specific T cell responses in CRC patients 
 
PBMC isolated from HLA-typed CRC patients, awaiting surgical resection of a 
primary colorectal tumour, were stimulated with pools of 20mer 5T4 peptides 
spanning the entire protein (Tables 2.3 and 2.4). Initially, cells were subjected to ex 
vivo IFN-γ ELISpot to identify 5T4 epitopes, however, responses were rarely detected 
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(2/16). Where responses were identified, these were of very low frequency (<10 
SFC/105 PBMC), an example of which is shown in CRC patient ‘MS16’ (Figure 3.2). 
 
5T4-specific T cells were detected more readily by IFN-γ ELISpot at day 12 
of culture. Representative experiments from three CRC patients are shown (Figure 
3.3). For patient ‘MS209’, peptide pools 1, 3, 7 and 13 were positive suggesting 
candidate peptides containing epitopes are peptides 1, 3, 37 and 39 (see matrix, Table 
2.4). Some of these responses were robust, reaching frequencies of > 200 T cells / 105 
cultured cells, enabling further analysis. However, some patients such as ‘MS201’ 
failed to mount any sizeable response and no definitive epitope could be detected 
(Figure 3.3A). Reasons for this will be explored later in the chapter. In total, 82% 
(22/27) of CRC patients tested produced an identifiable 5T4-specific T cell IFN-γ 
response to at least one 5T4 epitope.  
 
3.2.3 5T4 responses by T cells isolated from different tissues 
 
Although 5T4-specific T cells are identifiable amongst peripheral blood derived 
mononuclear cells, it is not known whether these cells can also be detected in other 
tissues. Lymphocytes were isolated from freshly resected colon specimens, which 
included, where possible, the colonic mucosa, tumour draining lymph nodes and the 
colorectal tumour. These lymphocytes were subjected to a 12-day culture period with 
5T4 peptide pool-pulsed autologous irradiated PBMC (as APCs) and tested for 
antigen-specific IFN-γ responses. In most cases (6/7), no 5T4 responses were detected 
amongst tumour-infiltrating lymphocytes. In one case (CRC patient MS14), a 5T4 
response to peptide pool 13 was detected in three compartments of blood, TDLN and 
tumour and an additional response to peptide pool 3 in blood  
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B: 
 
Figure 3.1 In vitro peptide stimulation of PBMC enriches for peptide specific 
CD4+ T cells after 12 days in culture. Freshly isolated PBMC from an HLA-DR1+ 
donor were stimulated with wild-type (Flu-1) or modified (Flu-3) HA(305-320) 
peptides and analysed by IFN-γ ELISpot for the number of IFN-γ+ T cells (per 105 
cells) both ex vivo (overnight stimulation) and following a culture period of 12 days in 
vitro (see Methods section 2.5, page 61 for details) (A). The same cells were also 
stained with class-II tetramers specific for the flu peptides ex vivo, or following the 12 
day period of culture (‘Flu 1 / Flu 3 Stimulated’) (B). Data is representative of three 
DR1+ donors.  
 
 79 
 
 
Figure 3.2 5T4-specific IFN-γ+ T cell responses amongst PBMC are rarely 
detected ex vivo. Freshly isolated PBMC from 16 CRC patients have been assessed for 
the number of IFN-γ+ T cells (per 105 PBMC) following overnight stimulation with the 
5T4 peptide pools (see Table 2.4, page 60 for 5T4 peptide pools and matrix system). 
Examples shown represent a positively identified (A: CRC patient ‘MS16’) and negative 
(B: CRC patient ‘MS17’) response. (* Indicates positive response; sfc = spot forming 
cell).   
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Figure 3.3 12-day in vitro culture of PBMC with 5T4 peptide pools enriches for 
measureable 5T4-specific T cell responses using IFN-γ ELISpot. Freshly isolated 
PBMC from 27 CRC patients were stimulated with a panel of 13 peptide pools covering 
the entire 5T4 sequence (see Table 2.4, page 60 for 5T4 peptide pools and matrix system) 
and cultured for a period of 12 days in vitro. Cultured PBMC were subsequently assessed 
for the number of IFN-γ+ T cells (per 105 cultured PBMC) specific for the 13 5T4 peptide 
pools, representative examples of which are shown (A: MS201, B: MS203, C: MS209; * 
indicates positive response; sfc = spot forming cell).   
1 2 3 4 5 6 7 8 9 10 11 12 13
0
50
100
150
200
5T4 Pool
-v
e 
C
on
tro
l
PH
A
*
*
*
*
sf
c/
10
5  C
ul
tu
re
d 
PB
M
C
 (I
FN
-γ
)
1 2 3 4 5 6 7 8 9 10 11 12 13
0
50
100
150
200
250
5T4 Pool
-v
e 
C
on
tro
l
PH
A
*
*
*
*
sf
c 
/ 1
05
 C
ul
tu
re
d 
PB
M
C
 (I
FN
-γ
)
1 2 3 4 5 6 7 8 9 10 11 12 13
0
50
100
150
200
5T4 Pool
-v
e 
C
on
tro
l
PH
A
= With Peptide
= Without Peptide
sf
c 
/ 1
05
 C
ul
tu
re
d 
PB
M
C
 (I
FN
-γ
)
A: MS201
B: MS203
C: MS209
 81 
 
Figure 3.4 T cells from different compartments respond to similar 5T4 epitopes 
in a CRC patient. Freshly isolated lymphocytes isolated from peripheral blood (A), 
tumour-draining lymph node (B) and colorectal tumour (C) from CRC patient MS14 
were stimulated with a panel of 13 peptide pools covering the entire 5T4 sequence (see 
Table 2.4, page 60 for 5T4 peptide pools and matrix system) and cultured for a period of 
12 days in vitro. Cultured lymphocytes were subsequently assessed for the number of 
IFN-γ+ T cells (per 105 cultured lymphocytes) specific for the 13 5T4 peptide pools. 
Highlighted results indicate similar 5T4 epitope responses amongst T cells from different 
tissues. (* indicates positive response; sfc = spot forming cell). 
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and TDLN, implicating peptide 39 as being an immunogenic epitope in this patient 
(Figure 3.4).   
 
3.2.4 5T4 T cell responses in healthy donors 
 
PBMC isolated from HLA-typed age-matched healthy donors were stimulated and 
cultured with the 5T4 peptide pools before analysis at day 12, as before. 
Representative experiments from three healthy donors are shown (Figure 3.5). These 
results were initially surprising, given the absence of ex vivo 5T4 responses in healthy 
donors found previously (Clarke, Betts et al. 2006); indeed healthy donors appeared 
to mount equal / superior cultured responses than CRC patients. In total, 100% 
(17/17) of healthy donors tested produced positive IFN-γ responses to ≥ 2 5T4 peptide 
epitopes, defined as two peptides that do not overlap and could individually contain 
putative epitopes. 
 
3.2.5 Identifying MHC Class-II restricted 5T4-derived epitopes 
 
When two positive responses to 5T4 peptide pools implicate an epitope, restimulating 
cultured cells can test the immunogenicity of this single peptide (example shown 
Figure 3.6). Alongside this, it is possible to test for a CD4 / CD8 response by using 
blocking antibodies to HLA class-I (W6/32) or HLA class-II (HLA-DR; L243 or 
HLA-DQ; 1A3). The vast majority of IFN-γ responses were found to be restricted to 
CD4+ T cells, probably reflecting the length of peptides used to stimulate the cells. 
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Figure 3.5 5T4-specific T cell responses are readily detectable in age-matched 
healthy donor controls following short-term culture. Freshly isolated PBMC from 
17 healthy donors were stimulated with a panel of 13 peptide pools covering the entire 
5T4 sequence (see Table 2.4, page 60 for 5T4 peptide pools and matrix system) and 
cultured for a period of 12 days in vitro. Cultured PBMC were subsequently assessed for 
the number of IFN-γ+ T cells (per 105 cultured lymphocytes) specific for the 13 5T4 
peptide pools, representative examples of which are shown (A: HD202, B: HD221, C: 
HD226; * indicates positive response; sfc = spot forming cell).   
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Figure 3.6 Peptide-specific CD4+ T cell responses identified after culturing 
PBMC with 5T4 peptide pools. Freshly isolated PBMC from CRC patient MS24 were 
stimulated with a panel of 13 peptide pools covering the entire 5T4 sequence (see Table 
2.4, page 60 for 5T4 peptide pools and matrix system) and cultured for a period of 12 
days in vitro. Cultured PBMC were subsequently assessed for the number of IFN-γ+ T 
cells (per 105 cultured lymphocytes) specific for the 13 5T4 peptide pools. Having 
identified positive 5T4 responses to peptide pools 3 (A) and 10 (B), cell lines were 
restimulated with corresponding peptides to identify specific epitopes. In this case, 
CD4+ T cells produced IFN-γ in response to peptides 21-23. This epitope is HLA-DR 
restricted as addition of the HLA-DR blocking antibody, L243 resulted in a 90% 
decrease in response to peptide pool 10. (* Indicates positive response; sfc = spot 
forming cell). 
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3.2.5.1 Generation of CD4+ 5T4-specific T cell clones 
 
5T4-specific T cell clones were created from a number of healthy donors and CRC 
patients, as previously described (Methods section 2.7). IFN-γ ELISpot was utilized to 
identify T cell clones, which became activated upon recognition of their cognate 
antigen. Cloned T cells were also FACS stained to check T cell sub-type; as expected, 
given the length of peptide used to stimulate these cells, all clones were CD4+ T cells 
(Figure 3.7). Where HLA-restriction was also definitively identified, this has been 
shown in red. 
 Two CD4+ T cell clones, which produced the most robust anti-5T4 responses, 
were expanded and analysed in more detail. Examples derived from a CRC patient 
(Figure 3.8A) and a healthy donor (Figure 3.8B) are shown. T cell clones were CD4+ 
and restricted by HLA-DR antigens (fine restriction mapping using 
matched/mismatched APCs showed HLA-DR1 (DRB1*01) in Figure 3.8A; HLA-
DR4 (DRB1*04) in Figure 3.8B). Predicted epitope sequences were identified using 
epitope prediction software, which analysed the ligation strength for the sequence of 
amino acids to the specific MHC class-II structure.  
Addition of whole 5T4 protein pulsed autologous irradiated APCs revealed the 
natural presentation of these 5T4 epitopes resulting in activation and IFN-γ 
production by these clones. As with other CD4+ T cell clones/lines previously tested 
in the lab (Godkin, Jeanguet et al. 2001; Gallagher, Lauder et al. 2009), they were 
also able to produce IL-10 after peptide stimulation, a possible result of repeat TCR 
triggering of these cells, employed as a mechanism to control excessive immune 
responses (Saraiva, Christensen et al. 2009). 
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Figure 3.7 5T4-specific T cell clones. Clones were generated from a number of 
healthy donors and CRC patients, examples of which are shown. See Methods section 
2.7, page 63 for information on the generation and cloning of 5T4-specific T cells). 
Clones were screened for 5T4 reactivity by IFN-γ ELISpot and analysed by FACS to 
identify T cell type. Where possible HLA-restriction was calculated by pulsing 
matched / mis-matched APCs with the specific 5T4 peptide before stimulating the T 
cell clone to test for reactivity (identified in red).  
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Figure 3.8. Cultured 5T4-specific CD4+ T cells can be cloned from CRC patients 
(A) and healthy donors (B). Graphs show IFN-γ / IL-10 production, detected using 
ELISpot, by 5T4-specific T cell clones co-cultured overnight with 5T4 peptide / 
protein-pulsed irradiated autologous PBMC in various indicated conditions. Results 
demonstrate the number of spot forming cells per 1000 5T4 clonal T cells plated. CD4 
against CD8 FACS plots of the clone are shown (gated on live cells). 
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3.2.6 Comparison of 5T4-specific T cell responses in CRC patients and healthy 
donors 
5T4 ELISpot data from all individuals (number of spot forming cells per 105 cultured 
PBMCs) were used to calculate the total summated response to all 5T4 peptides and 
the average response per 5T4 epitope. To distinguish between putative epitopes, 
distinct responses were defined as individual responses to non-overlapping peptides, 
i.e. responses to overlapping peptides were defined as containing one putative epitope. 
If doubt remained the lines were tested against individual peptides. The total response 
to the 5T4 peptide pools was significantly diminished in patients who were 
subsequently identified as having tumours which had penetrated the serosal surface of 
the bowel at operation and invaded local nymph nodes (i.e. Dukes’ C or TNM stage 
3+), as shown in Figure 3.9 (Dukes’ A vs. Dukes’ C CRC patients 548.1 ± 116.2 vs. 
210.1 ± 72.73; p = 0.017) and concordantly between T1 and T3-graded CRC patients 
(607.0 ± 163.4 vs. 258.4 ± 70.5; p = 0.041).  
 Very similar findings were obtained when comparing 5T4 responses on a per 
epitope response basis (Figure 3.10). Healthy donors demonstrated superior responses 
to patients with increasingly advanced tumours (HD vs. Dukes’ C: 127.4 ± 13.1 vs. 
48.54 ± 15.8; p = 0.0006 and HD vs. T3: 127.4 ± 13.1 vs. 46.7 ± 13.4; p = 0.0002). 
Again, anti-5T4 T cell responses decreased with tumour progression, significantly 
between Dukes’ A and Dukes’ C patients (130.1 ± 26.94 vs. 48.5 ± 15.77; p = 0.011), 
T1 and T3-graded patients (120.8 ± 6.3 vs. 46.7 ± 13.4; p = 0.011) and even between 
T2 and T3-graded patients (124.7 ± 38.3 vs. 46.7 ± 13.4; p = 0.024). 
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Figure 3.9 Total anti-5T4 T cell responses steadily decline in CRC patients with 
more advanced disease. Freshly isolated PBMC from 28 CRC patients  and 16 healthy 
donors were stimulated with a panel of 13 peptide pools covering the entire 5T4 sequence 
(see Table 2.4, page 60 for 5T4 peptide pools and matrix system) and cultured for a 
period of 12 days in vitro. Cultured PBMC were subsequently assessed for the number of 
IFN-γ+ T cells (per 105 cultured lymphocytes) specific for the 13 5T4 peptide pools. 
Positive responses were defined in terms of the overall number of IFN-γ producing 
5T4-specific T cells to all peptide pools per 105 cultured PBMC (i.e. ‘total 5T4 
response magnitude’). Significant differences and regression analysis are indicated; 
*p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 3.10 Epitope specific 5T4 T cell responses steadily decline in CRC 
patients with more advanced disease. Freshly isolated PBMC from 28 CRC patients 
and 16 healthy donors were stimulated with a panel of 13 peptide pools covering the 
entire 5T4 sequence (see Table 2.4, page 60 for 5T4 peptide pools and matrix system) and 
cultured for a period of 12 days in vitro. Cultured PBMC were subsequently assessed for 
the number of IFN-γ+ T cells (per 105 cultured lymphocytes) specific for the 13 5T4 
peptide pools. Positive responses were defined in terms of the average number of IFN-
γ producing 5T4-specific T cells to each putative 5T4 epitope per 105 cultured PBMC 
(i.e. total magnitude divided by number of individual epitope responses (‘5T4 
Magnitude / Epitope’)). Significant differences and regression analysis are indicated; 
*p < 0.05, **p < 0.01, ***p < 0.001. 
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These data demonstrate a steady reduction in the responsiveness of T cells to 
5T4 measured by IFN-γ production in patients with increasingly advanced colorectal 
tumours. Despite this, T cell immunity to the recall antigen, PPD, appears unaffected 
(Figure 3.11). There does not appear to be non-specific immunosuppression, as we 
and others have previously noted (Betts, Jones et al. 2011) (Tassi, Gavazzi et al. 
2008).  
In the cohort of patients tested, 6 out of 13 patients with local lymph node 
spread produced no detectable 5T4 T cell response post-culture, whereas every patient 
whose tumour was contained to the bowel wall produced a 5T4 response (106.7 ± 
19.1 vs. 48.5 ± 15.8; p = 0.027) (Figure 3.12A). However, no overall difference was 
noted between pathologically confirmed Dukes’ C1 / C2 and TNM N1 / N2 graded 
CRC tumours (Figure 3.12B), indicating that tumour spread to the apical lymph node 
does not result in a further reduction in 5T4-specific T cell responsiveness. 
The responses in all healthy controls (17/17) were robust, with a highly 
significant difference between healthy controls and patients with advanced cancer 
(HD vs. Dukes’ C: 478.1 ± 64.3 vs. 210.1 ± 72.7; p = 0.0097 and HD vs. T3: 478.1 ± 
64.3 vs. 258.4 ± 70.5; p = 0.028). At a cut off level of <200 SFCs/105, 0% (0/17) of 
healthy controls vs. 30% (8/27) of patients demonstrate such weak / absent responses 
(p = 0.031 Fishers’ exact test; specificity 100%). Equally, with a cut off level of <75 
SFCs/105/ 5T4 epitope, 6% (1/17) of healthy controls vs. 69% (11/27) of patients 
demonstrate poor responses (p = 0.0003 Fishers’ exact test; specificity 94%) (Table 
3.1). 12-month outcome data was available on 13 of 14 patients with Dukes’ C 
tumours, within which these 8 patients with low level total  
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Figure 3.11 PPD-specific T cell responses remain unaffected in CRC patients. 
Freshly isolated PBMC from 14 CRC patients and 11 healthy donors were stimulated 
with a panel tuberculin PPD and cultured for a period of 12 days in vitro. Cultured PBMC 
were subsequently assessed for the number of IFN-γ+ T cells (per 105 cultured 
lymphocytes) specific for PPD (i.e. spot forming cells – SFC).  
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Figure 3.12 The effect of tumour spread to lymph nodes and anti-5T4 T cell 
responses. Freshly isolated PBMC from 26 CRC patients were stimulated with a panel 
of 13 peptide pools covering the entire 5T4 sequence (see Table 2.4, page 60 for 5T4 
peptide pools and matrix system) and cultured for a period of 12 days in vitro. Cultured 
PBMC were subsequently assessed for the number of IFN-γ+ T cells (per 105 cultured 
lymphocytes) specific for the 13 5T4 peptide pools. Positive responses were defined in 
terms of the average number of IFN-γ producing 5T4-specific T cells to each putative 
5T4 epitope, per 105 cultured PBMC (i.e. total magnitude divided by number of 
individual epitope responses). This response was compared between CRC patients 
with and without histopathologically confirmed localized lymph node involvement 
(A) and between N1 and N2 graded patients (B). Significant differences are indicated; 
*p < 0.05.  
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Table 3.1 Statistical analysis of the difference in 5T4 T cell responses generated 
by healthy donor controls and colorectal cancer patients. 
 
 TOTAL 5T4 
RESPONSE 
5T4 RESPONSE PER 
EPITOPE 
Low-level response cut-
off point 
<200 SFCs/105 <75 SFCs/105/Epitope 
Healthy Controls 
0% (0/17) 6% (1/17) 
CRC Patients 
30% (8/27) 69% (11/27) 
Fishers’ Exact Test 
p = 0.031;  
Specificity 100% 
p = 0.0003;  
Specificity 94% 
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5T4 responses (<200 SFCs) reside. Five patients at 12 months had developed disease 
recurrence or metastatic disease, and of these patients, 80% (4/5) demonstrated low 
level (<200 SFCs) responses pre-operatively (Figure 3.13). 
 
Five patients with low-level pre-operative 5T4 responses were assessed 6-18 
months post-surgery. All 5 patients produced measureable increases in total IFN-γ 
production to all 5T4 peptides (pre-op responses; 107.6 ± 40.6 vs. post-op responses; 
267.4 ± 71.4 SFCs / 105 cultured cells, p = 0.058) (Figure 3.14A), and 4/5 patients had 
increased anti-5T4 T cell responsiveness on a per-epitope basis (pre-op responses; 
29.5 ± 13.0 vs. post-op responses; 95.6 ± 22.2, p = 0.038) (Figure 3.14B). 
 
3.2.7 CRC patients have an elevated proportion of peripheral Tregs 
3.2.7.1 Treg proportion and 5T4 T cell responses 
 
Tregs have previously been shown to actively impinge on 5T4-specific anti-tumour T 
cell responses (Clarke, Betts et al. 2006; Elkord, Burt et al. 2008; Betts, Jones et al. 
2011). It is also well documented that patients with cancer have increased frequencies 
of Tregs, as denoted by Foxp3 expression (Beyer and Schultze 2006). With the blood 
samples obtained from the same cohort of CRC patients used here for anti-5T4 T cell 
studies, flow cytometry was used to analyse the proportion of CD4+ T cells that 
expressed Foxp3 to determine whether increased numbers of Tregs could correlate 
with the reduction in 5T4 responses. Indeed, the proportion of Tregs was most 
significantly increased in the PBMC of CRC patients with more advanced disease 
and concomitantly reduced T cell responses (Dukes’ C vs. HD: 10.81% ± 0.79% vs. 
7.76% ± 0.68%; p = 0.016 and T3 vs. HD: 11.42% ± 0.61% vs. 7.75% ± 0.68%; p = 
0.0026) (Figure 3.15). Furthermore, the proportion of Tregs appeared to increase with  
 96 
 
 
 
 
 
Figure 3.13 Dukes’ C CRC patients with robust pre-operative 5T4 responses are 
less likely to develop metastatic disease. Freshly isolated PBMC, from CRC patients 
with histopathologically confirmed Dukes’ C tumours at resection, were stimulated 
with a panel of 13 peptide pools covering the entire 5T4 sequence (see Table 2.4, page 60 
for 5T4 peptide pools and matrix system) and cultured for a period of 12 days in vitro. 
Cultured PBMC were subsequently assessed for the number of IFN-γ+ T cells (per 105 
cultured lymphocytes) specific for the 13 5T4 peptide pools. Positive responses were 
defined in terms of the total number of IFN-γ producing 5T4-specific T cells to all 
positive 5T4 peptide pools, per 105 cultured PBMC (i.e. total magnitude). These 
responses were separated into two distinct groups based on whether they generated a 
good / poor total IFN-γ response to 5T4. A good response was considered to be a total 
5T4 magnitude greater than 200 (which corresponded with a 5T4 magnitude / epitope 
of greater than 75). A poor response was considered to be a total 5T4 magnitude less 
than 120 (which corresponded with a 5T4 magnitude / epitope of less than 50). 
Patients were assessed at 12 months post surgery for metastatic spread and data was 
correlated with pre-operative anti-5T4 responses. 
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Figure 3.14 The effect of colorectal tumour resection on anti-5T4 T cell responses. 
Freshly isolated PBMC, from 5 CRC patients, were stimulated with a panel of 13 
peptide pools covering the entire 5T4 sequence (see Table 2.4, page 60 for 5T4 peptide 
pools and matrix system) and cultured for a period of 12 days in vitro. Cultured PBMC 
were subsequently assessed for the number of IFN-γ+ T cells (per 105 cultured 
lymphocytes) specific for the 13 5T4 peptide pools. Positive responses were defined in 
terms of the total number of IFN-γ producing 5T4-specific T cells to all positive 5T4 
peptide pools, per 105 cultured PBMC (i.e. ‘total 5T4 response magnitude’) or the 
average number of IFN-γ producing 5T4-specific T cells to each putatively identified 
epitope (i.e. ‘magnitude / epitope’). The five CRC patients studied here had relatively 
poor pre-operative 5T4 T cell responses (1 Dukes’ B, 4 Dukes’ C) and were 
subsequently analysed for total 5T4 responsiveness (A) and average 5T4 
responsiveness per epitope (B) post-surgery. The responses were compared using a 
one-tailed paired t-test. Significant differences are indicated; *p < 0.05.   
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tumour progression in this cohort (T2 vs. T3: 8.48% ± 0.49% vs. 11.42% ± 0.61%; p 
= 0.0089).  
 
A comparison of Foxp3+ Treg proportion and 5T4 T cell responsiveness 
amongst individual donors was assessed (Figure 3.16). This identified a small, albeit 
not significant correlation between an increase in Treg proportion amongst peripheral 
T cells and the ability of these cells to mount an anti-5T4 response after short-term 
culture. Since peripheral Treg proportion increases with tumour advancement, Tregs 
could account for diminished 5T4 responses found in patients bearing more advanced 
tumours. 
 
3.2.7.2 Cultured 5T4 T cell responses following depletion of Tregs from PBMC 
 
The effect of removing Tregs prior to culture of PBMC with 5T4 peptide 
pools was studied in a number of healthy donors and CRC patients, an example of 
which is shown from a healthy donor ‘HD203’ (Figure 3.17). CD4+CD25hi Tregs 
were removed using anti-CD25 microbead MACS kits as described in the methods. 
This resulted in the removal of between >95% of Foxp3+ Tregs from the PBMC 
sample as determined by subsequent FACS analysis of sorted samples (see Appendix).  
When comparing 5T4 responses generated before and after Treg depletion, the 
magnitude of responses increased but also de novo responses were observed in donor 
‘HD203’. IFN-γ responses to peptide pools 3, 5 and 10 (implicating 5T4 peptides 21 
and 23) all increased after Treg depletion. In addition, responses were also generated 
to peptide pools 6, 8 and 12 (further implicating peptides 9, 11, 23, 32, 35 and 36). 
This raises the possibility that 5T4-specific Tregs exist to actively impinge upon the  
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Figure 3.15 Foxp3+ Regulatory T cell proportion increases in CRC patients with 
more advanced tumours. Freshly isolated PBMC from CRC patients and healthy 
age-matched controls were stained with fluorescently conjugated mAb to CD3, CD4 
and Foxp3 and assessed for the proportion of live CD3+CD4+ T cells that expressed 
intracellular Foxp3 by FACS. Results from CRC patients were correlated to 
histopathological tumour score. Significant differences are indicated; *p < 0.05, **p < 
0.01.  
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Figure 3.16 Treg proportion and 5T4 responsiveness. Freshly isolated PBMC were 
stimulated with a panel of 13 peptide pools covering the entire 5T4 sequence (see Table 
2.4, page 60 for 5T4 peptide pools and matrix system) and cultured for a period of 12 
days in vitro. Cultured PBMC were subsequently assessed for the number of IFN-γ+ T 
cells (per 105 cultured lymphocytes) specific for the 13 5T4 peptide pools. Positive 
responses were defined in terms of the total number of IFN-γ producing 5T4-specific 
T cells to all positive 5T4 peptide pools, per 105 cultured PBMC (i.e. ‘total 
magnitude’) or the average number of IFN-γ producing 5T4-specific T cells to each 
putatively identified epitope (i.e. ‘magnitude / epitope’). The percentage of PBMC-
derived CD4+ T cells expressing Foxp3 was correlated with the 5T4 response 
magnitude (A) and 5T4 magnitude per epitope (B) generated from the same PBMC 
sample amongst CRC patients and healthy age-matched donors. Lines of regression 
are shown (solid line = CRC patients; dashed line = healthy donors).    
6 8 10 12 14
0
250
500
750
1000
1250 CRC Patients
Healthy Donors
  r2 = 0.13
  p = 0.26
  r2 = 0.08
  p = 0.59
% CD4+ Expressing Foxp3
To
ta
l 5
T4
 R
es
po
ns
e 
M
ag
ni
tu
de
6 8 10 12 14
0
50
100
150
200
250
300 CRC Patients
Healthy Donors
  r2 = 0.14
  p = 0.24
r2 = 0.01
p = 0.85
% CD4+ Expressing Foxp3
5T
4 
R
es
po
ns
e 
M
ag
ni
tu
de
 / 
Ep
ito
pe
 101 
effector functions of 5T4-specific CD4+ effector T cells. Furthermore, Tregs appear to 
recognise a broad range of 5T4 epitopes in this donor. 
Further assessment of the response to 5T4 peptide 23 in donor HD203 
revealed how removal of Tregs before PBMC stimulation with the individual peptide 
can result in a seven-fold increase in the magnitude of IFN-γ production generated at 
day 12. Such robust responses were confirmed to derive from a memory T cell 
population, since depletion of CD45RO+ memory T cells before culture with peptide 
23 resulted in no discernible response (Figure 3.17C). 
 
3.2.8 Age-related effects on 5T4 T cell responses in CRC patients 
 
Ageing has been associated with a decline in T cell function leading to the 
concept of immune senescence and increased susceptibility to infectious diseases and 
cancer (Raynor, Lages et al. 2012). Results in this chapter have demonstrated healthy 
age-matched donors produce better responses than CRC-patients. By correlating 5T4 
responses with patient age, it was also noted that patients ≤ 60 years demonstrated 
better 5T4 responses on a per epitope basis than patients ≥ 80 years old (Figure 
3.18A: 120.1 ± 21.7 vs. 42.5 ± 18.2; p = 0.03). However, this finding was not 
mirrored in the total 5T4 responses (Figure 3.18B).  
Interestingly, in the cohort of patients tested here, there was a small but 
significant correlation between the age of patient at surgery and the tumour stage at 
resection (Figure 3.19A: Dukes’ A vs. Dukes’ B: 61.5 yrs ± 4.01 yrs vs. 74.83 yrs ± 
3.82 yrs; p = 0.038 and T1 vs. T4: 56.0 yrs ± 4.89 yrs vs. 79.67 yrs ± 7.69 yrs; p = 
0.041). This was not the case for two other cohorts of CRC patients (Figure 3.19B 
and C).  
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Overall, it seems that age of subject has little effect on measured CD4+ anti-
tumour responses. 
 
3.2.9 HLA-DR type and 5T4 T cell responsiveness 
 
If anti-5T4 CD4+ T cell responses are protective, it is reasonable to hypothesize 
that there would be an advantage in maintaining a broad response to multiple epitopes. 
This might mean certain HLA types which are associated with fewer epitopes (or 
homozygosity of the HLA-DR region) may be seen more frequently in patients compared 
to background control population. The number of 5T4 peptides associated with an 
individuals’ HLA-DR type is summarized in Figure 3.20.  Three immunodominant 
regions of the 5T4 protein were responsible for 64% of 5T4 peptide responses generated, 
namely amino acids 70-100, 200-240 and 380-410. Each HLA type was associated with 
several peptides, the range being 4 peptides with HLA-DRB1*1301 to 9 with HLA-
DRB1*0101. The HLA subtype frequencies for 52 CRC patients are summarized in Table 
3.2 compared to the background population. These data did not demonstrate an effect of 
HLA subtype on the breadth or magnitude of CD4+ T cell responses. Furthermore, no 
difference was found between homozygous and heterozygous donors for HLA-DR alleles 
and the number and magnitude of 5T4 responses generated (Figure 3.21). 
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Figure 3.17 Treg depletion from 
PBMC prior to culture with 5T4 
peptide pools. Freshly isolated PBMC 
(A) and CD25-depleted PBMC (B) 
from a healthy donor were stimulated 
with a panel of 13 peptide pools 
covering the entire 5T4 sequence (see 
Table 2.4, page 60 for 5T4 peptide 
pools and matrix system) and cultured 
for a period of 12 days in vitro. 
Cultured cells were subsequently 
assessed for the number of IFN-γ+ T 
cells (per 105 cultured lymphocytes) 
specific for the 13 5T4 peptide pools. 
Identified positive responses are 
shown (*). In the same donor, having 
identified 5T4 peptide 23 as being 
immunogenic, cell lines were 
established to this peptide in whole 
PBMC, CD25-depleted PBMC and 
CD45RO-depleted PBMC before 
subsequent analysis of peptide 23-
specific IFN-γ production at day 12 
by ELISpot (C).!
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Figure 3.18 The effect of ageing on anti-5T4 responses in CRC patients. Freshly 
isolated PBMC from 27 CRC patients were stimulated with a panel of 13 peptide pools 
covering the entire 5T4 sequence (see Table 2.4, page 60 for 5T4 peptide pools and 
matrix system) and cultured for a period of 12 days in vitro. Cultured PBMC were 
subsequently assessed for the number of IFN-γ+ T cells (per 105 cultured lymphocytes) 
specific for the 13 5T4 peptide pools. Patient age at the time of going to surgery was 
correlated with the average number of IFN-γ producing 5T4-specific T cells to each 
putatively identified epitope (i.e. ‘magnitude / epitope’) (A) and to all positive 5T4 
peptide pools, per 105 cultured PBMC (i.e. ‘total magnitude’)  (B). Significant 
differences are indicated; *p < 0.05.  
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Figure 3.19 Analysis of patient age vs. tumour stage at resection. The age of the 
patient at time of surgery was correlated with tumour stage data taken from 
histopathological data of the excised tumour sample in three cohorts; a cohort of 
patients where 5T4 responses were measured (A), a cohort including patients from 
(A) but inclusive of all patients studied in this thesis (B) and an entirely distinct 
cohort taken from a previous PhD student in this lab (C: data from Gareth Betts).   
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Figure 3.20 HLA-DR type and 5T4 T cell epitopes. Every positively identified 5T4 
T cell response was correlated to donor HLA-DR type (see Methods section 2.6.2, 
page 63 for definition of positive response). Graph indicates 5T4 peptides that would 
regularly generate an immune response (Black = positive response identified in ≥50% 
of donors tested, dark grey = positive response identified in 30-49% of donors tested 
and light grey = positive response identified in 20-29% of donors tested).  
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Table 3.2: A comparison of HLA-DR allele frequencies between CRC patients 
and the population of Wales. 
 
 Allele number CRC 
Patients (n = 52) 
Allele frequency 
CRC Patients (%) 
Allele frequency 
Wales (%) 
HLA-DRB1*01 15 15.4 11 
HLA-DRB1*15 12 13.2 14.3 
HLA-DRB1*03 11 12.1 15.2 
HLA-DRB1*04 26 28.6 20.4 
HLA-DRB1*07 13 14.3 14.7 
HLA-DRB1*08/09/10 6 6.6 3.3 
HLA-DRB1*11/12 8 8.8 5.8 
HLA-DRB1*13 10 9.9 9.7 
HLA-DRB1*14 1 1.1 2.3 
 
Allele frequency = total number of copies / 2n (Allele frequency Wales based on 
39,979 subjects) 
Phenotype frequency = number of individuals with gene / n  
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Figure 3.21 HLA-DR zygosity does not affect the number of positive 5T4 epitope 
responses generated. Freshly isolated PBMC from 12 CRC patients were stimulated 
with a panel of 13 peptide pools covering the entire 5T4 sequence (see Table 2.4, page 60 
for 5T4 peptide pools and matrix system) and cultured for a period of 12 days in vitro. 
Cultured PBMC were subsequently assessed for the number of IFN-γ+ T cells (per 105 
cultured lymphocytes) specific for the 13 5T4 peptide pools. The HLA-DR zygosity of 
the CRC patients was correlated with the number of putative 5T4 epitope responses 
that patient produced a positive IFN-γ response. Statistics show the results of an 
unpaired t-test.   
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3.2.10 Expression of 5T4 in cancerous / healthy / inflamed human tissue 
 
The rationale for healthy donors producing sizeable anti-5T4 T cell responses 
remains unclear, although it is now well established that healthy donors do have 
tumour antigen-specific T cells present in the T cell pool (Danke, Koelle et al. 2004), 
(Campi, Crosti et al. 2003). In addition, 5T4-specific T cells have also previously 
been identified amongst healthy donors (Elkord, Burt et al. 2008), however reasons 
for this have not been explored until now. Although previous work analysing 5T4 
expression on healthy tissue, including healthy colon samples, found minimal 
expression  (Starzynska, Rahi et al. 1992), I hypothesised that inflamed tissue may 
upregulate such molecules to facilitate an inflammatory responses. The expression of 
5T4 on inflamed tissue has not previously been determined.  
 Patients undergoing colectomy for Crohn’s disease or ulcerative colitis were 
consented and samples of inflamed colon were taken from surgery and analysed for 
expression of 5T4. Alongside this, a placenta was obtained from a woman undergoing 
an elective Caesarean section, for use as a positive control, since 5T4 is ubiquitously 
expressed and was originally identified on placental syncytiotrophoblasts, 
extravillous cytotrophoblast and the amniotic epithelium (Hole and Stern 1988). 5T4 
expression was positively identified on placenta and colorectal tumour samples taken 
from this cohort of CRC patients (Figure 3.22). As expected healthy background 
colonic mucosa did not stain for 5T4. However, two colon sections from patients with 
inflammatory gut conditions (Crohn’s disease and IBD) stained positive for 5T4. An 
example is shown of 5T4 expression within the setting of intestinal focal cryptitis. 
This finding requires further research to examine if other inflammatory conditions 
upregulate 5T4. 
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Figure 3.22 5T4 Immunohistochemistry staining of frozen sections. The 
expression of 5T4 was assessed on placenta (positive control), colorectal tumours, 
healthy colon and inflamed colonic tissue. Negative isotype controls (mouse IgG1) 
were performed alongside 5T4 staining on sections from the same samples. 
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3.2.11 5T4-specific IL-10 responses 
 
So far in this chapter, the response to 5T4 epitopes have been defined in terms of 
IFN-γ production, since IFN-γ is produced upon activation of T cells with their 
cognate antigen. Another cytokine produced by subsets of CD4+ T cells that has not 
been explored is interleukin-10 (IL-10), which, in contrast to IFN-γ, has potent 
suppressive effects upon many cell types, including other CD4+ T cells (Fujio, 
Okamura et al. 2010). It was hypothesized that if 5T4-specific Tregs are indeed 
suppressing activation or effector function of 5T4-specific effector T cells, they 
themselves may be producing IL-10 to reduce the immune response. IL-10 ELISpots 
were therefore carried out with whole PBMC alongside CD25-depleted PBMC to 
identify whether CD25hiCD4+ T cells were responsible for inhibiting anti-5T4 
immune responses via IL-10 production. 
 
 Results from one healthy donor show that where IFN-γ has been produced in 
response to a 5T4 epitope, IL-10 is also produced, i.e. positive responses were found 
to peptides 2, 4, 26, 28, 38 and 40 in both ELISpots (Figure 3.23A). Following 
depletion of CD25hi Tregs from the peripheral blood, some IFN-γ responses were 
diminished, e.g. peptides 2, 26 and 38, and new responses were identified, e.g. 
peptide 11. It is possible that removal of CD25hi CD4+ T cells could remove 
activated 5T4-specific T effector cells as well as 5T4-specific T regulatory cells prior 
to culture (Figure 3.23B). Interestingly, the IL-10 responses to certain peptides (e.g. 
peptide 28) remain unchanged, but other de novo responses were identified (i.e. 
peptide pools 9 and 12). This suggests that IL-10 production is not limited to classical 
CD4+CD25hiFoxp3+ regulatory T cells, but is produced in sizeable quantities by other 
Foxp3- helper T cells.  
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A: HD212 PBMC 
 
B: HD212 CD25-depleted PBMC 
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Figure 3.23 5T4-specific T cell 
production of IFN-γ  and IL-10 
after short-term culture. Freshly 
isolated PBMC (A) and CD25-
depleted PBMC (B) from healthy 
donor ‘HD212’ were stimulated with a 
panel of 13 peptide pools covering the 
entire 5T4 sequence (see Table 2.4, 
page 60 for 5T4 peptide pools and 
matrix system) and cultured for a 
period of 12 days in vitro. Cultured 
PBMC were subsequently assessed for 
the number of IFN-γ+ and IL-10+ T 
cells (per 105 cultured lymphocytes) 
specific for the 13 5T4 peptide pools. 
(* indicates positive response).!
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3.2.11.1 5T4-specific IL-10 responses in pregnant women 
 
Given the expression of 5T4 on trophoblasts, it is essential that pregnant women do 
not mount an immune response directed towards targeting 5T4-positive cells. Thus, 
regulation of 5T4-specific T cell responses must be robust to counteract this effect. 
To test this hypothesis, freshly isolated PBMC from three pregnant women (each in 
second trimester) were obtained and subjected to ex vivo IFN-γ and IL-10 ELISpots, 
testing for their reactivity to the 5T4 peptide pools. As expected, there were no IFN-γ 
responses to any 5T4 peptide (example shown in Figure 3.24A); however, a number 
of peptide pools produced sizeable IL-10 responses. In one donor in particular, 
peptide pools 4 and 8, implicating peptide 10 as being an immunogenic epitope, 
stimulated T cell IL-10 production (Figure 3.24B and C).   
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Figure 3.24 ex vivo 5T4-specific T cell responses in a pregnant woman. Freshly 
isolated PBMC from a pregnant woman were assessed for the number of IFN-γ+ (A) 
and IL-10+ (B) T cells (per 105 PBMC) following overnight stimulation with the 5T4 
peptide pools (see Table 2.4, page 60 for 5T4 peptide pools and matrix system). ELISpot 
well images of positive (5T4 PP4 and PP8) and negative (5T4 PP1) IL-10 responses 
are shown (C).  
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3.2.12 5T4 responses in CRC patients treated with TroVax® and 
cyclophosphamide  
 
Following on from a large body of evidence in mice and humans demonstrating that 
regulatory T cells actively suppress 5T4-specific effector T cells, a phase II clinical 
trial was established to test the effect of Treg depletion alongside concurrent T cell 
stimulation with the 5T4-encoding, MVA-based vaccine TroVax®, in patients with 
metastatic colorectal cancer.   
 During this course of treatment, blood samples were frequently taken to assess 
for a number of immune parameters (see Appendix for trial flowchart). Cell counts 
from these samples indicate that in two patients recruited to the study, the number of 
CD4+ and CD8+ T cells per µl of whole blood increased significantly over a short 
period of time (Figure 3.25). In the space of four days, the number of CD4+ T cells in 
Patient 101 tripled from 366/µl to 1094/µl and the number of CD8+ T cells increased 
from 55/µl to 250/µl over eight days. Likewise, in Patient 102, CD4+ T cells more 
than doubled in the space of 12 days, from 335/µl to 843/µl and CD8+ T cells 
increased from 34/µl to 390/µl over the same period of time. A similar pattern was 
observed in NK and NKT cell numbers. Cell counts consistently reduced over the 
following weeks after the end of cyclophosphamide treatment.  
 Foxp3+ regulatory T cell numbers in peripheral blood during treatment 
fluctuated greatly. In Patient 101, numbers actually doubled from 56/µl to 120/µl over 
the first four days. However, this coincided with a demonstrable increase in the CD4+ 
effector T cell population; when analysing the overall proportion of Foxp3+ Tregs 
amongst the peripheral CD4+ T cell subset, this decreased by over 30% over the first 
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Figure 3.25 Whole blood cell counts from two patients taking low-dose 
cyclophosphamide. 50mg B.D. cyclophosphamide was given to patients for an initial 
7-day period, followed by one-week off, then a further 6-days on (pale blue blocks). 
CD4+, CD8+ T cells, Foxp3+ Tregs, NK and NKT cell counts per µl of whole blood 
were measured using flow cytometry-based methods. Patients were followed-up for a 
further 5-7 weeks to assess longer-term effects.    
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Figure 3.26 Proportion of CD4+ T cells expressing Foxp3 in two patients taking 
low-dose cyclophosphamide. 50mg B.D. cyclophosphamide was given to patients 
for an initial 7-day period, followed by one-week off, then a further 6-days on (pale 
blue blocks). Over this time, freshly isolated PBMC were stained and analysed by 
FACS to assess for the proportion of Foxp3+ regulatory T cells present amongst live 
peripheral CD4+ T cells.  
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four days (Figure 3.26). By the end of metronomic cyclophosphamide treatment, the 
Treg proportion had reduced in Patient 101 by 24% and in Patient 102 by 5%. It is 
clear from the two patients studied here, however, that there is no long-term decrease 
in the proportion or number of Foxp3+ regulatory T cells following cyclophosphamide 
as these quickly return to baseline levels. In addition, there was no great difference in 
the mean fluorescence intensity of Foxp3 expression on Tregs throughout treatment, 
despite initial reductions and consequent fluctuations (Figure 3.27). Neither patient 
relapsed throughout the course of the trial. More patients are currently under study to 
determine whether these results are reproducible.  
 The transcription factor Helios has previously been shown to denote a 
population of Foxp3+ regulatory T cells derived from the thymus (Thornton, Korty et 
al. 2010), although this has recently been called into question (Gottschalk, Corse et al. 
2012). Regardless, it is now established that this marker designates a more 
suppressive subset of Foxp3+ Treg (Elkord and Al-Ramadi 2012). The expression of 
Helios was monitored in the Foxp3+ Treg subset in these patients taking 
cyclophosphamide. In both patients, initial reductions in their proportions were found, 
indicating that cyclophosphamide was selectively depleting the more suppressive 
Helios+Foxp3+ Treg subset (Figure 3.28). However, the proportion of these cells 
recovered in both patients and no significant difference was found in either patient by 
the end of treatment; indeed in Patient 101, the proportion had actually increased. 
 The primary endpoint of this trial is to achieve an increase in anti-tumour 
immune responses at week 7 (day 43) in patients treated with both low-dose 
cyclophosphamide and TroVax® in comparison to controls. To do this, T cell 
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Figure 3.27 Mean fluorescence intensity of Foxp3 expression on CD4+Foxp3+ 
regulatory T cells in two patients taking low-dose cyclophosphamide. 50mg B.D. 
cyclophosphamide was given to patients for an initial 7-day period, followed by one-
week off, then a further 6-days on (pale blue blocks). Over this time, freshly isolated 
PBMC were stained and analysed by FACS to assess for the mean fluorescence 
intensity of Foxp3 on live CD4+Foxp3+ peripheral Tregs.  
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Figure 3.28 Proportion of CD4+Foxp3+ Tregs expressing Helios in two patients 
taking low-dose cyclophosphamide. 50mg B.D. cyclophosphamide was given to 
patients for an initial 7-day period, followed by one-week off, then a further 6-days on 
(pale blue blocks). Over this time, freshly isolated PBMC were stained and analysed 
by FACS to assess for the proportion of live CD4+Foxp3+ peripheral Tregs expressing 
Helios.   
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IFN-γ responses to 5T4 were measured using ELISpot at various time-points 
throughout the trial, again following a period of in vitro culture with 5T4 peptide 
pools, as described previously in this chapter. In Patient 102, who received low-dose 
cyclophosphamide alone, increases in anti-5T4 T cell responsiveness were found, 
both in terms of the cumulative response to all peptide pools, and the average 
response to each putative epitope, reaching a peak at day 15 (Figure 3.29). Responses 
soon dropped by day 29 and by day 43, these returned to baseline levels. This result 
indicates that administering metronomic low-dose cyclophosphamide alone can 
improve anti-tumour immune responses over a short period of time. However, T cell 
immune responses are also improved to the re-call antigens, tuberculin purified 
protein derivative and the influenza protein haemagglutinin (X-31) (Figure 3.31). 
Thus, the improvements in T cell IFN-γ production during cyclophosphamide 
treatment are not specific for 5T4-specific T cells. 
 Patient 101, who received low-dose cyclophosphamide followed by TroVax® 
vaccinations, responded in a similar fashion to the cyclophosphamide therapy, again 
reaching a peak at day 15 (Figure 3.30). However, instead of returning to baseline 
soon after stopping cyclophosphamide, the TroVax® vaccinations appear to sustain 
the existing anti-5T4 immune response up until week 7. After this, a reduction in 5T4 
responses was noted, potentially due to the larger proportion of Foxp3+ regulatory T 
cells observed at day 57 (see Figure 3.26). Indeed between day 43 and day 57, a 30% 
increase in the proportion of CD4+ T cells expressing Foxp3 was found. It appears 
that TroVax® induces Foxp3+ Tregs and it is highly probable that this subset of cells 
is responsible for suppressing anti-5T4 T cell responses in culture, given the data 
previously described in this chapter. In addition, T cell responses to the re-call 
antigens were high at day 71 (Figure 3.31), despite relatively poor 5T4 T cell 
 122 
responses (Figure 3.30) and a very high proportion of peripheral CD4+ T cells 
expressing Foxp3 (Figure 3.26). 
 Out of a total of ten patients currently enrolled on the trial, six have received 
low-dose cyclophosphamide. In agreement with the two patients studied in detail here, 
all patients demonstrated a transient depletion of peripheral blood-derived Foxp3+ 
Tregs in the first 22 days of treatment (Figure 3.32A). This reduction in Treg 
proportion corresponds with a significant increase in the total magnitude of 5T4 
responses generated (Figure 3.32B). This was not found in the four patients who did 
not receive cyclophosphamide. 
 In the same ten patients, seven received TroVax® vaccinations and their 5T4 
T cell responses measured at day 0 and day 43 to assess the effectiveness of the 
vaccine to stimulate a T cell response. Overall, the data reveal a significant increase in 
the absolute difference in the magnitude of IFN-γ responses generated on a per 
epitope basis (Figure 3.33A). A similar trend was found in total 5T4 responses, albeit 
insignificant given the low numbers of patients at this point (Figure 3.33B). Thus, the 
5T4 T cell responses generated by patient 101 appear to be replicable in the early 
stages of this trial. 
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Figure 3.29 5T4-specific T cell responses in CRC patient ‘102’ taking low-dose 
cyclophosphamide. 50mg B.D. cyclophosphamide was given to patient 102 for an 
initial 7-day period, followed by one-week off, then a further 6-days on (pale blue 
blocks). Over this time, freshly isolated PBMC were cultured with 5T4 peptide pools 
and analysed at day 12 by IFN-γ ELISpot for the total 5T4 response magnitude and 
5T4 magnitude per epitope. 
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Figure 3.30 5T4-specific T cell responses in CRC patient ‘101’ taking low-dose 
cyclophosphamide followed by four rounds of vaccination with TroVax®. 50mg 
B.D. cyclophosphamide was given to patient 101 for an initial 7-day period, followed 
by one-week off, then a further 6-days on (pale blue blocks). Following this, TroVax® 
vaccinations were administered (pale red blocks). Over this time, freshly isolated 
PBMC were cultured with 5T4 peptide pools and analysed at day 14 by IFN-γ 
ELISpot for the total 5T4 response magnitude and 5T4 magnitude per epitope.  
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Figure 3.31 T cell responses to re-call antigens after low-dose cyclophosphamide 
± TroVax® vaccination. Freshly isolated PBMC were cultured with the re-call 
antigens, tuberculin purified protein derivative (PPD) or haemagglutinin X-31 (HA) 
and specific T cell responses measured at day 14 by IFN-γ ELISpot.   
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Figure 3.32 Low-dose cyclophosphamide reduces Treg proportion resulting in 
enhanced anti-5T4 T cell responses. Six metastatic (Stage IV) CRC patients were 
given 50mg B.D. cyclophosphamide at indicated time-points (grey bars) and a further 
4 patients were assigned to a control group (no treatment). Treg proportion amongst 
peripheral blood was analysed throughout (A). Corresponding measurements of total 
5T4 response (as defined in previous figures) were taken before the start (Day 1) and 
after (Day 22) treatment, resulting in a significant increase in the overall anti-5T4 
response in the six patients taking cyclophosphamide; two-tailed t-test: *p < 0.05 (B).  
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Figure 3.33 Absolute difference in 5T4 T cell response magnitude between day 0 
and day 43 of trial. Measured IFN-γ responses (sfc/105) to the 5T4 peptide pools 
were measured at day 0 and day 43 and the absolute difference in the magnitude per 
epitope or total magnitude were calculated (as defined in previous figures). 
Significant differences are indicated; *p < 0.05.  
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3.3 Discussion 
 
In this Chapter, an analysis of anti-tumour T cell responses to the oncofoetal antigen, 
5T4, was performed. Specifically, experiments focused on investigating the range and 
magnitude of anti-5T4 T cell responses generated by cancer patients awaiting surgical 
resection of a colorectal tumour and comparing these to healthy age-matched donor 
controls. In this process, a number of 5T4-specific T cell clones were established, 
with the aim of producing class-II tetramers to help identify tumour-specific T cells 
present in other tissues by FACS. The effects of age, individual HLA-type, Treg 
proportion and progressive tumour growth on 5T4 T cell responses were also studied 
to decipher the mechanisms of tumour-mediated immunosuppression. 
 
Successful anti-tumour adaptive immunity is dependent on activation of helper 
CD4+ T cells by antigens upregulated in neoplastic cells. In CRC it appears that this 
process becomes restricted allowing for growth, and metastatic spread, of cancerous 
tissue (Clarke, Betts et al. 2006; Betts, Jones et al. 2011). The results in this chapter 
advance previous studies by demonstrating that the actual magnitude of anti-tumour 
CD4+ T cell responses measured in peripheral blood can be correlated to the stage of 
the colorectal tumour, and indeed, can predict progression to metastatic spread. 
 
Here, the oncofoetal antigen 5T4 was used as a candidate tumour-specific 
antigen. Utilizing 41 overlapping 20mer peptides allowed an unbiased approach to 
epitope mapping and negated the requirement for peptide binding algorithm software, 
as 5T4 peptides with high HLA binding affinities may not necessarily be those 
recognised in vivo. This is due to negative thymic deletion of T cells with high 
affinities for self-antigens, although other non-deleting mechanisms can also control 
the avidity with which T cells recognize self-antigens (Anderton and Wraith 2002). 
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5T4-specific T cell Responses in Healthy Donors 
 
A range of 5T4-derived CD4+ T cell epitopes was identified for individuals of 
each HLA-DR subtype using the 5T4 peptide pool matrix system. It was surprising 
that such robust responses to these epitopes were found in healthy controls, and raises 
the important question as to how these T cells are maintained at a high frequency in 
the CD45RO+ memory pool. Although tumour-specific T cells have previously been 
encountered in healthy donors (Campi, Crosti et al. 2003; Danke, Koelle et al. 2004; 
Pickford, Watson et al. 2007; Elkord, Burt et al. 2008; Tassi, Gavazzi et al. 2008), no 
studies have been undertaken to ascertain why they exist. It was hypothesized here 
that 5T4 expression might not just be limited to colorectal tumours and placenta; one 
possibility is transient up-regulation of 5T4 in subjects with periods of inflammation 
of the colon. Patients suffering from the inflammatory bowel diseases ulcerative 
colitis or Crohn’s disease, who underwent resection of the inflamed colon, were 
enrolled in this study to perform 5T4 immunohistochemistry analysis on obtained 
sections. We found widespread 5T4 expression in inflamed tissue of the gut, most 
obvious in areas of cryptitis, a common occurrence in IBD patients where an 
intestinal crypt has become inflamed. It is therefore plausible that 5T4-specific T cell 
responses may be produced to help resolve bouts of inflammation, perhaps 
gastroenteritis, encountered by an individual. 5T4-specific Tregs may also exist to 
regulate the anti-inflammatory response. It would be interesting to measure the 
magnitudes of 5T4 immune responses in such patients when inflammation is at its 
most severe. In addition, other inflamed tissues should be assessed for 5T4 
expression, since this has not been explored previously.  
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A further possibility is that the existence of 5T4 immune responses in healthy 
donors reflects a continuing process of tumour immunosurveillance. This hypothesis 
requires T cells to recognize and target cancerous cells in order to prevent 
carcinogenesis and help maintain regular cellular homeostasis. Since 5T4 is 
expressed predominantly on well-differentiated cancerous tissue (Southall, Boxer et 
al. 1990), the existence of memory 5T4-specific T cell populations in healthy donors, 
which are capable of inducing cell death in 5T4-positive tumour cells (Al-Taei, 
Salimu et al. 2012) further supports this hypothesis.  
 
Decreased 5T4 T cell Responses Correlates with Disease Progression 
 
A major finding from the work presented in this chapter was the identification 
of decreased CD4+ T cell responses to 5T4 significantly correlating with a steadily 
worse histopathological tumour grade (i.e.T1→T2→T3→T4). This indicates that 
patients with more advanced tumours, both in terms of invasiveness through the 
bowel wall and direct size / burden, have a reduced capacity for T cell-mediated anti-
tumour immunity. This was further substantiated by follow-up data showing that 
those patients bearing advanced tumours with lymph node involvement, yet who had 
robust pre-operative 5T4 T cell responses, were 30% less likely to develop metastatic 
disease by 12-months post-surgery. Given the role of 5T4 in facilitating metastatic 
spread (Carsberg, Myers et al. 1996; Southgate, McGinn et al. 2010), it appears that 
5T4 T cell reactivity is also related to the ability of an individual to control cancerous 
disease from metastasizing. The measured loss of anti-tumour CD4+ T cell responses 
in blood also provide a basis for further studies to examine the usefulness of 
measuring T cell responses as a disease biomarker, since an average epitope-specific 
response of ≥75 SFC/105 cultured cells distinguished CRC patients and controls with 
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a specificity of 94%. No such blood test currently exists and it may prove very useful 
in determining the course of treatment given to cancer patients, as patients with 
poorer responses will require more aggressive therapy to eradicate the tumour. 
 
Although an inadequate anti-5T4 immune response in CRC patients is found 
pre-surgery compared to responses in healthy controls, responses to the tuberculin 
recall antigen, PPD, remained unimpaired, confirming a tumour-antigen specific 
defect, as shown previously (Clarke, Betts et al. 2006). This is consistent with other 
reports identifying a reduction in CEA-specific T cell responses in pancreatic cancer 
patients, whilst anti-viral haemagglutinin-specific responses were analogous to 
healthy controls (Tassi, Gavazzi et al. 2008). A potential Th2 skew of anti-tumour T 
cells could be leading to the poor responses, since a Th1 response is required for 
maximal anti-tumour immunity (Hung, Hayashi et al. 1998). CEA-specific T cells 
isolated from cancer patients predominantly produce the Th2 cytokines IL-4 and IL-5, 
whereas the same cell subset from healthy donors produce IFN-γ. Crucially, this skew 
was limited to tumour-specific T cells and antiviral immunity remained unimpaired 
between cancer patients and healthy donors (Tassi, Gavazzi et al. 2008). Therefore, 
the resultant loss of 5T4-specific T cell responses found in more advanced disease 
may be the result of loss of Th1 function in these cells, rather than a reduction in 
numbers or responsiveness. It will be interesting to determine a possible immune 
deviation amongst 5T4-specific T cell responses as tumours progress, using IL-4 / IL-
5 ELISpots.  
A change of cytokine profile amongst tumour-specific T cells would most 
likely be caused by factors within the tumour microenvironment, where these cells 
may encounter antigen-loaded dendritic cells with Th2 polarizing capabilities (Moser 
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and Murphy 2000; Protti and De Monte 2012). It would be interesting to confirm the 
presence of 5T4-specific T cells amongst colorectal tumour infiltrating lymphocytes, 
since it is within this microenvironment that these cells must exert effector functions 
to eradicate cancerous cells (Bindea, Mlecnik et al. 2010). Although some evidence 
was provided for 5T4 T cell reactivity in the tumour and tumour draining lymph node 
in this chapter, this was not reproducible (1 CRC tumour out of 6 identified a positive 
5T4 T cell line) and was limited to analysis of IFN-γ production. Th1 responses could 
either be impeded by large proportions of suppressive T cells present amongst 
lymphocyte subsets isolated from these compartments (see Chapter 4) or a Th2 skew 
of these cells would require analysis of Th2 / Th17 cytokines by ELISpot. 
 
Tumour-specific Regulatory T cells 
A large body of evidence also shows that regulatory T cells can suppress anti-
tumour T cell responses (reviewed in (Nishikawa and Sakaguchi 2010)). Cancer-
bearing individuals have increased proportions of Tregs in the periphery as defined 
by high levels of cell surface CD25 expression and, more recently, by intracellular 
Foxp3 expression (Betts, Clarke et al. 2006; Beyer and Schultze 2006; Miller, 
Lundberg et al. 2006; Ling, Pratap et al. 2007). Our lab recently reported that the 
presence of CRC drives a population of Tregs that inhibit anti-tumour immune 
responses to the tumour associated antigens 5T4 and CEA, and although excision of 
the tumour lead to normalization of Treg numbers, suppression of T cell responses 
prior to resection was still associated with tumour recurrence at 12 months (Betts, 
Jones et al. 2011). Although increased proportions of Tregs in the peripheral blood of 
cancer-bearing individuals has been widely reported, there are currently no studies 
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analysing changes in Treg proportion with tumour advancement. In the cohort of 
CRC patients examined here, a significant increase was noted in the proportion of 
peripheral blood-derived Tregs (i.e. CD4+ T cells expressing the transcription factor 
Foxp3) as tumours progressed, defined by histopathological grading of tumour 
invasion through the bowel wall. The reason for elevated Treg proportions during 
malignancy is unclear. A possible explanation is that tumour antigens such as 5T4 
and CEA are expressed to prevent immune recognition by stimulating regulatory T 
cells. Such antigens are expressed during foetal development as they are hypothesized 
to control maternal immune recognition of the partially allogeneic foetus. This is 
demonstrated by CEA-CEACAM-1 interactions directly suppressing T cell responses 
(Gray-Owen and Blumberg 2006). It is also possible that expression of such 
molecules drives proliferation, conversion or accumulation of regulatory T cells, 
owing to their large proportions within the tumour microenvironment (see Chapter 4).  
 
Removal of Tregs in vitro resulted in greater 5T4 responses to certain epitopes, 
de novo epitope responses and no difference in response to other epitopes. Thus, it 
appears that Tregs are capable of suppressing only certain effector 5T4 T cell 
responses, meaning that Tregs don’t recognize all 5T4 epitopes that stimulate effector 
T cell responses. This is important for future potential immunotherapy; by defining 
5T4-derived MHC-class II restricted epitopes, superior peptide-based vaccines could 
be designed to incorporate CD4+ T effector cell epitopes whilst minimising 5T4-
specific Treg activation, with the potential to induce maximal anti-tumour effects. 
Work is on-going to definitively identify 5T4 Treg epitopes with this prospective 
treatment approach in mind. 
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 A trend was also found between decreased 5T4 T cell responses after culture 
if the initial proportion of Foxp3+ Tregs was relatively higher. It is tempting to 
speculate that Tregs may be responsible for inhibiting the establishment of 5T4-
specific effector T cell activation and expansion over the 2-week period of culture, 
thus resulting in the diminished 5T4 responses identified in patients with more 
advanced tumours. If Tregs are stimulated by TAAs in vivo, this might inhibit 
effective cancer immunotherapy (Welters, Kenter et al. 2010). Furthermore, in Patient 
101, a reduction in 5T4 T cell responsiveness was noted following the fourth 
TroVax® vaccination. This correlated with a stark increase in the proportion of 
peripherally derived Tregs and therefore the proportion of Tregs plated in the PBMC 
culture will be greater. If TroVax® has indeed induced a 5T4-specific Treg response, 
this may explain the decrease in responses found following repeat TroVax® 
vaccination in this patient.  
 
Tolerance to tumour antigens could also be accomplished via “ignorance” of 
effector T cells to respond to such antigens in vivo, or further regulation by IL-10 
secreting Tr1 cell subsets (Pickford, Watson et al. 2007). 5T4-specific IL-10 
responses were readily detectable in vitro, even after Treg depletion, suggesting that 
Foxp3- Tr1 cells could be capable of inhibition of effector T cell responses. However, 
IFN-γ production was still mostly unaffected to the same epitope responses, although 
further experiments will be required to determine whether blocking IL-10 increases 
these responses further.  
 
Depleting Tregs and Stimulating 5T4 Responses in CRC Patients 
 
It has previously been proposed that a low 50mg B.D. iterative dosage of 
cyclophosphamide, referred to as “metronomic” therapy, was sufficient to selectively 
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deplete CD4+CD25+ regulatory T cells (Ghiringhelli, Menard et al. 2007). This 
therapy had the dual benefit of restoring T and NK cell effector functions and could 
therefore be considered as an effective immunotherapeutic adjunct. Here, two patients 
were recruited and given the same dose and regime previously identified to be 
effective; specifically, 50mg B.D. was taken for an initial 7-day period, followed by 
one week off, then a further 7-days back on treatment. TroVax® would then be 
administered to patients 24 hours following their last dose of cyclophosphamide. 
Preliminary findings from this trial reveal a striking increase in the CD4+ and CD8+ T 
cell number after cyclophosphamide treatment; despite small increases in Foxp3+ 
Treg numbers, overall proportions of Tregs reduced in both patients. This response 
was also short-lived and TroVax® vaccination resulted in a further enlargement of the 
Treg proportion; this is in contrast to intravenous use of cyclophosphamide to deplete 
Tregs where an overall reduction in Treg numbers was still present 24 days after 
injection (Walter, Weinschenk et al. 2012).  
 
One of the most compelling results of cyclophosphamide treatment in this trial 
was the induction of 5T4-specific T cell responses found in both patients at day 15 
after the start of treatment. Very similar findings were obtained in a trial using 
identical cyclophosphamide therapy, whereby endogenous breast tumour–reactive T 
cells were detected in 27% of patients before cyclophosphamide treatment, which 
increased to 73% by day 14. Most strikingly, an increase in breast tumour–reactive T 
cells was associated with both stable disease and overall survival (Ge, Domschke et al. 
2012). However, 5T4-specific T cell responses quickly diminished after completion 
of cyclophosphamide therapy; TroVax® vaccination was necessary and sufficient to 
sustain this 5T4 response. Although early findings from the trial indicate that these 
results appear reproducible, the results from all 54 enrolled patients will be analysed 
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throughout the trial and immunological responses correlated to clinical outcome to 
assess whether metronomic cyclophosphamide can enhance the effects of active 
immunotherapy. 
 
Conclusion 
 
In summary, an in depth analysis of oncofoetal antigen 5T4-specific T cell responses 
was performed, which revealed several interesting findings. Namely, these were: 
- A significant and highly specific reduction of 5T4-specific T cell IFN-γ 
production in CRC patients with more advanced Dukes’ C tumours, which 
was irrespective of HLA-type and age; 
- Low pre-operative 5T4 T cell responses was indicative of an increased 
likelihood of metastatic disease 12 months after surgery; 
- An increase in the proportion of peripheral Tregs as the colorectal tumour 
progresses, corresponding with poorer 5T4-specific T cell responses; 
- The identification of robust anti-5T4 memory T cell responses in healthy 
donors and its expression on inflamed tissue in the gut; 
- Metronomic low-dose cyclophosphamide therapy increases 5T4-specific T cell 
responses, re-call T cell responses, CD4+ and CD8+ T cell numbers and 
partially reduces Treg proportions; 
- TroVax® appears to induce an increase in the Treg proportion in one CRC 
patient. 
Collectively, the data presented in this chapter support the hypothesis that Foxp3+ 
regulatory T cells actively impinge upon anti-tumour immune responses. In addition, 
they provide the basis for further studies to examine the usefulness of measuring anti-
tumour T cell responses as a disease biomarker. Finally, preliminary data from 
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TaCTiCC, using Treg depletion strategies alongside immunotherapeutic vaccines, is 
providing useful insights into the effectiveness of this treatment regime in patients 
with metastatic colorectal cancer. 
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Chapter 4 – Phenotypic and Functional Analysis of Colorectal 
Tumour-Infiltrating Lymphocytes 
 
4.1 Introduction 
 
The adaptive immune system can be directed against neoplastic, transformed cells 
(Schreiber, Old et al. 2011). Although there is evidence that an increased CD3+ T cell 
infiltrate improves prognosis in CRC (Galon, Costes et al. 2006), the fact that tumours 
still progress demonstrates a failure of anti-tumour immune responses to control the 
lesion effectively. Immunologically, there are several explanations that may work 
singularly or in conjunction to explain this observation. The tumour 
microenvironment seems to suppress immune responses as the tumour progresses, 
potentially reflecting a functional switch in tumour-infiltrating dendritic cells (DCs) 
towards an immunosuppressive phenotype (Scarlett, Rutkowski et al. 2012). This 
switch is encouraged by suppressive cytokines and growth factors within the tumour, 
including IL-10 (Fujio, Okamura et al. 2010), TGF-β (Wrzesinski, Wan et al. 2007; 
Flavell, Sanjabi et al. 2010), vascular endothelial growth factor (VEGF) (Ellis and 
Hicklin 2008) and the activity of indoleamine 2,3-dioxygenase (IDO) (Munn and 
Mellor 2007). Hence, anti-tumour T cells become less responsive in advanced 
tumours (Nagaraj, Gupta et al. 2007).  
In addition to these factors, an antigen-specific suppression of effector T cell 
responses is mediated by a population of CD4+Foxp3+ regulatory T cells (Tregs) 
(Nishikawa and Sakaguchi 2010) (Gallimore and Godkin 2008), either directly or 
through indirect effects on DCs (Liang, Workman et al. 2008; Shevach 2011). These 
Tregs have an important role in preventing autoimmunity, but may also control 
immune responses to a range of tumours (Betts, Clarke et al. 2006). Work from this 
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laboratory has previously found that the presence of CRC is associated with an 
expanded and distinct population of Tregs in blood, which specifically inhibits anti-
tumour immune responses (Clarke, Betts et al. 2006). Resection of the primary 
tumour led to a reduction in the magnitude of this peripheral Treg population, and 
pre-operative suppression of tumour-specific T cell function was associated with 
tumour recurrence one year later (Betts, Jones et al. 2011). However, a number of 
reports have demonstrated decreased Foxp3+ Treg infiltrates in more advanced 
tumours that correlate with poor disease outcome (Salama, Phillips et al. 2009; Frey, 
Droeser et al. 2010). Differences in the proportions of peripheral and intra-tumoural 
Foxp3+ Tregs could account for these seemingly disparate findings, but it is also 
possible that regulatory T cell populations other than Foxp3+ Tregs mediate 
suppression of anti-tumour responses.  
To understand the role of intra-tumoural Tregs, this chapter demonstrates 
work undertaken to perform a detailed phenotypic and functional analysis of various 
T cell subsets that infiltrate human colorectal tumours. Multi-parameter flow 
cytometry and functional assays of distinct populations isolated by fluorescence-
activated cell sorting (FACS) were used to compare tumour-infiltrating lymphocytes 
(TILs) with the corresponding CD4+ T cell subsets in healthy colon and peripheral 
blood. A marked difference in the phenotype of Foxp3+ Tregs was observed, with 
intra-tumoural Tregs expressing far greater levels of markers associated with 
suppression. These data reveal the presence of a novel suppressive CD4+ T cell 
population within colorectal tumours that is phenotypically and functionally distinct 
from CD4+Foxp3+ T cells and could be contributing to immunological suppression of 
anti-tumour T cell responses. 
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4.2 Results 
4.2.1 Analysis of Foxp3 expression amongst T cell subsets in peripheral blood, 
colon and tumour.  
 
The transcription factor Foxp3 is still widely regarded as the best marker for 
determining T cell subsets with suppressive capabilities and has been used extensively 
to identify regulatory T cells in patients with cancer (Kryczek, Liu et al. 2009; 
Nishikawa and Sakaguchi 2010). Initially, intracellular Foxp3 expression was 
analysed amongst CD4+ T cells isolated from peripheral blood, colonic mucosa and 
colorectal tumour specimens, by flow cytometry. Examples of Treg identification and 
gating strategies are shown (Figure 4.1).  
 
Compared to healthy age-matched controls (HD), the overall proportion of 
CD4+ T cells expressing Foxp3 in the peripheral blood of CRC patients (n=13) was 
increased (patients 10.88% ± 0.77% vs. controls 7.77% ± 0.68%, p = 0.019; Figure 
4.2A). The relative proportions of Foxp3+ T cells remained remarkably consistent in 
CRC patients between peripheral blood and unaffected background colonic tissue 
(blood 10.88% ± 0.77% vs. colon 10.80% ± 0.87%); however, a significant increase 
was observed amongst colorectal tumour-infiltrating CD4+ T cells (tumour 21.77% ± 
2.46%; vs. colon, p = 0.0027 ; vs. blood, p = 0.0024). This is consistent with previous 
data obtained in our lab in a mouse model of cancer (Betts, Twohig et al. 2007) and 
other human tumours (Beyer and Schultze 2006; Whiteside 2012) and is indicative of 
a suppressive tumour microenvironment. However, the overall fluorescence intensity 
of Foxp3 expression did not significantly differ amongst CD4+Foxp3+ T cells in blood, 
colon or tumour (Figure 4.2B). Thus, whilst the overall proportion of CD4+ T cells 
expressing Foxp3 is greatest in the tumour, they may be no more suppressive on an  
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Figure 4.1 Ex vivo phenotypic analysis of regulatory CD4+Foxp3+ T cells in CRC 
patients. Representative bivariate flow cytometry plots showing Foxp3 expression on 
live CD4+ T cells obtained from matched peripheral blood, unaffected colon and 
colorectal tumour samples. A lymphocyte gate was initially drawn based on forward 
scatter vs. side scatter profiles (top three plots). Next, a gate was placed around those 
lymphocytes that did not take up the live/dead-aqua stain (middle three plots). Finally, 
live lymphocytes were analysed for CD4 and Foxp3 expression, using the gating 
strategy shown above (bottom three plots).   
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Figure 4.2 A comparison of CD4+ T cells expressing Foxp3 in different 
compartments. (A) Percentage of live CD4+ T cells expressing Foxp3 in PBMC 
samples from age-matched healthy donors (HD; n=6; mean age = 71 years), and 
PBMC, unaffected colon and tumour samples from CRC patients (n = 13; mean age, 
72 years). Significant differences are indicated; *p < 0.05, **p < 0.01. (B) Mean 
fluorescence intensity of Foxp3 expression on live CD4+ T cells.  
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individual cell basis than comparable cells found in peripheral blood or colon 
(Chauhan, Saban et al. 2009). 
 
Low levels of Foxp3 expression amongst intratumoural single positive CD8+ 
T cells were observed (Figure 4.3: 1.66% ± 0.46%; n = 8), in keeping with previous 
reports indicating that between 1-2% of CD3+CD8+ T cells express CD25 and Foxp3 
in colorectal cancer tissue (Chaput, Louafi et al. 2009). This subset of cells, although 
only comprising a very small fraction of the total T cell pool, has been shown to bear 
suppressive characteristics in vitro. In the majority of tumour specimens, CD4+CD8+ 
double positive T cells were also identified and a relatively greater proportion of these 
cells expressed Foxp3 (Figure 4.3B; CD4+CD8+ T cells 22.95% ± 5.5% vs. CD8+ T 
cells 1.66% ± 0.48%, p=0.0053). This is very similar to the proportion of single 
positive CD4+ T cells that express Foxp3 (CD4+ T cells 22.23% ± 3.22%). This 
double positive colorectal tumour infiltrating T cell fraction has recently been 
described to possess significant anti-tumour reactivity, via the production of TNF-α 
(Sarrabayrouse, Corvaisier et al. 2011); increased Foxp3 expression could be 
indicative of the activated status of these cells (Morgan, van Bilsen et al. 2005). 
Indeed, the vast majority (~90%) of Foxp3+ T cells in the colorectal tumour samples 
analysed here were single-positive CD4+ T cells (Figure 4.3C). 
 
In results Chapter 3, increased proportions of Foxp3+ Tregs amongst 
peripheral blood-derived CD4+ T cells, were identified as the tumours progressed to 
more advanced stages. When analysing T cells that infiltrate colorectal 
adenocarcinomas, the relative proportions of Foxp3 expressing CD4+ T cells 
significantly increases as tumours progress from Dukes’ A to Dukes’ C (Figure 4.4A: 
Dukes’ A 17.03% ± 2.22% vs. Dukes’ C 26.03% ± 2.49%, p=0.023), indicating that   
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Figure 4.3 Colorectal tumour-derived single-positive CD8+ T cells do not express 
Foxp3. Representative bivariate flow cytometry plots showing live CD4+ and CD8+ T 
cells obtained from colorectal tumour samples and the subsequent analysis of 
intracellular Foxp3 expression in the various subsets (A).  
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Figure 4.3 Cont’d. Colorectal tumour-derived single-positive CD8+ T cells do not 
express Foxp3. Analysis of CD3+ T cells from 9 colorectal tumour specimens for 
Foxp3 expression (B). Having gated on all live CD3+Foxp3+ TILs, the relative 
proportion of each subset (single positive CD4+ / single positive CD8+ / double 
positive CD4+CD8+) expressing Foxp3 reveals that the vast majority are single 
positive CD4+ T cells. Significant differences are indicated; **p < 0.01, ***p < 0.001.   
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Figure 4.4 Increased Intracellular Foxp3 Expression in Intratumoural T cells as 
Tumours Progress. The proportion of live intratumoural CD4+ (A), CD8+ (B) and 
CD4+CD8+ double positive T cells (C) that express Foxp3 were correlated to Dukes’ 
classification of the tumour at time of excision. (Dukes’ A; n = 6, Dukes’ C; n = 7). 
Significant differences are indicated; *p < 0.05.  
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these cells accumulate within tumours as they become more invasive. Similar, albeit 
non-significant increases were also found in single positive CD8+ (Figure 4.4B) and 
double positive CD4+CD8+ T cells expressing Foxp3 (Figure 4.4C). Whilst this data 
corresponds favourably with previous findings from other laboratories, whereby CD4 
and CD8 Treg infiltration correlates positively with tumour stage and microinvasive 
status (Chaput, Louafi et al. 2009), studies using immunohistochemistry to perform 
the same analysis in colorectal tumour tissue do not find this correlation 
(Loddenkemper, Schernus et al. 2006; Ling, Pratap et al. 2007). 
 
4.2.2 Naturally-occurring and induced Treg infiltration of colorectal tumours 
 
Our lab reported previously that conversion of effector T cells into Tregs does 
not account for the increased proportion of Tregs found in a murine tumour model 
(Hindley, Ferreira et al. 2011). Helios, a member of the Ikaros family of transcription 
factors, was recently identified as a marker of thymus-derived Tregs (Thornton, Korty 
et al. 2010). The majority of Foxp3+ Tregs in CRC patients were Helios+, indicating 
that these populations predominantly comprised naturally occurring Tregs (Figure 
4.5A). However, the proportion of intra-tumoural Foxp3+ Tregs that expressed Helios 
was slightly lower compared to the corresponding peripheral blood populations, 
suggesting that the degree of conversion may be slightly increased in the tumour 
(tumour 58.54% ± 1.56% vs. blood 67.61% ± 2.25%, p = 0.012). Nonetheless, this 
difference was small, indicating that conversion does not account for the substantial 
enrichment of Foxp3+ Tregs in colorectal tumours. Based on the expression of Helios, 
approximately half of the Tregs in unaffected colon specimens appeared to be 
peripherally induced (colon 49.76% ± 2.77% vs. blood 67.61% ± 2.25%, p = 0.001). 
These findings are in line with previous reports demonstrating that the conversion of 
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Foxp3- T cells into Foxp3+ T cells physiologically expands the Treg repertoire in the 
gut (Barnes and Powrie 2009). Thus, consistent with our previous findings in murine 
models, the enrichment of Tregs in tumours appears to be mainly constituted from a 
thymus-derived population (Hindley, Ferreira et al. 2011).  
 
An interesting observation was that the proportion of PBMC-derived Tregs 
expressing Helios significantly increases with tumour advancement (Figure 4.5B; 
Dukes’ A to D linear regression: p = 0.0002, r2 = 0.63). Whilst healthy age-matched 
donors have significantly greater proportions of Helios+ Tregs than Dukes’ A CRC 
patients (HD 74.6% ± 1.94% vs. Dukes’ A 62.73% ± 1.46%, p = 0.0023), this in turn 
is significantly lower than patients with more advanced Dukes’ C / D patients (Dukes’ 
A 62.73% ± 1.46% vs. Dukes’ C 71.32% ± 2.54%, p = 0.035; vs. Dukes’ D 81.34% ± 
2.62%, p = 0.0007). This could reflect an induction of peripherally induced Tregs at 
early tumour stages or that Tregs in patients with more advanced tumours have a 
greater suppressive capacity. This finding was not replicated amongst intratumoural 
Foxp3+ Tregs (Figure 4.5C) and Helios expression remained consistent with tumour 
advancement. Notably, a higher mean fluorescence intensity (MFI) of Foxp3 on 
intratumoural Helios+ Tregs was also found (Figure 4.5D), indicative of the increased 
suppressive potential of this T cell subset (Chauhan, Saban et al. 2009). 
In an attempt to define exhausted T cells (Sakuishi, Apetoh et al. 2010), the 
markers PD-1 and TIM-3 were included in the FACS staining panel. The T cell subset 
identified as having the greatest proportion of double positive PD-1+TIM-3+ T cells 
was intratumoural CD4+Foxp3+Helios+ Tregs (Figure 4.6). Such an exhausted 
phenotype amongst TILs is thought to hinder productive anti-tumour immunity, but 
could also be upregulated on highly activated T cells. 
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A: 
  
B: PBMC-derived Tregs 
 
Figure 4.5 Ex vivo Helios expression amongst CD4+ T cells. Intracellular 
expression of the Helios transcription factor was assessed on CD4+Foxp3+ Tregs () 
and CD4+Foxp3- T cells () isolated from blood (PBMC), unaffected colon and 
tumour samples from CRC patients (A). Peripheral blood-derived CD4+Foxp3+ Tregs 
were analysed for the expression of Helios and correlated to CRC patients Dukes’ 
classification (B). Significant differences are indicated; *p < 0.05, **p < 0.01, 
***p<0.001.  
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C: Tumour-derived CD4+Foxp3+ Tregs  
 
D: 
 
 
Figure 4.5 Cont’d. Ex vivo Helios expression amongst CD4+ T cells. Tumour-
derived CD4+Foxp3+ Tregs were analysed for the expression of Helios and correlated 
to CRC patients Dukes’ classification (C). Significant differences are indicated; *p < 
0.05, **p < 0.01, ***p<0.001. The mean fluorescence intensity of Foxp3 was 
subsequently examined in colorectal tumour-infiltrating CD4+Foxp3+ Helios+ and 
Helios- Tregs, an example of which is shown with corresponding histogram (D).   
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Figure 4.6 CD4+Foxp3+ Helios+ TILs display the most exhausted phenotype. Live 
CD4+Foxp3+/- (top four plots) and CD4+Foxp3+Helios+/- T cells (bottom four plots), 
found in the colon and tumour, were analysed for the co-expression of PD-1 and TIM-
3 by FACS. 
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4.2.3 The majority of CD4+Foxp3+ regulatory T cells express ICOS 
 
The inducible T cell co-stimulator (ICOS) molecule is expressed on T follicular 
helper cells (TFH) and activated T cells; interactions with the ICOS-ligand enhance T 
cell proliferation, cytokine production and survival (Mahajan, Cervera et al. 2007). 
ICOS is also expressed abundantly on CD4+CD25highFoxp3+ Tregs, particularly those 
found in tumours (Strauss, Bergmann et al. 2008). Here, a similar pattern was 
identified in this cohort of CRC patients; an example of ICOS expression amongst 
colorectal CD4+ TILs is shown, alongside representative Foxp3 and Ki67 expression 
of ICOS+ and ICOS- subsets (Figure 4.7A). ICOS expression appeared to define a 
large proportion of the CD4+Foxp3+ TILs (Figure 4.7B). In all patients studied, ICOS 
was expressed mainly on CD4+Foxp3+ T cells compared to CD4+Foxp3- T cells in 
blood, colon and tumour (Figure 4.7C). The low levels of ICOS expression on 
CD4+Foxp3- cells did not differ significantly by site (blood 13.91% ± 2.56% vs. colon 
16.24% ± 4.07% vs. tumour 20.61% ± 3.49%, p = 0.37). However, in line with 
previous reports, CD4+Foxp3+ TILs expressed significantly higher levels of ICOS 
than peripheral blood CD4+Foxp3+ T cells (blood 45.46% ± 2.58% vs. colon 39.10% 
± 6.81% vs. tumour 60.78% ± 4.42%, p = 0.039). Furthermore, there was a very 
strong correlation between Foxp3 expression and ICOS expression on CD4+ TILs (p 
= 0.004, R2 = 0.71; Figure 4.7D).  
CD4+ICOS+/- T cells were purified from colorectal tumour specimens to 
further assess their functional capacity. In a standard three day in vitro proliferation 
assay, CD4+ICOS+ TILs were significantly more proliferative in response to 
stimulation with αCD3/28 beads compared to the corresponding CD4+ICOS- T cell 
subset (Two-way ANOVA of CD4+ICOS+ vs. CD4+ICOS- at each cell count; 
p<0.0001; Figure 4.8A), a finding that is paralleled by ex vivo Ki67 staining (Figure 
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4.7A). In addition, isolated TILs were added back to FACS-sorted autologous PBMC-
derived CD4+CD25- T cells, stimulated with αCD3/28 beads, to assess for 
suppression over a 3-day assay. Varying degrees of suppression were found and due 
to excessive proliferation of isolated TILs in some experiments, this lead to a 
potential underestimation of the suppressive effect, as analysed by tritiated thymidine 
incorporation (Figure 4.8B). Where suppression could be analysed, what is striking 
from this data is that, although CD4+ICOS+ TILs were highly suppressive in vitro as 
expected, the CD4+ICOS- TIL subset were in fact more suppressive at every 
regulatory to effector cell ratio. However, this should be interpreted with caution 
since the effector T cells present in the culture produce IL-2, which may cause the 
CD4+ICOS+ T cells to proliferate more than the CD4+ICOS- T cells, thus masking 
their suppressive effect. 
Taken together, the expression patterns of Foxp3, Helios and ICOS delineate a 
population of naturally occurring, highly proliferative Treg that infiltrate colorectal 
tumours. 
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Figure 4.7 Ex vivo ICOS expression amongst CD4+ T cells. Representative flow 
cytometry profiles showing immunofluorescence staining of live CD4+ICOS+ and 
CD4+ICOS- TILs, and their corresponding expression of Foxp3 and Ki67 (A and B). 
Cell surface expression of ICOS was assessed on CD4+Foxp3+ Tregs () and 
CD4+Foxp3- T cells () isolated from blood (PBMC), unaffected colon and tumour 
samples from CRC patients. Significant differences are indicated; *p < 0.05. (C) 
Linear regression comparing the percentage of intra-tumoural CD4+ T cells 
expressing ICOS with the percentage of intra-tumoural CD4+Foxp3+ Tregs (D).   
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Figure 4.8 CD4+ICOS+ / ICOS- T cell function. CD4+ICOS+ and CD4+ICOS- TILs 
were FACS sorted from a Dukes’ A colorectal tumour and matched healthy colonic 
mucosa. (A) CD4+ICOS+/- TILs were stimulated with αCD3/28 beads for 72 hours. 
Each cell dilution was carried out in duplicate. Two-way ANOVA with results of 
Bonferroni post-test analysis are indicated (***p<0.001, **p < 0.01). Sorted TILs 
were added back to autologous CD4+CD25- effector T cells (FACS sorted from 
peripheral blood sample) at indicated ratios and cultured for a 72-hour period (B). 
Proliferation over the final 6 hours was measured by tritiated thymidine incorporation 
and % suppression calculated. Data is compiled from four independent experiments. 
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4.2.4 CD4+Foxp3- and CD4+Foxp3+ T cells derived from blood, healthy colon and 
colorectal tumours are phenotypically distinct 
A detailed phenotypic analysis of CD4+ T cells was conducted using a panel 
of antibodies specific for the markers CD25, CTLA-4, CD39, LAG-3, CD103, ICOS 
and Ki67, many of which are associated with natural Tregs (Miyara, Yoshioka et al. 
2009). Representative flow cytometry plots are shown in Figure 2.4. Specifically, 
CD4+Foxp3+ and CD4+Foxp3- T cells from blood, healthy colon and colorectal 
tumour were compared (Figure 4.9 and Tables 4.1-4.3). CD4+ T cells derived from 
each compartment expressed distinct patterns of these phenotypic markers. 
Expression levels of several markers, such as CTLA-4 and CD39, increased steadily 
on both CD4+Foxp3+ and CD4+Foxp3- T cells when comparing blood to healthy colon 
to tumour (Figure 4.9). Many markers associated with Tregs, such as the IL-2 
receptor α-chain CD25 and CTLA-4, are also known to be present on activated T cells 
(Kmieciak, Gowda et al. 2009). Accordingly, this upregulation could reflect an altered 
state of activation in these distinct colonic and tumoural niches. This is illustrated by 
CD25 expression (Figure 4.9A), which remained relatively stable on Foxp3+ T cells 
but was significantly increased amongst Foxp3- T cells (blood 9.69% ± 1.08% vs. 
colon 28.93% ± 3.51%, p = 0.0009; blood vs. tumour 41.23% ± 3.05%, p < 0.0001). 
Likewise, a greater proportion of intra-tumoural CD4+Foxp3- T cells proliferate in 
comparison to blood and colon, as denoted by Ki67 expression (blood 5.39% ± 0.46% 
vs. colon 7.37% ± 1.43%, p = 0.27; blood vs. tumour 26.07% ± 3.96%, p = 0.0015; 
colon vs. tumour, p = 0.0039) (Figure 4.9D). Reduced levels of the IL-7 receptor 
CD127 and the anti-apoptotic protein BCL-2 were also observed amongst the 
CD4+Foxp3- TILs (Figure 4.9G and H, respectively). CTLA-4 (Figure 4.9B), which  
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is an important negative immunomodulator that decreases cellular cytokine 
production and proliferation (Schneider, Downey et al. 2006), followed a similar 
pattern of expression to CD25 (blood 5.54% ± 1.77% vs. colon 28.03% ± 7.66%, p = 
0.024; blood vs. tumour 43.61% ± 5.51%, p = 0.0004). There was also a significant 
increase in CTLA-4 expression on intra-tumoural Foxp3+ Tregs (blood 51.34% ± 
6.91% vs. colon 77.08% ± 6.83%, p = 0.0052; blood vs. tumour 89.60% ± 3.72%, p = 
0.0002). 
 
CD39 is an ectonucleotidase, which together with CD73 drives catabolism of 
extracellular ATP resulting in the generation of adenosine, an immunosuppressive 
molecule often elevated in cancer tissue (Deaglio, Dwyer et al. 2007). Both molecules 
are often expressed on Foxp3+ T cells, and generation of adenosine by these cells is 
one of the means by which intra-tumoural Tregs may enact their suppressive function 
(Deaglio, Dwyer et al. 2007). We found that Foxp3+ Tregs displayed markedly 
increased expression of CD39 in healthy colon and tumour (blood 44.10% ± 4.94% vs. 
colon 75.42% ± 8.16%, p = 0.0003; blood vs. tumour 90.83% ± 4.53%, p < 0.0001) 
(Figure 4.9C). However, as with CTLA-4, a marked and significant increase in CD39 
expression was also observed amongst intra-tumoural Foxp3- T cells (blood 5.24% ± 
0.99% vs. colon 55.58 ± 9.85%, p = 0.0011; blood vs. tumour 74.8% ± 6.79, p < 
0.0001). 
The marked increase in CD39, together with CD25 and CTLA-4, in the 
Foxp3- population suggests a possible regulatory role for these cells within the tumour 
environment. Accordingly, we examined other markers associated with regulatory 
function, including the CD4 homologue, lymphocyte activation gene-3 (LAG-3) 
(Huang, Workman et al. 2004; Woo, Turnis et al. 2012). Although expression of 
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LAG-3 amongst CD4+Foxp3+ and CD4+Foxp3- T cells was comparable (Figure 4.9E), 
intra-tumoural levels were markedly increased on both CD4+Foxp3- TILs (blood 
10.0% ± 3.1% and colon 11.44% ± 3.74% vs. tumour 34.92% ± 8.18%, p = 0.023) 
and CD4+Foxp3+ Tregs (blood 7.24% ± 1.56% and colon 12.69% ± 2.49% vs. tumour 
28.18% ± 5.68%, p = 0.02).  
The αE integrin, CD103, binds to the receptor E-cadherin and is thought to 
play a role in T cell retention within the gut (Schon, Arya et al. 1999); it has also been 
shown to denote populations of highly suppressive CD25+ and CD25- T cells 
(Lehmann, Huehn et al. 2002). In the cohort of patients studied here, CD103 
expression was elevated in colorectal tumours, particularly within the CD4+Foxp3- 
population (blood 2.08% ± 0.22% vs. colon 9.54% ± 2.49%, p = 0.022; blood and 
colon vs. tumour 34.83% ± 8.06%, p = 0.01; Figure 4.9F). Recent reports claim that 
CD103 expression is significantly increased on CRC-resident Tregs compared to 
unaffected colon (Svensson, Olofsson et al. 2012); however, despite a trend, this was 
not found to be the case in this cohort (colon 5.56% ± 1.50% vs. tumour 10.19% ± 
2.66%, p = 0.13). 
In summary, a significant proportion of intra-tumoural CD4+Foxp3- cells 
demonstrated a unique phenotype characterized by high expression levels of 
molecules predominantly associated with Tregs, including CD25, CD39, CTLA-4, 
LAG-3, and CD103 (summarized in Figure 4.9 and Tables 4.1-4.2). This finding 
warranted further investigation into the function of these CD4+Foxp3- cells and, 
specifically, to determine whether they could contribute to intra-tumoural 
immunosuppression.  
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Figure 4.9 Ex vivo phenotypic analysis of CD4+Foxp3+ and CD4+Foxp3- T cells in 
different compartments. Compiled flow cytometry data are shown for expression of 
CD25 (A), CTLA-4 (B), CD39 (C), Ki67 (D), LAG-3 (E) and CD103 (F) amongst 
CD4+Foxp3+ Tregs () and CD4+Foxp3- T cells () in matched blood (PBMC), 
unaffected colon and tumour samples. Significant differences are indicated; *p < 0.05, 
**p < 0.01, ***p < 0.001.   
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Figure 4.9 Cont’d. Ex vivo phenotypic analysis of CD4+Foxp3+ and CD4+Foxp3- 
T cells in different compartments. Compiled flow cytometry data are shown for 
expression of CD127low (G) and BCL-2 (H) amongst CD4+Foxp3+ Tregs () and 
CD4+Foxp3- T cells () in matched blood (PBMC), unaffected colon and tumour 
samples. For BCL-2, data are shown as mean fluorescence intensity (MFI). 
Significant differences are indicated; *p < 0.05, **p < 0.01, ***p < 0.001.   
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Table 4.1: Phenotypic overview of CD4+Foxp3+/- T cells. 
 
 
 
Table 4.2: Phenotypic overview of CD4+ICOS+/- T cells. 
 
- = Average Expression < 10% of cells 
+ = Average Expression 10% - 24.9% of cells 
++ = Average Expression 25% - 49.9% of cells 
+++ = Average Expression > 50% of cells 
  
  CTLA-4 LAP LAG-3 CD39 CD103 Ki67 CD25 Helios ICOS 
T
um
ou
r CD4+FoxP3- ++ ++ ++ +++ ++ ++ ++ - + 
CD4+FoxP3+ +++ + + +++ + ++ +++ +++ +++ 
C
ol
on
 CD4
+FoxP3- ++ + - +++ + - + - + 
CD4+FoxP3+ +++ + - +++ - + ++ ++ ++ 
P
B
M
C
 CD4+FoxP3- - - - - - - - - + 
CD4+FoxP3+ ++ - - ++ - ++ ++ +++ ++ 
  Foxp3 LAG-3 CD39 CD103 Ki67 CD25 Helios LAP 
T
um
ou
r CD4+ICOS- - ++ +++ ++ ++ ++ - ++ 
CD4+ICOS+ ++ + +++ + ++ ++ ++ + 
C
ol
on
 CD4
+ICOS- - + ++ - - + - + 
CD4+ICOS+ ++ + +++ - + + + + 
P
B
M
C
 CD4+ICOS- - - - - - - - - 
CD4+ICOS+ ++ - ++ - + ++ ++ - 
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4.2.5 CD4+LAP+Foxp3- TILs act as a major regulatory T cell subset 
The latency-associated peptide (LAP) has previously been described as a 
marker of regulatory T cells in human peripheral blood that are distinct from 
conventional Foxp3+ Tregs (Gandhi, Farez et al. 2010). Here, LAP expression was 
analysed on CD4+Foxp3+ and CD4+Foxp3- T cells from blood, healthy colon and 
tumour samples. Although comparable levels were observed in peripheral blood, LAP 
expression was markedly increased on both Foxp3+ T cells (blood 3.56% ± 0.63% vs. 
colon 16.59% ± 1.18%, p < 0.0001; blood vs. tumour 24.96% ± 3.01%, p = 0.0007) 
and Foxp3- T cells (blood 2.15% ± 0.56% vs. colon 17.72% ± 2.13%, p = 0.0001; 
blood vs. tumour 28.24% ± 3.69%, p = 0.0007) in healthy colon and tumour samples 
(Figure 4.10A). This marked enrichment of CD4+LAP+ T cells was most striking in 
early stage Dukes’ A tumours (Figure 4.10B). It has previously been shown that 
CD4+Foxp3-LAP+ T cells are found at significantly greater proportions amongst 
peripheral blood-derived T cells in CRC patients with metastatic disease 
(Mahalingam, Lin et al. 2012); whilst a positive trend was found here between early 
(Dukes’ A/B) and later stage (Dukes’ C) CRC patients, this was not significant (p = 
0.18; Figure 4.10C). 
The majority of CD4+LAP+ TILs co-expressed LAG-3, CD25 and PD-1 
(Figure 4.10D and Table 4.3); in contrast, <10% of the corresponding CD4+LAP- cells 
expressed LAG-3 and CD25. Of note, however, most CD4+LAP+ TILs (> 85%) did 
not express Foxp3. Although a greater proportion of CD4+LAP+ T cells express both 
PD-1 and TIM-3 in the tumour than the colon, this is no greater than CD4+LAP- TILs 
(Figure 4.10E). 
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Collectively, these observations demonstrate that the CD4+LAP+ T cell subset 
is largely distinct from conventional Foxp3+ Tregs and significantly enriched in 
tumours compared to blood (Figure 4.11). The co-expression of the suppressive 
markers CD25, CD39, CTLA-4, Helios and LAP were visually collated by importing 
representative FACS data, from live CD4+Foxp3+ and CD4+Foxp3- T cells present in 
peripheral blood, background colonic mucosa and colorectal tumours, into SPICE 
charts (Figure 4.12). Such analysis reveals the marked co-expression of regulatory 
markers, with a profound accumulation around CD4+LAP+Foxp3- T cells that 
infiltrate colorectal tumours. In addition, whilst these markers associate with Foxp3 
expression in CD4+ T cells present in peripheral blood and normal colon, this is not 
the case for T cells in the tumour and as such, Foxp3 may not necessarily be a good 
marker to distinguish suppressive from non-suppressive T cells in colorectal cancer. 
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B: Tumour-derived CD4+LAP+ T cells 
 
C: PBMC-derived CD4+Foxp3-LAP+ T cells 
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Figure 4.10 CD4+ T cells 
expressing LAP and 
LAG-3, but not Foxp3, 
are enriched in 
colorectal tumours. 
Expression of LAP on 
CD4+Foxp3+ Tregs () 
and CD4+Foxp3- T cells 
() from matched blood, 
unaffected colon and 
tumour samples (A), with 
the latter stratified as 
originating from histo-
pathologically confirmed 
Dukes’ grade A (early) 
and Dukes’ grade C 
(advanced) tumours (B).  
The proportion of 
peripheral blood-derived 
CD4+Foxp3- T cells 
expressing LAP was 
correlated to early (Dukes’ 
A/B) or advanced (Dukes’  
C) tumours (C). 
Significant differences are 
indicated; **p < 0.01, 
***p < 0.001.  
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Figure 4.10 Cont’d. CD4+ T cells expressing LAP and LAG-3, but not Foxp3, are 
enriched in colorectal tumours. Representative phenotypic analysis of CD4+LAP+ and 
CD4+LAP- TILs, showing expression profiles of LAG-3, CD25, PD-1 and Foxp3 (D), 
and dual expression of PD-1 and TIM-3 (E).  
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Table 4.3: Phenotypic overview of CD4+LAP+/- T cells. 
 
 
- = Average Expression < 10% of cells 
+ = Average Expression 10% - 24.9% of cells 
++ = Average Expression 25% - 49.9% of cells 
+++ = Average Expression > 50% of cells 
  
  CTLA-4 Foxp3 LAG-3 CD39 CD103 Ki67 CD25 ICOS 
T
um
ou
r CD4+LAP- +++ ++ - +++ + ++ - + 
CD4+LAP+ +++ + +++ +++ ++ ++ +++ + 
C
ol
on
 CD4
+LAP- ++ + - ++ - + - - 
CD4+LAP+ ++ + - +++ - + +++ + 
P
B
M
C
 CD4+LAP- + - - - - - - + 
CD4+LAP+ + - - - - + +++ ++ 
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Figure 4.11 Expression of membrane bound TGF-β1 (LAP) on live Foxp3+/- 
CD4+ T cells. Representative bivariate FACS plots showing the expression of LAP on 
CD4+ T cells isolated from peripheral blood, colon and tumour samples. The highest 
proportion of LAP expression is amongst CD4+Foxp3- T cells found infiltrating 
colorectal tumours.   
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Figure 4.12 Concatenated ex vivo phenotypic analysis of CD4+Foxp3+ and 
CD4+Foxp3- T cells in different compartments originating from one 
representative CRC patient. Pie charts shows the relative proportion of live Foxp3+ 
(blue) and Foxp3- (grey) CD4+ T cells in each compartment; pie chart arcs show 
expression of the indicated markers in these subsets.   
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Next, PBMC, colon and tumour infiltrating lymphocytes were stimulated 
polyclonally with PMA and ionomycin to determine cytokine production, namely 
IFN-γ, IL-10 and IL-17A, by CD4+LAP+ T cells present in these compartments. Upon 
stimulation, around 15-20% of CD4+LAP+ T cells in peripheral blood produce the 
potent, multifunctional Th1 cytokine, IFN-γ (Figure 4.13A), consistent with previous 
observations from other groups (Gandhi, Farez et al. 2010; Mahalingam, Lin et al. 
2012). However, this cell subset produces far less IFN-γ in the colon (Figure 4.13B) 
and almost no IFN-γ in the tumour (Figure 4.13C), where CD4+LAP- T cells 
significantly predominate the IFN-γ production (CD4+LAP- 28.3% ± 2.8% vs. 
CD4+LAP+ 2.2% ± 1.1%, p = 0.013). 
 
IL-17A-secreting CD4+ ‘Th17 cells’ have been implicated in a number of 
autoimmune disorders but play important roles in anti-microbial immunity (Weaver 
and Hatton 2009; Maloy and Powrie 2011) and have been shown to enhance (Martin-
Orozco, Muranski et al. 2009) and suppress anti-tumour immune responses (Ma and 
Dong 2011). Here, very little IL-17A production was detected amongst T cells 
derived from the peripheral blood of CRC patients (Figure 4.13A). The small 
population of Th17 cells detected (~0.3% of CD4’s) were CD4+LAP- T cells. A 
greater proportion of CD4+ T cells produced IL-17A in the colon (5-10% of CD4’s; 
Figure 4.13B), unsurprising given their aforementioned role in anti-microbial 
immunity. Here, little difference was observed between the proportion of CD4+LAP+ 
and CD4+LAP- T cells producing this cytokine (CD4+LAP- 7.2% ± 0.3% vs. 
CD4+LAP+ 5.7% ± 3.9%, p = 0.73). In the colorectal tumour specimens analysed, 
over 10% of the CD4+LAP- T cell population produced IL-17A, whilst CD4+LAP+ T 
cells produced relatively little (CD4+LAP- 13.8% ± 2.6% vs. CD4+LAP+ 4.5% ± 1.9%, 
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p = 0.0503; Figure 4.13C). It has been shown that high expression of IL-17 in 
colorectal tumours is detrimental to patient survival (Tosolini, Kirilovsky et al. 2011). 
Very little production of the immunosuppressive cytokine IL-10 was detected 
amongst peripheral blood-derived CD4+ T cells (Figure 4.13A). This is in stark 
contrast to the colon and tumour-infiltrating lymphocytes, as CD4+LAP+ T cells 
produced large amounts of IL-10 (Figure 4.13B and C). Indeed, these cells 
represented the predominant CD4+ T cell fraction responsible for IL-10 production in 
these compartments of these CRC patients (Colon; CD4+LAP- 0.9% ± 0.05% vs. 
CD4+LAP+ 9.4% ± 0.6%, p = 0.0042 / Tumour; CD4+LAP- 1.1% ± 0.4% vs. 
CD4+LAP+ 33.5% ± 5.4%, p = 0.013) 
CD4+LAP+ T cells also stained for membrane-bound active TGF-β without 
prior activation (Figure 4.14), indicating that LAP expression denotes populations of 
cells that produce TGF-β, consistent with previous reports (Saito, Kinoshita et al. 
2001). This was to be expected, since TGF-β is secreted in a complex with latent 
TGF-β binding protein and LAP (Taylor 2009). The immunosuppressive effects of 
CD4+CD25+ T cells are largely mediated by cell-contact dependent mechanisms, with 
membrane-bound TGF-β shown to contribute to such regulation (Nakamura, Kitani et 
al. 2001). 
Together, these data illustrate how phenotypically comparable T cell subsets 
can take on divergent functions in different compartments, and support the premise 
that LAP expression denotes a population of intra-tumoural CD4+Foxp3- cells with 
considerable immunosuppressive potential. 
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A: PBMC 
 
B: Colon 
 
C: Tumour 
 
Figure 4.13 CD4+LAP+ TILs produce IL-10. Intracellular cytokine staining of 
stimulated CD4+LAP+ and corresponding CD4+LAP- live T cells from matched 
peripheral blood (A), unaffected colon (B) and tumour samples (C). Representative 
profiles for IL-17A, IFN-γ and IL-10 are shown from a CRC patient with a Dukes’ B, 
T3-staged tumour.   
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Figure 4.14 CD4+LAP+ TILs stain positive for active TGF-β1. Representative 
example of TGF-β1 expression on resting, live CD4+LAP+ TILs (A: Solid black line 
= TGF-β1, grey shading = isotype control).   
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To assess the functional significance of LAP expression, CD4+LAP+ and 
CD4+LAP- T cells were purified from colorectal tumour samples by FACS (Figure 
4.16B). Stimulation of the CD4+LAP+ TIL population in vitro with αCD3/CD28 beads 
revealed that nearly 90% of these cells were capable of cell division over a 3-day 
proliferation assay (Figure 4.15); this stands in marked contrast to the anergic 
phenotype described for conventional Tregs in vitro (Min, Thornton et al. 2007), 
despite the high degree of turnover seen in vivo (Vukmanovic-Stejic, Zhang et al. 
2006). Proliferation of potentially suppressive T cell populations negates the use of 
tritiated thymidine incorporation to analyse for suppression, since the turnover of the 
suppressive population can potentially mask the inhibition of responder T cells, as 
previously noted. Instead, a CFSE / PKH-26-based suppression assay was utilized, so 
that the division index of suppressor and responder T cell subsets could be analysed 
independently over the course of the suppression assay.  
The ability of CD4+LAP+ and CD4+LAP- T cells to inhibit effector CD4+ T 
cell proliferation in vitro was assessed using standard suppressor assays and compared 
to conventional Tregs, which were sorted as CD4+CD25hiCD127lo T cells (Foxp3 
expression > 90%; Figure 4.16A).  Autologous PBMC-derived CD4+CD25- T cells 
(Foxp3 expression < 5%) labeled with CFSE were used as targets in these suppression 
assays, co-cultured with isolated TIL subsets, labelled with PKH-26, at ratios of 1:1, 
1:0.5, 1:0.1 and 1:0.01. A direct comparison of CD4+LAP+ T cells, CD4+LAP- T cells 
and conventional Tregs demonstrated that LAP+ TILs were able to suppress target cell 
proliferation ~50-fold more potently than either of the other two subsets (data from 
four independent experiments; Figure 4.17A). Interestingly, the CD4+LAP- population 
could still suppress at higher ratios, possibly due to the presence of Foxp3+ Tregs. The 
suppressive effects of CD4+LAP+ TILs were largely mediated by TGF-β, since 
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addition of the TGF-β blocking antibody 1D11 partially restored effector T cell 
proliferation levels, reducing the suppressive effects of these cells by over 50% 
(Figure 4.17B).  
Thus, tumour-derived CD4+ T cells expressing LAP are highly 
immunosuppressive, despite low levels of Foxp3 expression, and represent a major 
regulatory T cell population amongst colorectal TILs.   
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Figure 4.15 In vitro proliferative capacity of CD4+LAP+ TILs. Upon stimulation 
with CD3/CD28 beads, CD4+LAP+ TILs are highly proliferative in vitro over the 
course of a three day culture, as denoted by dilution of the cell tracking dye, PKH-26 
(solid black line = live CD4+LAP+ T cells labelled with PKH-26, grey shading = 
PKH-26-labelled unstimulated CD4+ T cell control).  
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Figure 4.16 Fluorescent Activated Cell Sorting of T cell Populations. 
Representative flow cytometry plots showing the gating strategy used to sort live 
CD4+CD25hiCD127lo Tregs and live CD4+CD25- T effector cells from PBMCs, and 
Foxp3 expression profiles in these subsets (A). Representative flow cytometry plots 
showing the gating strategy used to sort doublet-excluded, live (CD8-) CD4+LAP+ and 
CD4+LAP- TILs (B).  
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Figure 4.17 CD4+LAP+ 
TILs are >100 fold more 
suppressive than 
conventional Tregs in 
vitro. (A) CD4+CD25hi 
CD127lo T cells were 
FACS-purified from 
PBMCs, together with 
CD4+LAP+ and 
CD4+LAP- T cells from 
the colorectal tumour of 
the same patient and co-
incubated with autologous 
CD4+CD25- T effector 
cells at the indicated ratios 
(1 = 4 x 104 cells). 
Suppression indicates the 
percent reduction in 
proliferation of activated 
autologous effector T cells 
over a period of 60 hours. 
Data is inclusive of four 
independent experiments, 
showing degree of 
variability at each ratio 
(mean ± SEM). (B) 
Addition of the αTGF-β 
blocking antibody 1D11 
(10 µg/ml final 
concentration) restored 
proliferation of effector T 
cells cultured at an E:T 
ratio of 25:1. Histogram 
shows raw CFSE dilution 
of each indicated 
condition, plus graphical 
data analysing the 
corresponding division 
index and % suppression. 
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4.3 Conclusion 
 
Adaptive immune responses can control tumours, as illustrated by successful 
vaccination and adoptive immunotherapy studies (Restifo, Dudley et al. 2012). 
However, many immunotherapy trials have shown poor response rates, potentially 
due to the inhibition of tumour-specific responses by immune regulatory networks. A 
large body of data now associate increased frequencies of CD4+Foxp3+ T cells 
(Tregs) with a range of tumours (Betts, Clarke et al. 2006). Furthermore, Treg 
accumulation is linked with poor outcome in several malignancies, including ovarian 
cancer (Curiel, Coukos et al. 2004) and CRC (Betts, Jones et al. 2011). Previous work 
from this laboratory showed that anti-tumour CD4+ T cell responses were reduced in 
patients with CRC prior to resection of the tumour; this phenomenon was related to 
Treg frequencies in peripheral blood, defined initially by high levels of CD25 
expression on CD4+ T cells (Clarke, Betts et al. 2006), and more recently by 
expression of the transcription factor Foxp3 ((Betts, Jones et al. 2011) and Chapter 3). 
 Despite substantial evidence indicating that regulatory T cells impinge upon 
anti-tumour immune responses in patients with cancer (Nishikawa and Sakaguchi 
2010), many studies in humans have focused largely on blood-derived Tregs. This 
raises the question of whether intra-tumoural Tregs carry out the same function as 
those in blood. Indeed, the role of colorectal tumour-infiltrating Tregs in particular 
has been widely debated (Ladoire, Martin et al. 2011). Aberrant intra-tumoural 
expression of Foxp3, which may not denote a homogenous population of suppressive 
T cells, has been mooted as a reason why Treg numbers seem to be high in early 
tumours with a better prognosis (Morgan, van Bilsen et al. 2005; Ziegler 2007; 
Kmieciak, Gowda et al. 2009). Here, CD4+Foxp3+ and CD8+Foxp3+ T cell infiltration 
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were actually found to increase in proportion with advancing tumour stage, in keeping 
with previous analysis of colorectal tumours by FACS (Chaput, Louafi et al. 2009). 
Studies using immunohistochemistry to perform the same analysis in colorectal 
tumour tissue do not find this correlation (Loddenkemper, Schernus et al. 2006; Ling, 
Pratap et al. 2007). This has led some groups to question the usefulness of 
immunohistochemical analysis of Foxp3 in human tumours (Badoual, Hans et al. 
2009), since other non-suppressive T cells can upregulate Foxp3 (Walker, 
Kasprowicz et al. 2003; Roncador, Brown et al. 2005) in addition to significant 
cytoplasmic expression within colorectal tumour cells themselves (Karanikas, 
Speletas et al. 2008). This may explain why some groups have found an association 
between improved survival and a higher density of intratumoural Foxp3+ T cells, 
despite their well-documented suppressive effects on anti-tumour immunity 
(Nishikawa and Sakaguchi 2010; Betts, Jones et al. 2012). This apparent contradiction 
may be resolved by clinical trials that deplete Foxp3+ Tregs in CRC patients as a 
potential adjuvant to anti-tumour T cell stimulation (see Chapter 3). Nonetheless, 
detailed insights into the complexity and function of colorectal tumour-infiltrating T 
cell subsets are essential to guide the rational manipulation of T cell responses for the 
purpose of optimizing anti-tumour immunity. 
Access to matched blood, healthy colon and colorectal tumour samples from 
multiple CRC patients enabled us to conduct a detailed phenotypic comparison of 
CD4+ T cells derived from these different compartments. The relative proportion of 
CD4+ T cells that expressed Foxp3, conventionally classified as Tregs, was 
significantly higher within tumours compared to healthy colon. Expression of Helios 
was confined to this Foxp3+ population, an indication that these cells are potentially 
more suppressive than the corresponding CD4+Foxp3+Helios- subset, given their 
 181 
higher levels of Foxp3 expression ((Figure 4.5D) and (Chauhan, Saban et al. 2009; 
Elkord and Al-Ramadi 2012)). Furthermore, an intriguing and highly significant 
increase in the proportion of peripheral Tregs expressing Helios was noted, as 
tumours advanced from Dukes’ A to Dukes’ D. This could reflect an increase in the 
output of thymic-derived Tregs in response to prolonged or heightened tumour-
specific T cell activation, or it could represent an increase in the suppressive capacity 
of the peripheral Tregs in an attempt to mediate self-tolerance. It would be of interest 
to define the specificity of these T cells to see if the increased proportions of Tregs 
found in CRC patients over healthy donors is due to chronic stimulation by tumour-
associated antigens. Within the colorectal tumour, whilst the majority of Foxp3+ 
Tregs were Helios+, this proportion was significantly lower than found in blood. This 
suggests that there is an additional element of Treg induction occurring in the tumour 
microenvironment. In the colon, there appears to be an even greater induction of 
Tregs, a probable result of the necessity to maintain intestinal homeostasis in the 
presence of immunogenic gut microflora (Maloy and Powrie 2011). 
Foxp3+ Tregs were found to be highly enriched for ICOS-expressing cells. 
ICOS has previously been demonstrated to provide a critical signal for the 
development of Th17 cells and follicular-helper T cells (TFH), since ICOS-deficient 
mice have diminished numbers of these cell types (Bauquet, Jin et al. 2009). ICOS 
also appears to be critical to regulatory T cell maintenance within the tumour 
microenvironment; the expression of ICOS-L by tumour cells can promote the 
activation and expansion of CD4+Foxp3+ T cells, a large proportion of which express 
ICOS, thus maintaining high expression of Foxp3 amongst TILs (Martin-Orozco, Li 
et al. 2010). Within a melanoma microenvironment, ICOShi Tregs have been shown to 
mediate stronger suppression than ICOS- Tregs (Strauss, Bergmann et al. 2008). 
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Analysis of the function of colorectal TILs based on ICOS expression in this chapter 
was restricted by the use of tritiated thymidine incorporation to analyse for 
suppression. However, both ICOS+ and ICOS- CD4+ TILs appeared capable of 
mounting a regulatory effect upon stimulated effector CD4+CD25- T cells, suggesting 
that both isolated cell fractions contain suppressive T cell subsets and highlighting the 
heterogeneity of regulatory T cells within the tumour microenvironment. 
An extensive comparison of CD4+Foxp3+ and CD4+Foxp3- populations 
revealed that the expression of other markers classically associated with Tregs in 
peripheral blood, including CD25, CTLA-4, CD39 and CD127, were less specific for 
intra-tumoural Foxp3+ cells (Figure 4.12). This raised the possibility that cells other 
than Foxp3+ T cells were capable of mediating immunosuppression within the tumour 
environment and further questions its usefulness as a marker for defining regulatory T 
cells in this compartment. Such suppressive molecules are upregulated on effector 
memory T cells during antigen-driven activation; strikingly, however, intra-tumoural 
CD4+Foxp3- cells did not express the activation marker ICOS, thereby suggesting that 
their unique phenotypic profile was not solely the result of T cell activation.  
Expression of the ectonucleotidase CD39 suggested that intra-tumoural 
CD4+Foxp3- T cells might exert a regulatory role. This was further borne out by 
analyses of LAP and LAG-3 expression. Suppressive T cells that express LAP but not 
Foxp3 have previously been identified in humans (Gandhi, Farez et al. 2010) and their 
presence amongst colorectal TILs has recently been verified (Mahalingam, Lin et al. 
2012). In addition, T cell expression of the CD4 homologue and negative regulator, 
LAG-3, has been shown to maintain tolerance to self and tumour antigens by directly 
regulating CD8+ T cell effector function (Grosso, Kelleher et al. 2007; Matsuzaki, 
Gnjatic et al. 2010); synergy between LAG-3 with PD-1 on TILs has also been shown 
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to promote tumoural immune escape in a number of models (Woo, Turnis et al. 2012). 
In the work presented here, a large proportion of CD4+ T cells that expressed LAP, 
part of the membrane-bound latent TGF-β complex, were detected. LAP requires 
cleavage by certain integrins and proteases before active TGF-β can be released (Tran 
2012), but its expression is associated with cells capable of suppression, since 
membrane bound TGF-β is a major mechanism of cell contact-dependent 
immunosuppression (Nakamura, Kitani et al. 2001). Increased proportions of 
CD4+LAP+ T cells amongst peripheral blood and tumour-infiltrating lymphocytes 
have recently been described, however functional analysis of these cells was limited 
to blood-derived samples (Mahalingam, Lin et al. 2012). In agreement with this work, 
we found LAP was only expressed on very small populations of T cells in the 
peripheral blood; indeed, LAP expression appeared to be specifically associated with 
the tumour microenvironment. These CD4+LAP+ cells co-expressed LAG-3 in the 
tumour, but only a minority expressed Foxp3, consistent with descriptions of LAG-3+ 
T cells that infiltrate Hodgkin lymphomas and bear suppressive activity without 
Foxp3 expression (Gandhi, Lambley et al. 2006). Functional analysis revealed that 
these cells produced IL-10 and TGF-β, and exerted suppressive activities in vitro that 
were around 50-fold more potent than “conventional” PBMC-derived Foxp3+ Tregs. 
These cells appeared incapable of producing IFN-γ within the tumour, and therefore 
represent a functionally distinct CD4+LAP+ T cell subset from the corresponding cells 
derived from blood ((Figure 4.13) and (Mahalingam, Lin et al. 2012)). In addition, 
CD4+LAP+ T cells isolated from peripheral blood have previously been described as 
hypoproliferative in vitro (Gandhi, Farez et al. 2010); although upon further analysis 
of this data, ~10% are Ki67+ ex vivo (similar data was found here; Table 4.3) and they 
do proliferate in vitro, albeit only to half the extent of CD4+LAP- T cells. 
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Overall, these data reveal the presence of a potent suppressive CD4+Foxp3- T 
cell population within the colorectal tumour regulatory landscape. These CD4+LAP+ 
T cells, which co-express significant levels of CTLA-4, LAG-3, PD-1, CD39, CD25, 
CD103 and Ki67, appear to be highly activated, divide easily both in vivo and in vitro, 
and are distinct from the regulatory populations found in healthy colon and peripheral 
blood. Recent studies by Donkor and colleagues demonstrated that oncogene-induced 
prostate tumour growth and metastasis could be blocked by increased cytotoxic T cell 
activity, but that the failure of immune protection involved TGF-β-mediated 
suppression of tumour antigen-specific T cell responses. Most compellingly, the 
major source of TGF-β was the T cells themselves, rather than either the tumour cells 
or CD4+Foxp3+ regulatory T cells (Donkor, Sarkar et al. 2011; Sarkar, Donkor et al. 
2011). This is in close agreement to the work presented in this chapter, whereby a 
major regulatory subset of TIL that does not require Foxp3 for suppression, but 
instead expresses TGF-β and IL-10, has been identified. Indeed, TGF-β appears to 
play a substantial role in the suppressive capabilities of these cells, although the role 
of IL-10 needs to be elucidated further. This CD4+LAP+ T cell population likely 
controls anti-tumour immune responses in the local environment, even in the face of 
systemic anti-tumour responses present in the early stages of colorectal tumour 
development.  
Therapeutic strategies that aim to overcome regulatory T cell activity as a 
means of enhancing anti-tumour immune responses need to take into account this 
novel intra-tumoural subset of highly suppressive CD4+Foxp3- T cells identified in 
this chapter. This may include selective blockade of TGF-β signalling, specifically 
mediated by T cells, which adversely polarize the tumour environment (Flavell, 
Sanjabi et al. 2010). Future studies will also analyse whether blocking LAG-3 
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signalling can enhance anti-tumour responses and improve the responsiveness of 
effector Th1 responses (as previously shown (Grosso, Kelleher et al. 2007)), crucial to 
the host for effective tumour eradication (Bos and Sherman 2010; Tosolini, 
Kirilovsky et al. 2011). LAG-3 blocking antibodies are currently in the pre-clinical 
stage of development, but it is hoped future immunotherapeutic regimes could 
incorporate this to enhance anti-tumour immunity. 
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Chapter 5 – Final Discussion 
 
This thesis has examined the role of effector and regulatory T cell subsets on the 
progression of colorectal carcinoma in humans. The major focus of this work centred 
around two key areas crucial to immunological tumour control: analysing the 
existence and functional capabilities of oncofoetal antigen-specific effector and 
regulatory T cells; and in depth phenotypic and functional evaluation of T cells that 
infiltrate colorectal tumours, comparing these to corresponding subsets found in 
healthy colonic mucosa and peripheral blood. The results of these experiments 
provide further evidence of increased immunological regulation of anti-tumour T cell 
immune responses in patients with colorectal cancer. Initially, this was shown by an 
increase in the proportion of peripheral blood derived Foxp3+ Tregs as tumours 
became more advanced, which corresponded with a significant reduction in the 
magnitude of 5T4-specific Th1 responses generated by these patients. Furthermore, 
tumour infiltrating Foxp3+ T cells displayed a phenotype associated with enhanced 
immunosuppression over Foxp3+ cells in the colon and peripheral blood; however, a 
significant proportion of Foxp3- TILs expressed regulatory markers such as LAG-3 
and LAP, and displayed the most prominent suppressive characteristics in vitro. 
Together, these findings support the rationale for inhibiting T cells capable of anti-
tumour immunosuppression with concurrent stimulation of anti-tumour effector 
responses in the treatment of colorectal cancer.  
It is now well established that some T cells do possess the capability of 
tumour control, following the observation that higher densities of intratumoural 
CD3+CD45RO+ T cells resulted in a longer median patient survival, regardless of 
histopathological tumour stage (Galon, Costes et al. 2006). This is a striking finding 
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as previously the staging of the tumour had been the gold standard for prognosis, and 
is still being used today to direct treatment. These results suggest that T cells can 
mediate effective deletion of cancerous cells in the colon, or at least can positively 
contribute to the control of tumour burden. However, T cell sub-populations vary 
enormously in function and a number of subsets exist with the capacity to actively 
suppress antigen-specific T cell responses, including the thymus-derived Foxp3+ 
regulatory T cells (Tregs) which, as demonstrated in this thesis, are particularly 
abundant in colorectal cancer patients and are also enriched within the colorectal 
tumour microenvironment (Chapter 4 and (Ling, Pratap et al. 2007)). Whilst there 
seems to be a logical rationale to selectively deplete Foxp3+ Tregs to enhance anti-
tumour immunity (Betts, Clarke et al. 2006), the observation that early stage CRC is 
enriched for Foxp3+ Tregs, and therefore is associated with improved patient outcome 
after tumour resection, raises a cautionary note (Salama, Phillips et al. 2009).  
 
5.1 5T4-specific T cell responses in CRC patients and healthy donors 
T cells are capable of attacking neoplastic cells through recognition of tumour-
associated antigens (TAA) presented to them by antigen-presenting cells (APCs). 
Numerous TAAs for human carcinomas have been identified and current strategies 
for prospective immunotherapy include the identification of TAA-derived epitopes 
presented on MHC class I and class II molecules to CD8+ and CD4+ T cells, 
respectively, since both subsets of T cell are important for effective anti-tumour 
immunity (Campi, Crosti et al. 2003; Shingler, Chikoti et al. 2008; Bos and Sherman 
2010). The oncofoetal antigens CEA and 5T4 represent excellent targets for 
immunotherapy as they are abundantly expressed on colorectal cancer cells but less so 
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on healthy tissue (Figure 3.22 and (Starzynska, Rahi et al. 1992; Hammarstrom 
1999)).  
T cells specific for such antigens, identified using the highly sensitive IFN-γ 
ELISpot assay, are found in CRC patients (Clarke, Betts et al. 2006; Smyth, Elkord et 
al. 2006; Elkord, Burt et al. 2008; Betts, Jones et al. 2011) and interestingly, in 
healthy donors (Chapter 3 and (Elkord, Burt et al. 2008)), suggesting a role in tumour 
immunosurveillance. The presence of autoreactive T cells in the peripheral blood of 
healthy individuals, with medium to high avidity for their cognate antigen, has 
previously been documented (Danke, Koelle et al. 2004). In this study, 5/7 healthy 
donors had detectable NY-ESO-1-specific CD4+ T cells ex vivo, analysed by MHC 
class-II specific tetramers. The conclusions from this work were that autoreactive T 
cells are present in all healthy donors since thymic deletion is not 100% efficient. 
Given that, for the work presented here, PBMCs were cultured in vitro, it is perhaps 
not surprising that healthy individuals produced such robust responses to the 
oncofoetal antigen, since culturing PBMCs magnifies antigen-specific T cells (Ebert, 
MacRaild et al. 2012). In fact, healthy donors demonstrated a greater magnitude of 
5T4-specific T cell responses than CRC patients (see Chapter 3.3 and Figure 5.1). 
Subsequent analysis of the diminished T cell responses measured in CRC 
patients revealed that there was a gradual and significant loss in response correlating 
with the steady progressive worsening of the cancer stage. Hence, the size of the 5T4 
response, measured in patients pre-operatively, may identify those with more 
advanced (or aggressive?) tumours, and also identify subjects most likely to develop 
early metastatic disease. The loss of responses did not seem to be influenced by the  
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Figure 5.1 Overview of 5T4 T cell Origin and Consequent Suppression by Tregs. 
In healthy individuals, 5T4 is not expressed or is expressed at very low levels by 
normal tissue. 5T4 is upregulated on inflamed tissue in the gut, and found on tumour-
initiating cells (cancer stem cells), thus 5T4 T cell responses may arise from 
mechanisms of inflammatory resolution, immunosurveillance or incomplete thymic 
deletion, where they are regulated by 5T4-specific Tregs in the periphery. In the 
presence of a primary colorectal adenocarcinoma, decreased 5T4-specfic T cell 
responses are found in the blood of these patients. However, removal of Tregs both in 
vitro and in vivo can restore some of these responses. Thus, the tumour drives a 
population of regulatory T cells, which increase in proportion with tumour 
advancement and lead to further suppression of 5T4-specific Th1 responses.  
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subjects HLA type, or range of epitopes recognised, but most strikingly corresponded 
with a tumour-specific population of regulatory Foxp3+ T cells. This predictable 
decline from healthy age-matched controls to CRC patients is such that a cut off of in 
the frequency of responses (200 cognate CD4+ T cells / 105 cultured cells) is 100% 
specific for the presence of CRC in the subjects studied so far. Results from this thesis 
open up the potential to extend this study to other tumour antigens and larger cohorts 
(for 5T4), and use blood from patients undergoing bowel cancer screening to assess 
its applicability i.e. loss of 5T4 response as a biomarker of disease. 
In this thesis, 5T4-specific T cell responses were largely limited to the analysis 
of the effector cytokine IFN-γ, produced by T cells activated in the presence of their 
cognate antigen. The expression of IFN-γ by helper and cytotoxic T cells has 
previously been shown to be most beneficial for maximal anti-tumour effects; in 
addition to CD28, granzyme B and perforin, the expression of these effector 
molecules within colorectal tumours resulted in prolonged disease-free survival for 
that patient (Tosolini, Kirilovsky et al. 2011). However, even in the presence of large 
numbers of tumour-specific T cells, tumours may continue to progress due to T cell 
dysfunction via a skew in the cytokine profile of these cells (Boon, Coulie et al. 2006; 
Tassi, Gavazzi et al. 2008). Indeed for CRC, a skewed Th17 profile appears to be 
detrimental: patients with high levels of IL-17 in tumours, produced by Th17 T cells 
and macrophages, have a significantly worse disease-free survival than patients with 
low IL-17 levels (Tosolini, Kirilovsky et al. 2011). This may be a result of IL-17 
encouraging local production of VEGF, facilitating angiogenesis and tumour growth 
(Liu, Duan et al. 2011). An extensive cytokine profiling of 5T4-specific T cells was 
not studied here; however, it will be interesting to determine whether the reduction in 
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IFN-γ producing 5T4-specific T cell responses with tumour progression could also be 
due to a change in cytokine production or a decrease in overall numbers of these cells.  
 
5.2 Regulatory T cells and Cancer Progression 
Since many tumour-associated antigens are also self-antigens, mechanisms of 
immunological tolerance can restrict the effectiveness of tumour-specific effector T 
cells. In order to maintain tolerance, Tregs are capable of suppressing such responses 
(Nishikawa and Sakaguchi 2010) and it is apparent that tumours employ Tregs as a 
defence mechanism against host immune surveillance (Curiel 2007). Intratumoural 
Tregs appear to play a role in cancer progression, since their selective depletion 
results in tumour rejection in many mouse models of cancer (Gallimore and Godkin 
2008). In CRC, patients have increased proportions of Tregs in peripheral blood and 
amongst tumour-infiltrating lymphocytes (TILs), and mounting evidence suggests that 
these cells impinge upon the beneficial TAA-specific responses (Vence, Palucka et al. 
2007; Bonertz, Weitz et al. 2009). This is further substantiated by experiments 
presented in this thesis, since using low-dose cyclophosphamide to reduce the 
proportion of peripheral Tregs in patients with metastatic colorectal cancer resulted in 
enhanced anti-5T4 T cell responses. Previous work from this lab also identified that 
surgical removal of the primary tumour is effective in normalizing peripheral Treg 
levels in CRC patients and in unmasking previously suppressed anti-tumour T cell 
responses (Betts, Jones et al. 2012). Furthermore, Treg-mediated suppression of 
tumour-specific CD4+ T cells prior to surgery was associated with tumour recurrence 
at 12 months and 5 years (unpublished data). These findings imply that depletion of 
Tregs in CRC patients before the onset of metastatic disease (i.e. post-surgical 
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removal of a primary colorectal adenocarcinoma) might enhance overall patient 
survival.  
Yet the role of Tregs that infiltrate colorectal tumours is under debate (Ladoire, 
Martin et al. 2011), as some reports demonstrate that a favourable prognosis i.e. early 
tumour stage is associated with a higher density of tumour-infiltrating Foxp3+ cells 
(Salama, Phillips et al. 2009; Frey, Droeser et al. 2010), in contrast to other groups 
that did not find this (Loddenkemper, Schernus et al. 2006). This paradox could be 
explained by divergent expression of Foxp3 that may not be denoting a homogenous 
population of suppressive T cells, and potential inaccuracies encountered when 
measuring Foxp3 expression by immunohistochemistry, as discussed in Chapter 4.3. 
Indeed, Foxp3 can become upregulated on activated effector T cells with apparently 
no regulatory function (Ziegler 2007; Hoffmann, Boeld et al. 2009), so caution must 
be taken to denote Foxp3+ T cells as ‘regulatory’. Other theories have been proffered 
for this counter-intuitive observation. Matera et al. speculated that Foxp3+ Tregs do 
not possess immunosuppressive function in the context of CRC and instead their 
presence might just be a homeostatic mechanism to control a robust immune response 
(Matera, Sandrucci et al. 2010). Others have hypothesized that Tregs can attenuate a 
Th17-mediated pro-inflammatory and tumour-enhancing response (Ladoire, Martin et 
al. 2011). Whilst this may be plausible, there is currently no evidence to suggest that 
Foxp3+ T cells isolated ex vivo from colorectal tumour tissue can enhance an anti-
tumour immune response, in fact, only the opposite has been found so far (Kryczek, 
Liu et al. 2009). However, this studied relied on CD25 as a marker for Foxp3+ T cells, 
which can also denote a population of highly suppressive Foxp3- T cells, as 
demonstrated in Chapter 4. 
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It seems certain tumour microenvironments, including CRC, facilitate the 
development and expansion of highly suppressive populations of T cells (Chaput, 
Louafi et al. 2009; Kryczek, Liu et al. 2009; Camisaschi, Casati et al. 2010) the 
complexity of which we are only just beginning to appreciate (outlined in Figure 5.2). 
It is probable that the mucosal environment of the intestine plays a role in determining 
the constituents of intratumoural T cells. Tregs have a role in ameliorating gut 
inflammation and therefore could help prevent carcinogenesis by controlling tumour-
promoting inflammation (Maggio-Price, Treuting et al. 2006; Mantovani, Allavena et 
al. 2008). As discussed in the Introduction, mucosal integrity, microbiota, and 
inflammation all play a role in the pathogenesis of CRC, and Tregs actively impinge 
on Th17 cells, thus limiting the survival and invasion of aberrant epithelial cells 
(Grivennikov, Wang et al. 2012; Gallimore and Godkin 2013). However, if a tumour 
develops despite the control of inflammation, Foxp3+ T cells may now contribute to 
tumour progression by actively impinging on anti-tumour responses, demonstrating 
an apparent shift from host protection to tumour protection (Whiteside 2012). It is 
also likely that regulatory CD4+ T cells other than naturally occurring 
CD4+CD25hiFoxp3+ Tregs are contributing to immune suppression; these include 
inducible Tr1 (IL-10 producing) and Th3 (TGF-β-producing) subsets, which display 
variable expression profiles of CD25 and Foxp3 and are important mediators of 
intestinal homeostasis (Maynard, Harrington et al. 2007; Josefowicz, Niec et al. 2012). 
The work in this thesis identified a highly suppressive population of Foxp3-CD4+ 
colorectal TILs; these cells co-express LAP, LAG-3 and CD25, produce the 
immunosuppressive cytokines IL-10 and TGF-β, and demonstrate marked suppressive 
properties in vitro. TGF-β-producing CD4+Foxp3- T cells have recently been shown 
to impede immunosurveillance in models of prostate and breast cancer  
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Figure 5.2 Colorectal tumour-infiltrating T cells exert opposing effects, reflecting 
their heterogeneous nature. CD4+ and CD8+ T cells produce effector molecules 
capable of anti-tumour effects. However, the tumour microenvironment consists of 
many cells capable of potent suppression, including both Foxp3+ and Foxp3- 
regulatory T cells. Hence, tumours are able to grow even in the presence of large 
numbers of T cells.  
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(Donkor, Sarkar et al. 2011; Sarkar, Donkor et al. 2011), by directly inhibiting 
cytotoxic T cell responses to tumours. The removal of the TGF-β-producing CD4+ T 
cells resulted in markedly enhanced tumour control and almost completely diminished 
the metastatic spread of the tumour. This is in accordance with studies demonstrating 
the importance of TGF-β in inducing epithelial-to-mesenchymal transition, an integral 
process in the invasion and metastatic potential of all carcinomas (Xu, Lamouille et al. 
2009). The TGF-β-producing CD4+Foxp3- cells discovered infiltrating oncogene-
induced prostate cancer most likely represent a very similar population of cells 
identified here in human colorectal TILs and almost certainly contribute towards 
tumour progression. This work, alongside the recent dispute over the prognostic effect 
of Foxp3+ Tregs, means that we may be placing too much emphasis on this 
transcription factor to denote the regulatory T cell populations in tumours, since 
clearly other regulatory populations not expressing Foxp3 exist. 
 
5.3 Novel Immunotherapeutic Strategies for CRC 
Successful immunotherapy for CRC will most likely require a multi-faceted 
approach to boost tumour-specific effectors with concurrent depletion or blockade of 
tumour-specific regulators. For tumour cell eradication to occur, sufficient numbers of 
effector T cells with the ability to recognize tumour antigens with high avidity must 
be generated. These cells must then be able to infiltrate the tumour to enact effector 
mechanisms and not be adversely influenced by regulatory mechanisms that T cells 
can be induced to express within the tumour microenvironment (Figure 5.3). Whilst 
adoptive therapy of tumour-specific T cells holds significant promise (Parkhurst, 
Yang et al. 2011), an ideal scenario would be to administer an anti-cancer vaccine to 
boost the patients’ own anti-tumour T cell responses. However, vaccinating patients  
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Figure 5.3 Regulatory Functions Employed by Tumour-Infiltrating CD4+ T cells. 
Many antigens with immunosuppressive functions exist in humans to regulate 
immune responses, and many are expressed in abundance upon intratumoural T cells, 
which can act to intrinsically suppress cellular activation, or extrinsically regulate 
other cells, as indicated. These include (but is not limited to): Cytotoxic T lymphocyte 
antigen-4 (CTLA-4 / CD152); the negative immunomodulator PD-1 (CD279); the 
membrane bound latent form of TGF-β (LAP); the IL-2 receptor (CD25); and LAG-3 
(CD223) which inhibits TCR-mediated signaling and regulates homeostatic T cell 
expansion. 
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with whole tumour antigens has yielded disappointing data from phase II/III trials for 
a variety of reasons (Amato, Hawkins et al. 2010). One issue that arises from 
targeting T cells in this manner is the activation of TAA-specific Tregs (Vence, 
Palucka et al. 2007; Bonertz, Weitz et al. 2009; Ebert, Macraild et al. 2012), which 
will in turn suppress any beneficial response. Preliminary evidence for this occurring 
in metastatic CRC patients following TroVax® vaccination is also demonstrated here 
(Chapter 3). Depleting Tregs whilst stimulating the anti-tumour T cells has already 
been shown to induce potent anti-tumour responses (Dannull, Su et al. 2005; Walter, 
Weinschenk et al. 2012). Indeed, depleting Tregs alone using low-dose 
cyclophosphamide unmasks significant anti-tumour responses in metastatic cancer 
patients (Chapter 3 and ((Ghiringhelli, Menard et al. 2007; Ge, Domschke et al. 
2011)). The activation of tumour-specific Tregs could also be avoided with 
knowledge of tumour-specific epitopes recognised by both effector and regulatory T 
cell subsets. In Chapter 3, depletion of CD25hi Tregs prior to culture with 5T4 peptide 
pools revealed that in the donors tested, some effector T cell responses were 
augmented, whilst others remained unaffected. This indicates that some Tregs 
recognize the same 5T4 epitopes as effector T cells, but crucially, some effector T cell 
epitopes are not recognised. These specific epitopes could be exploited to stimulate an 
anti-tumour response, whilst minimizing the activation of Tregs and subsequent 
suppression of responses. Work is now ingoing to study a much larger group of 
individuals to pinpoint more precise HLA-restricted 5T4 epitopes recognised by 
regulatory and effector T cells. 
Even if we can negate the function of Tregs by depletion or by specifically 
activating effector T cell subsets, tumour-specific T cells are further constrained by a 
number of highly immunosuppressive factors within the tumour microenvironment. 
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Recently it has been shown that inhibition of dendritic cell (DC) maturation via high 
levels of intratumoural CCL2, CXCL1, CXCL5 and VEGF can lead to a reduction in 
antigen presentation to T cells in CRC (Michielsen, Hogan et al. 2011) and crucially 
can skew an effective Th1 response (Minkis, Kavanagh et al. 2008). Furthermore, this 
tumour-induced immunosuppression is heightened at later stages of tumour 
development, further compounding the use of beneficial immunotherapeutic agents in 
patients with end-stage CRC. It is probable that agents to reduce these other 
mechanisms of tumour-induced immunosuppression, such as targeted blocking of 
suppressive antigens, cytokines and regulatory chemokine molecules, may be 
necessary for immunotherapeutic success. 
The latency-associated peptide (LAP) displayed significant expression 
amongst colorectal CD4+Foxp3- TILs and produced potent immunosuppressive 
effects. This homodimeric molecule non-covalently encases TGF-β to form a latent, 
inactive TGF-β complex on the cell surface. This latent form is unable to bind to its 
receptor until proteolytic cleavage (or structural modification) causes a 
conformational change to LAP that exposes active TGF-β (Tran 2012). A number of 
studies, including the work in this thesis, show that within the tumour 
microenvironment, TGF-β is having an adverse effect on anti-tumour T cell 
responses; so finding ways of inhibiting the release of active TGF-β could enhance 
effector T cell responses. However, potential targeting of TGF-β signalling in humans 
to treat cancer is fraught with danger given its pleiotropic properties; whilst TGF-β 
can promote cancer progression by inhibiting beneficial immune responses, it also 
serves to suppress tumour cell growth (Pu, Collazo et al. 2009) and maintain 
homeostasis in a whole host of systems throughout the body (Taylor 2009). 
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Nevertheless, a number of therapies are currently being developed in an effort to 
target this pathway in cancer. Some of the most promising include a TGF-β1 
neutralizing antibody (Genzyme, GC-1008; (J. C. Morris 2008)), the silencing 
oligonucleotide, Trabedersen (Antisense Pharma, AP12009) and a TGF-β1 receptor 
kinase inhibitor (Lilly Research Laboratories, LY364947). (Other novel therapies 
targeting TGF-β in cancer are reviewed in (Flavell, Sanjabi et al. 2010) and (Akhurst 
and Hata 2012)).  
More targeted therapies could arguably arise from the modulation of LAP by 
disabling processes allowing for the activation of TGF-β by cells that produce it, such 
as the CD4+LAP+ TILs identified here. Inhibition of LAP cleavage by certain 
integrins, e.g. αvβ6, has garnered recent interest, since this integrin is essential for the 
release and activation of TGF-β in human tumours, and greater expression of this 
integrin in colorectal, lung, breast and skin carcinomas is associated with metastatic 
spread (Bandyopadhyay and Raghavan 2009). Indeed, antibody blockade of αvβ6 has 
been shown to inhibit tumour progression in vivo (Van Aarsen, Leone et al. 2008). 
Given that αvβ6 is not expressed on normal epithelial cells, this may be one way to 
selectively target T cell-mediated suppression by TGF-β production within tumours. 
Phenotypic analysis of the CD4+LAP+ suppressive TILs found that these cells 
co-express the MHC class-II binding CD4 homologue, LAG-3. This marker has 
previously been shown to confer suppressive activity by T cells (Huang, Workman et 
al. 2004) and by CD4+Foxp3- T cells infiltrating Hodgkin’s lymphomas (Gandhi, 
Lambley et al. 2006). Furthermore, dual expression with PD-1 negatively regulated 
NY-ESO-1-specific CD8+ T cell responses in ovarian cancer (Matsuzaki, Gnjatic et al. 
2010) and dual anti-LAG-3/anti-PD-1 antibody treatment cured most mice of 
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established tumours that were largely resistant to single antibody treatment (Woo, 
Turnis et al. 2012). Here, over 90% of colorectal CD4+LAG-3+ TILs expressed PD-1, 
and these cells were shown to induce significant inhibitory effects upon effector T 
cells. Other regulatory markers such as CTLA-4 are also found on these cells; 
however, CTLA-4 serves as a dominant off-switch by blocking CD28 signalling and 
consequent T cell activation (Walker and Sansom 2011). Therefore it comes as no 
surprise that the anti-CTLA-4 antibody Ipilimumab (recently approved for the 
treatment of malignant melanoma) can cause severe autoimmunity since it also 
inhibits homeostatic functions of regulatory T cells throughout the body, especially in 
the skin and gut (Weber 2009). Hence, a key challenge for future immunotherapy is to 
achieve increased efficacy without enhanced toxicity. PD-1 and LAG-3 appear to 
serve a more subtle and precise down-regulation of immune functions and their 
expression is more restricted to TILs (Chapter 4 and (Turnis M.E. 2012), thus 
antibodies to PD-1 and LAG-3 may promote potent anti-tumour immune response but 
exhibit less systemic toxicity.  
Emerging evidence from multiple clinical trials blocking certain 
immunosuppressive checkpoints, such as CTLA-4 (Ipilimumab) or PD-1 (BMS-
936558) indicates that preventing tumour-induced T cell suppression or exhaustion 
restores protective immunity against established cancers, hence advanced tumours 
remain somewhat immunogenic. This is counter-intuitive to the immunoediting 
hypothesis described earlier, since tumours were thought to escape immune 
recognition by becoming less immunogenic. Instead, it seems that the tumours can 
exhaust effector T cells, but the potential for reigniting an immunological anti-tumour 
response still exists. The PD-1 antibody currently being tested in clinical trials was 
found to produce objective responses in ~28% of patients with renal cell carcinoma or 
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melanoma (Topalian, Hodi et al. 2012). An antagonist LAG-3 antibody has also been 
developed (ImmuTune IMP701, Immutep), specifically to block LAG-3-mediated 
immune down-regulation in the treatment of cancer and chronic infectious diseases. 
This therapy is currently in the preclinical phase of development but the first in-
human trials are expected to start in the coming years. 
 
5.4 Concluding Remarks 
Research in the field of cancer immunology has intensified in recent years 
with the realization that the immune system offers a viable approach to eradicating 
tumour cells, which could one day lead us to a cure for cancer. In 2011, the anti-
CTLA-4 antibody, Ipilimumab, became the first immune therapy approved by the 
FDA for use in advanced melanoma, being the first drug ever proven to prolong 
survival in advanced melanoma. This is only the first example in a growing list of 
promising immune therapies that aim to break tumour tolerance and enhance anti-
tumour immunity; a number of other prospective treatments in the pipeline are 
discussed here, with experimental evidence to reinforce their usage presented in this 
thesis. A key focus for this work was to definitively identify some of the regulatory 
processes that hinder anti-tumour specific T cell responses, by analysing the 
phenotype and function of T cells found in the tumour, colon and peripheral blood in 
patients with cancer. It is hoped that such knowledge will aid strategies to enhance 
novel immunotherapies by maximizing beneficial anti-tumour specific effector T cell 
responses and minimise the effects of suppressive T cells. Identifying these regulatory 
populations and pathways is the beginning of the battle: working out how to control 
or remove these cells and whether this benefits patient management are the future 
challenges.  
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Appendix 
 
 
 
 
CEA-specific T cell responses and 5-year tumour recurrence. Irrespective of the 
tumour stage, patients with a pre-operative anti-CEA T cell response were more likely 
to suffer a tumour recurrence (A and B). Significant difference is indicated (** P < 
0.01). 
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a b s t r a c t
Tumor-specific T cells must overcome a multitude of suppressive mechanisms to destroy cancerous cells
effectively. Furthermore, it appears that the tumor microenvironment facilitates the development of
highly immunosuppressive T cells, which may also allow subsequent tumor progression. In colorectal
cancer, the relationship between regulatory T cells (e.g. FoxP3+ Tregs) and tumor prognosis and progres-
sion is less clear, despite their well-documented ability to impinge on anti-tumor immune responses.
Here we explore our current knowledge of colorectal TIL heterogeneity, deciphering subsets which
may be of benefit or detriment.
! 2012 Elsevier Inc. All rights reserved.
1. Introduction
The role of host immunity in response to human colorectal car-
cinoma has garnered significant interest since the discovery of a
correlation between the degree of infiltrating lymphocytes into
tumors and enhanced patient survival [1–3]. Recently, Galon and
colleagues made the observation that higher densities of intratu-
moral CD3+CD45RO+ T cells resulted in a longermedian patient sur-
vival, regardless of pathological tumor stage [4]. This is a striking
finding as previously the staging of the tumor had been the gold
standard for prognosis. These results suggest some T cells possess
the capability of tumor control and can presumably mediate effec-
tive deletion of cancerous cells in the colon. However, CD4+ T cell
populations vary in function and a number of subsets exist with
the capacity to actually suppress antigen-specific T cell responses,
including the thymus-derived Foxp3+ regulatory T cells (Tregs)
which are particularly abundant in cancer patients and may also
be enriched within the tumor microenvironment [5]. Whilst there
seems to be a logical rationale to deplete Tregs to enhance anti-
tumor immunity [6], the observation that early stage colorectal
cancer (CRC) is enriched for Tregs raises a cautionary note [7]. This
short reviewwill discuss our understanding of how different CD4+ T
cells interact with CRCs, both to our benefit and detriment, and how
we might manipulate particular T cell subsets to treat CRC.
2. CRC-specific effector T cell responses
T cells are capable of attacking neoplastic cells through recogni-
tion of tumor-associated antigens (TAA) presented to them by anti-
gen-presenting cells (APCs). Numerous TAAs for human carcinomas
have been identified and current strategies for prospective immu-
notherapy include the identification of TAA-derived epitopes pre-
sented on MHC class I and class II molecules to CD8+ and CD4+ T
cells, respectively, since both subsets of T cell are important for
effective anti-tumor immunity [8–10]. The oncofoetal antigens
CEA and 5T4 represent excellent targets for immunotherapy as they
are abundantly expressed on colorectal cancer cells but less so on
healthy tissue [11,12]. T cells specific for such antigens, identified
using the highly sensitive IFN-c ELISpot assay, are found in CRC
patients [13–16] and interestingly, in healthy donors, suggesting
a role in immunosurveillance. For such cells to exert maximal
anti-tumor effects, a Th1-associated helper and cytotoxic response
has been shown to be most beneficial, whereby the expression of
IFN-c, CD28, granzyme B and perforin results in prolonged dis-
ease-free survival [17]. Indeed for CRC, a skewed Th17 profile
appears to be detrimental: patients with high levels of IL-17 in
tumors, produced by Th17 T cells and macrophages, have a signifi-
cantly worse disease-free survival than patients with low IL-17
levels [17]. This may be a result of IL-17 encouraging local produc-
tion of VEGF, facilitating angiogenesis and tumor growth [18].
3. Regulatory T cells and CRC
Since many TAAs are also self-antigens, mechanisms of immu-
nological tolerance can restrict the effectiveness of tumor-specific
effector T cells. In order to maintain tolerance, Tregs are capable
of suppressing such responses [19] and it is apparent that tumors
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employ Tregs as a defense mechanism against host immune sur-
veillance [20]. Intratumoral Tregs appear to play a role in cancer
progression, since their selective depletion results in tumor rejec-
tion in many models of cancer [21]. In CRC, patients have increased
proportions of Tregs in peripheral blood and amongst tumor-infil-
trating lymphocytes (TILs) [5], and mounting evidence suggests
that these cells impinge upon the beneficial TAA-specific responses
[22,23]. We recently identified that surgical removal of the primary
tumor is effective in normalizing Treg levels in CRC patients and in
unmasking previously suppressed anti-tumor T cell responses. Fur-
thermore, Treg-mediated suppression of tumor-specific CD4+ T
cells prior to surgery was associated with tumor recurrence at
12 months [16]. This finding implies depletion of Tregs in CRC
patients post-surgery might enhance patient survival.
Yet the role of Tregs that infiltrate colorectal tumors is under
debate [24], as some reports demonstrate that a favorable progno-
sis i.e. early tumor stage is associated with a higher density of tu-
mor-infiltrating Foxp3+ cells [7,25], in contrast to other groups that
did not find this [26]. This paradox could be explained by aberrant
expression of Foxp3 that may or may not be denoting a truly
homogenous population of suppressive T cells. Indeed, Foxp3 can
become upregulated on activated effector T cells with apparently
no regulatory function [27,28]. Other theories have been proffered
for this counter-intuitive observation. Matera et al. speculated that
Foxp3+ Tregs do not possess immunosuppressive function in the
context of CRC and instead their presence might just be a homeo-
static mechanism to control a robust immune response [29]. Oth-
ers have hypothesized that Tregs can attenuate a Th17-mediated
pro-inflammatory and tumor-enhancing response [24]. Whilst this
may be plausible, there is currently no evidence to suggest that
Tregs isolated ex vivo from colorectal tumor tissue can enhance
an anti-tumor immune response, in fact, only the opposite has
been found so far [30].
It is probable that the mucosal environment of the intestine
plays a role in determining the constituents of intratumoral T cells.
Tregs have a role in ameliorating gut inflammation and therefore
could help prevent carcinogenesis by controlling tumor-promoting
inflammation [31,32]. However, if a tumor develops despite the
control of inflammation, Foxp3+ T cells may now contribute to tu-
mor progression by actively impinging on anti-tumor responses,
demonstrating an apparent shift from host protection to tumor
protection [33]. It is also likely that regulatory CD4+ T cells other
than naturally occurring CD4+CD25hiFoxp3+ Tregs are contributing
to immune suppression; these include inducible Tr1 (IL-10 produc-
ing) and Th3 (TGF-b-producing) subsets, which display variable
expression profiles of CD25 and Foxp3 and are important media-
tors of intestinal homeostasis [34,35]. We have recently identified
a highly suppressive population of Foxp3!CD4+ TILs in CRC, which
demonstrate marked suppressive properties in vitro (unpublished
data). TGF-b-producing CD4+Foxp3! T cells have been shown to
impede immunosurveillance in a model of prostate cancer [36]
and spontaneous mammary cancer [37]. It seems certain tumor
microenvironments, including CRC, facilitate the development
and expansion of highly suppressive populations of T cells
[30,38,39] the complexity of which we are only just beginning to
appreciate (outlined in Fig. 1).
4. T cell-mediated immunotherapeutic strategies for treating
CRC
Successful immunotherapy for CRC will most likely require a
multi-faceted approach to boost tumor-specific effectors with con-
current depletion of tumor-specific regulators. Whilst adoptive T
cell therapy holds significant promise [40], an ideal scenario would
be to administer an anti-cancer vaccine to boost the patients’ own
anti-tumor T cell responses. However, vaccinating patients with
whole tumor antigens has yielded disappointing data from phase
II/III trials for a variety of reasons [41]. One issue that arises from
targeting T cells in this manner is the activation of TAA-specific
Fig. 1. Colorectal tumor-infiltrating T cells exert opposing effects, reflecting their heterogeneous nature. CD4+ and CD8+ T cells produce effector molecules capable of anti-
tumor effects. However, the tumor microenvironment consists of many cells capable of potent suppression, including both Foxp3+ and Foxp3! regulatory T cells. Thus, tumors
are able to grow even in the presence of large numbers of T cells.
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Tregs [22,23], which will in turn suppress any beneficial response.
Depleting Tregs whilst stimulating the anti-tumor T cells has al-
ready been shown to induce potent anti-tumor responses [42]. In-
deed, depleting Tregs alone using low dose cyclophosphamide
unmasks significant anti-tumor responses in cancer patients
[43,44]; thus we have started a clinical trial using a vaccine and
low dose cyclophosphamide in CRC patients in anticipation of
similar beneficial findings [45].
Even if successful depletion of Tregs from colorectal tumors
occurs, effective tumor-specific T cell responses are further con-
strained by a number of highly immunosuppressive factors within
the tumor microenvironment. Recently it has been shown that
inhibition of dendritic cell (DC) maturation via high levels of intra-
tumoral CCL2, CXCL1, CXCL5 and VEGF can lead to a reduction in
antigen presentation to T cells in CRC [46] and crucially can skew
an effective Th1 response [47]. Furthermore, this tumor-induced
immunosuppression is heightened at later stages of tumor devel-
opment, further compounding the use of possible beneficial immu-
notherapeutic agents in patients with end-stage CRC. It is possible
that agents to reduce these other mechanisms of tumor-induced
immunosuppression, such as targeted blocking of suppressive
cytokines and regulatory chemokine molecules, may be necessary
for immunotherapeutic success.
5. Conclusion
Deciphering the phenotype and function of T cells infiltrating
CRC is a priority for understanding the role of both Tregs and other
regulatory CD4+ T cell populations. The recent question over the
prognostic effect of Foxp3+ Tregs means that we may be placing
too much emphasis on this transcription factor to denote the reg-
ulatory T cell populations in tumors, since clearly other regulatory
populations not expressing Foxp3 exist. Identifying these regula-
tory populations is the beginning of the battle: working out how
to control or remove these cells and whether this benefits patient
management are the future challenges.
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